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 The origins of metabolic pathways and the evolution of the enzymes that 
comprise them have provoked intense debate and spawned a number of theories.  The 
“patchwork” theory of Jensen, in which existing enzymes are combined to give new 
pathways, is one.  Another emerging theme is that of “catalytic promiscuity,” the 
ability of an enzyme to catalyze a low-level activity that differs from its physiological 
function.  Such an activity can be amplified through mutation(s) to yield a more 
efficient enzyme.  These ideas are often used to explain the origins of 
“superfamilies,” which consist of enzymes that catalyze different reactions yet share 
sequence and/or structural homology. 
 The catechol meta-fission pathway, a plasmid-encoded degradation pathway 
for simple aromatic compounds, is rich in enzyme chemistry and replete with 
 v
 
structural and evolutionary diversity.  4-Oxalocrotonate tautomerase (4-OT), the best 
characterized enzyme in this pathway, is a member of the tautomerase superfamily.  
Two additional enzymes, YwhB, an enzyme of unknown function, and trans-3-
chloroacrylic acid dehalogenase (CaaD) are also members.  One defining feature of 
this superfamily is the conservation of an N-terminal proline which functions as a 
catalytic base.  CaaD catalyzes dehalogenation via a hydration mechanism.  Through 
site-directed mutagenesis, kinetic and pH rate analysis, and irreversible inhibition 
with 3-halopropiolates, Pro-1 of the β-subunit of CaaD was identified as a general 
acid catalyst instead of a general base catalyst, thus differentiating it from the rest of 
the superfamily.  4-OT and YwhB also catalyze dehalogenation, but at a low level.  
These results suggest that one or both enzymes may be the ancestor(s) of CaaD.  Both 
enzymes are also inhibited by 3-halopropiolates, but by a different mechanism than 
that observed for CaaD. 
2-Hydroxymuconate semialdehyde dehydrogenase (2-HMSD) immediately 
precedes 4-OT in the meta-fission pathway and is a member of the aldehyde 
dehydrogenase superfamily.  Its catalytic mechanism may utilize a cysteine to form a 
thiohemiacetal intermediate, which is followed by hydride transfer to NAD+.  2-
HMSD has been characterized with several substrates, and site-directed mutagenesis 
has identified the essential catalytic cysteine.  Additionally, 2-HMSD is reversibly 
inhibited by a product analog.  This work sets the stage for further investigaton of its 
structure and mechanism. 
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Retro-evolution of Metabolic Pathways.  
 
The origin of metabolic pathways and the evolution of enzymes have 
intrigued scientists over the past several decades.  Several hypotheses have been 
advanced to address these questions.  Two of the most popular theories were 
suggested quite early – the retro-evolution or retrograde theory by Horowitz, and the 
recruitment theory proposed by Jensen (1-3).  In 1945, Horowitz suggested that 
enzymes evolved in a backwards fashion.  The first organisms might have lived in a 
“highly complex chemical environment” which provided all of the nutrients, such as 
vitamins, amino acids, and sugars, necessary for life (1).  Over time, these nutrients 
became depleted.  Organisms that were able to synthesize such compounds gained a 
selective advantage over those that could not.  Initially, such syntheses were one-step 
biochemical pathways that allowed the organism to use an existing precursor to 
generate the necessary nutrient (Figure 1).   
The expansion of pathways in this manner assumes a common link between 
proteins and the genes that encode them.  Since the substrate of one reaction is the 
product of the immediately preceding reaction, one might suppose that the enzymes 
that catalyze both reactions share some active-site architecture.  The “easiest” way to 
capitalize on such similarity is to duplicate an existing gene and modifiy it by 
mutation, creating a new protein to catalyze a preceding step.  In Horowitz’s view, 
Enzyme 2 (Figure 2) arises as a result of the duplication and mutation of Enzyme 1.  
These enzymes are homologous, meaning that they share sequence and/or structural 
similarity.  Thus, as pathways grew in size and complexity, they expanded in a 
backwards or retrograde fashion.  The “last” protein in the pathway (Enzyme 1, 
Figure 2) is the ancestral parent of all of the proteins that precede it in the series.  
Each additional new enzyme would confer an evolutionary advantage on the host 
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organism since it would provide another means for the host to synthesize needed 
materials.   
 Horowitz believed that his retrograde evolution theory gained more 
credibility when operons were discovered (2).  An operon is defined as a series of 
genes, clustered together on a chromosome or a plasmid, that have a common control 
mechanism (4).  Horowitz considered two possibilities for the origin of an operon.  
Either the genes of an operon may have originated in different regions of the 
chromosome(s) and were transposed, over time, into their positions in the final 
sequence, or they might have originated in series.  Horowitz believed that the former 
hypothesis was unlikely.  On the other hand, the latter hypothesis was both supported 
by and gave support to the retrograde theory.  Since it was also shown at this time that 
the genes of a biosynthetic pathway were not required to be clustered in operons (5-
7), Horowitz believed that the presence of an operon implied a common ancestor. 
 Horowitz’s retrograde model is vulnerable in many aspects.  Many 
intermediates in metabolism are so unstable that they would not exist long enough for 
an enzyme to evolve to use them as substrates (3).  Another issue is the availablility 
of metabolic intermediates.  As these compounds are removed from the environment, 
retrograde evolution becomes impossible (8).  Moreover, if the retrograde theory 
were true in all cases, then every pathway would contain homologous enzymes.  
Although there are cases in which homologous enzymes are encoded sequentially in 
the genome, these are the exception and not the rule.  One such example is found in 
the histidine biosynthetic pathway of bacteria, where two enzymes that share 
homology and catalyze successive reactions are consecutively encoded (9-11). 
 
(Potential) Retrograde Evolution:  PFACRI and ImGPS  
 
In histidine biosynthesis, two enzymes involved in consecutive reactions are 
phosphoribosyl-formimino-5-aminoimidazole carboxamide ribonucleotide isomerase 
(PFACRI or HisA) and imidazole-3-glycerol phosphate synthase (ImGPS or HisF)   
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(Figure 3).  These enzymes share 25% sequence identity and a common (β/α)8 barrel 
structural motif (9-11).  Both enzymes share several conserved amino acids in their  
active sites and contain repeated structural patterns of symmetrical loops of the same 
size and conformation (12).   A comparison of the N-terminal and C-terminal halves 
(“half-barrels”) of each protein shows that invariant residues are located at 
structurally identical positions (11).  These half-barrel structures are essentially 
superimposble, suggesting that both enzymes may have evolved from a common 
ancestral half-barrel (13, 14).  ImGPS is able to catalyze the PFACRI reaction at a 
low level (kcat/Km = 0.1 mM-1 s-1), but the reverse is not true (11).  The structural, 
sequence, and mechanistic evidence indicates that this pair of enzymes support 
Horowitz’s retrograde evolution theory. 
 
Catalytic Promiscuity and the Patchwork Evolution Model 
 
 The ability of ImGPS to catalyze the PFACRI reaction at a low level is an 
example of what has been called “catalytic promiscuity” (15).  This phenomenon, 
described in detail by O’Brien and Herschlag, involves the use of active-site features 
in a particular enzyme to catalyze an alternative and likely unintended reaction.  
Many enzymes exhibit catalytic promiscuity, which is one of the themes that will be 
addressed by the work described in this dissertation.   
Such promiscuity lends credence to the second major theory regarding the 
evolution of metabolic pathways.  First proposed by Ycas in 1974, the “patchwork 
evolution” model was refined by Jensen in 1976 (16, 3).  Jensen suggested that early 
enzymes possessed very broad substrate specificity, allowing them to react with a 
wide range of substrates.  This could have allowed early organisms to maximize their 
catalytic potential with the few enzymes they may have possessed.  Over time, genes 
for these enzymes would be duplicated, permitting mutations to occur that would 
increase their specificity.  The patchwork model assumes the existence of at least a 
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few early enzymes, the origins of which must have been from some other means such 
as that described in Horowitz’s theories. 
 
Patchwork Evolution:  The Pentachlorophenol Degradation Pathway 
 
The origins of a number of metabolic pathways can be explained by the 
patchwork model.  One elegant example can be found in the soil bacterium 
Sphingomonas chlorophenolica.  This particular organism is able to degrade 
pentachlorophenol (PCP), a xenobiotic pesticide, and use it as a sole source of carbon 
and energy (17).  The degradation pathway is shown in Figure 4. 
The pathway begins with the conversion of PCP to tetrachlorohydroquinone, 
which is catalyzed by PCP hydroxylase (PcpB) (18).  Subsequently, TCHQ 
dehalogenase performs two reductive dehalogenations to form trichlorohydroquinone 
(TriCHQ) and then 2,6-dichlorohydroquinone (DCHQ) (19).  The aromatic ring is 
then cleaved by an Fe2+-dependent extradiol dioxygenase, PcpA (20).   
The first enzyme in the pathway, PcpB, is a flavin monooxygenase that 
requires molecular oxygen and two equivalents of NADPH to convert PCP to TCHQ 
(18).  This step of the pathway appears to be rate-limiting (17).  Unlike most flavin 
monooxygenases, PcpB displays broad substrate specificity.  It is thus likely that this 
enzyme was recently recruited to utilize PCP as a substrate and has not yet optimized 
its new function. 
 TCHQ dehalogenase is a member of the zeta class of the glutathione S-
transferase (GST) superfamily (21, 22).  GSTs typically catalyze the nucleophilic 
attack of glutathione to form a glutathione conjugate, which is often used by 
organisms to detoxify alkylating agents (23).  One of the GSTs, maleylacetoacetate 
(MAA) isomerase, appears to be the precursor for TCHQ dehalogenase.  Both 
enzymes share significant active site architecture, and TCHQ can catalyze the 
glutathione-dependent isomerization of a double bond in MAA with similar kinetic 
parameters to those measured for MAA isomerase (21, 24).  These observations 
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suggest that an MAA isomerase was recruited to fulfill the dehalogenase role in this 
particular pathway.  Indeed, an MAA isomerase has been discovered in S. 
chlorophenolica that appears to have the “promiscuous” ability to catalyze the TCHQ 
dehalogenation (24). 
 Copley has suggested that the original functions of PcpB and PcpA were to 
cleave naturally occurring chlorinated compounds such as 2,6-dichlorophenol (17).  
Chlorophenols are naturally produced by insects and fungi (25, 26), so it is reasonable 
for soil bacteria to develop the ability to degrade such compounds.  A model for the 
patchwork assembly of the PCP degradation pathway is shown in Figure 5.  PcpB, 
which accepts chlorophenols as substrate, hydroxylates PCP.  Later, a MAA 
isomerase was recruited from an existing metabolic pathway to serve as the TCHQ 
dehalogenase.  Finally, PcpA could perform its normal function as a ring cleavage 
dioxygenase. 
 
Recruitment of Existing Enzymes:  Mandelate Racemase and Muconate-
Lactonizing Enzyme 
 
 The explanation for the origins of certain metabolic pathways using the 
recruitment model, as illustrated in the PCP degradation pathway, has been 
appropriated by others based on one of two lines of evidence.  The first line of 
evidence is that a particular enzyme is “catalytically promiscuous” (15).  Second, 
homologous enzymes can be shown to catalyze different reactions, thus suggesting a 
common ancestor.  One of the first instances in which the latter strategy might have 
been used is in the evolution of mandelate racemase (MR) and muconate-lactonizing 
enzyme (MLE), enzymes found in the mandelate and β-ketoadipate pathways, 
respectively (Figure 6) (27).  These pathways are found in various Pseudomonas 
species which can use either isomer of mandelate as a sole source of carbon and 
energy.  Mandelate is believed to be a breakdown product of lignin, a component of 
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plant cell walls.  The mandelate pathway generates benzoate, which funnels into the 
β-ketoadipate pathway and is converted to acetyl-CoA and succinate. 
 The first enzyme of the mandelate pathway is mandelate racemase, which 
catalyzes the racemization of R- and S-mandelate (Figure 7).  It is a homooctamer in 
solution and has an overall molecular weight of 320 kD.  This enzyme requires a 
divalent metal ion for activity, preferring magnesium over manganese (28).  The 
reaction proceeds by a so-called two base mechanism.  Residues on opposite sides of 
the substrate (Lys 166 and His 297) act as acids or bases depending on the direction 
of the isomerization.  Lys-166 removes the proton from the carbon adjacent to the 
carboxylate (designated the α-proton), while His-297 protonates the intermediate.  
The substrate is a bidentate ligand, possessing two points at which it can attach to the 
metal ion.  Mandelate thus binds one carboxylate oxygen and the α-hydroxyl to the 
metal ion (12).   
Muconate-lactonizing enzyme is found in the β-ketoadipate pathway (Figure 
6).  MLE, which is quite common among bacteria, catalyzes the interconversion of 
muconolactone with cis, cis-muconate (29).  The observed physiological reaction is 
the conversion of cis, cis-muconate to muconolactone (Figure 7).  Like MR, MLE is 
an octamer and requires a divalent ion for activity, with Mn2+ preferred over Mg2+.  
The reaction is initiated by the abstraction of the α-proton, analogous to the first step 
in the MR-catalyzed reaction.  A lysine residue (either 169 or 273) is thought to act as 
the general base (12). 
In 1990 it was discovered that the crystal structures of MR and muconate 
lactonizing enzyme (MLE) were nearly superimposable (30).  Both enzymes belong 
to the class of TIM-barrel enzymes which obtain their name from triose phosphate 
isomerase (TIM), the first enzyme shown to contain this particular structure.  The 
TIM-barrel fold is an eightfold repeat of a β-strand followed by an α-helix, 
designated (β/α)8 (31).  MR and MLE also share 26% sequence identity, which 
provides additional evidence for a possible common ancestor (27).  Despite structural 
similarities that occur to the level of the active site, neither enzyme has been shown to 
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catalyze the other’s reaction, even at a low level.  However, both mechanisms involve 
the abstraction of the α-proton, leading to a stabilized enolate intermediate (32).  It is 
thus likely that nature used a precursor with a similar active site structure and evolved 
it to fulfill the different functions that MR and MLE serve.  Perhaps MLE itself, 
which is more prevalent in bacterial species than is MR, was the ancestral enzyme 
recruited to perform the racemization.  Another, more likely, possibility is that an 





 The enzyme “superfamily” was coined by John Gerlt at the University of 
Illinois and Patricia Babbitt at the University of California-San Francisco, and others 
(33).  The discovery that mandelate racemase and muconate-lactonizing enzyme are 
homologous (in sequence and structure), although they catalyze different reactions, 
essentially began the discussion of enzyme superfamilies.  This finding suggested that 
enzymes related by divergent evolution could catalyze different overall reactions 
(12).  Enzyme superfamilies, which are a major theme of the work in this dissertation, 
involve a number of terms which are briefly outlined below. 
 A superfamily can be described in terms of either structure or function.  Gerlt 
and Babbitt have proposed a definition that encompasses both.  Terms in this 
dissertation that refer to superfamilies will be defined in the context Gerlt and Babbitt 
have suggested (12).  An enzyme family is a group of homologous enzymes that 
catalyze the same reaction, both mechanistically and in terms of substrate.  Members 
of a family often have 30% or greater sequence identity.  Frequently these enzymes 
are orthologs; that is, they are the same enzyme found in different species.  One 
example of a family of enzymes is the set of all triose phosphate isomerases.  The 
TIMs found in different organisms catalyze the same reaction using the same 
substrate.  An enzyme superfamily consists of groups of homologous enzymes that 
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catalyze either 1) the same reaction mechanistically but with different substrates or 2) 
different reactions sharing a common mechanistic feature.  The latter is made possible 
by conserved active site residues sharing the same function in all superfamily 
members.  Such enzymes often have less than 20% sequence identity. 
 
The Enolase Superfamily 
 
 As described in the previous section, mandelate racemase and muconate-
lactonizing enzyme are members of a superfamily.  MR and MLE are homologous, 
and they catalyze different reactions despite sharing active site elements.  Several 
other members of the MR/MLE superfamily, designated the enolase superfamily, 
have now been identified.  Each enzyme catalyzes a different reaction, but they all 
share the common ability to abstract the α-proton of a carboxylate.  These enzymes 
include the title enzyme, enolase, which catalyzes the β-elimination of water from 2-
phosphoglycerate to yield phosphoenolpyruvate (34), as well as a number of other 
enzymes whose reactions are illustrated in Figure 8.  The reactions involved are 
chemically difficult due to the high pKas of the protons involved.  However, the 
ability of these enzymes to stabilize the enolate ion lowers the pKa, enabling the 
reaction to occur (Figure 9). 
 
The Crotonase Superfamily – Stabilization of Enolate Anions 
 
 The members of the crotonase (“enoyl CoA hydratase”) superfamily share the 
common feature of the use of an oxyanion hole to stabilize enolate anions that arise 
during the hydrolysis of peptide bonds (36-38).  Crotonase catalyzes the addition of 
water to enoyl CoA esters, yielding 3-(S)-hydroxyl acyl CoA esters (39-41).   The 
reaction is the second step in the fatty acid β-oxidation pathway, which converts fatty 
acids to acetyl-CoA for use in the Krebs cycle.  No functional groups apart from those 
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comprising the oxyanion hole are conserved among these enzymes (12).  Reactions 
catalyzed by this superfamily are illustrated in Figure 10. 
Many of the members of the crotonase superfamily use coenzyme A (CoA) 
esters as substrates.  The structure of the oxyanion hole includes two perpendicular β-
sheets that are surrounded by α-helices (12).  In the coenzyme A-utilizing enzymes, 
the oxyanion hole is located at the opening of the active site, and the acyl group of the 
substrate enters a cavity that contains the catalytic groups.  Three of these enzymes, 
crotonase, 4-chlorobenzoyl CoA dehalogenase, and ∆3,5, ∆2,4-dienoyl CoA isomerase, 
have structures that are again nearly superimposable (12).  4-chlorobenzoyl 
dehalogenase catalyzes nucleophilic aromatic substitution via an arylated enzyme 
intermediate (42-46). This reaction is part of a pathway that allows soil bacteria to 
degrade halogenated aromatic compounds.  ∆3,5, ∆2,4-dienoyl CoA isomerase 
catalyzes a 1,5-proton transfer reaction which is utilized in the degradation of 
unsaturated fatty acids (47).  The structural commonalities among these enzymes 
suggest that divergent evolution may have yielded these varying activities.  For 
instance, experiments have succeeded in converting 4-chlorobenzoyl CoA 
dehalogenase into a low-level crotonase (47), indicating that at least these two 
enzymes may have had a common ancestor. 
 
 The Radical SAM Superfamily 
 
 One of the newest and least characterized superfamilies is denoted the radical 
S-adenosylmethionine (SAM) protein superfamily (49, 50).  This superfamily is based 
on a common mechanistic feature of radical formation upon reductive cleavage of 
SAM using an iron-sulfur cluster.  Radical SAM proteins catalyze a number of 
interesting, chemically difficult reactions including methylation, isomerization, ring 
formation, and protein radical generation.  The best characterized members of this 
superfamily include lysine 2, 3-aminomutase (LAM), lipoic acid synthase (LipA), 
and biotin synthase (BioB).  These reactions are illustrated in Figure 11.  LAM is part 
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of a metabolic pathway that allows anaerobic bacteria to utilize lysine as both a 
carbon and a nitrogen source, as well as being part of a biosynthetic pathway for 
antibiotics in Streptomyces (50-54).  Lipoic acid, the product of LipA, is required for 
the activity of several enzymes in the glycine cleavage system and the 
decarboxylation of α-keto acids, which are important metabolic processes (54).  
Biotin, which arises from the cyclization and insertion of sulfur into dethiobiotin by 
BioB, is an essential vitamin.   
 Previous work did not suggest that these proteins were homologous despite 
the presence of a conserved cysteine motif (56).  Sofia, et al., used intensive sequence 
analysis to detect a low level of sequence similiarity between these and other proteins, 
suggesting the presence of a common ancestor and predicting a common structural 
fold (49).  No crystal structures have been solved for any of these enzymes, although 
they have been the subjects of intense investigation (56-60).  However, the 
determination of one crystal structure will likely shed light on interesting 
evolutionary and mechanistic features for many, if not all, members of the radical 
SAM superfamily. 
 
The Catechol meta-Fission Pathway 
 
 The catechol meta-fission (MF) pathway (Figure 12) is a plasmid-encoded set 
of enzymes that allows organisms to use various aromatic compounds as sole sources 
of carbon and energy.  The particular plasmid of interest in the Whitman laboratory is 
the TOL (pWW0) plasmid from Pseudomonas putida mt-2, a soil bacterium (60).  
Aromatic compounds such as toluene and xylene are funneled into the pathway after 
enzyme-catalyzed conversion to catechol or substituted catechols.  Catechol-2,3-
dioxygenase (C2,3O) opens the ring, forming 2-hydroxymuconate semialdehyde (2-
HMS).  At this point, the MF pathway diverges.  Substituents on 2-HMS tend to 
determine the branch that is used for further processing.  In the multi-enzyme branch, 
2-hydroxymuconate semialdehyde dehydrogenase (2-HMSD) oxidizes 2-HMS to the 
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corresponding dienol acid, 2-hydroxymuconate.  Subsequently, 4-oxalocrotonate 
tautomerase (4-OT) converts the dienol to the conjugated ketone.  Decarboxylation of 
the conjugated ketone is catalyzed by 4-oxalocrotonate decarboxylase (4-OD), 
yielding 2-hydroxy-penta-2,4-dienoate (HPD) (62).  In the single enzyme branch, 2-
hydroxymuconate semialdehyde hydrolase (2-HMSH) directly hydrolyzes 2-HMS to 
form HPD.  The branches converge after the formation of HPD.  Vinylpyruvate 
hydratase (VPH) adds water to HPD, resulting in the formation of 2-oxo-4-
hydroxypentanoate (KHP).  Finally, KHP aldolase converts 2,4-HP to acetaldehyde 
and pyruvate, which are channeled into the Krebs cycle. 
The meta-fission pathway is an ideal model for the study of enzyme evolution 
for several reasons.  Since it is plasmid-encoded, it can be inferred that the MF 
pathway was constructed in response to environmental pressures.  It is likely that the 
enzymes of the TOL plasmid were recruited from existing metabolic pathways, in 
accordance with Jensen’s hypothesis (3).  Evolution of the MF pathway may share 
similiarities with that of the evolutionary scheme proposed by Copley for 
pentachlorophenol degradation (17).  However, the MF pathway is highly optimized 
for degradation, in contrast to the pathway used for pentachlorophenol.  Due to the 
differences in sizes, structures (that have been solved), and substrate requirements of 
these enzymes and the inherent instability of some of the pathway intermediates, it is 
not likely that this pathway evolved in the manner espoused by Horowitz’s retrograde 
evolution theory. 
Furthermore, many of the enzymes of this pathway show sequence similarity 
to enzymes from other organisms.  For some of these enzymes, the sequence 
similarity was originally only obvious for orthologs.  For instance, when 4-OT was 
initially investigated, only other 4-OTs from other bacteria apparently shared 
homology with it (63).  As the field of bioinformatics has grown and genomic 
sequencing projects have been completed, it has become apparent that the enzymes of 
the meta-fission pathway also belong to enzyme superfamilies.  2-HMSD and 4-OT, 
two of the major topics of this dissertation, are prime examples of this phenomenon.  
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4-OT is a member of the tautomerase superfamily, and 2-HMSD is a member of the 
aldehyde dehydrogenase superfamily.  These enzymes, and their respective 
superfamilies, are discussed below. 
  
The Aldehyde Dehydrogenase (ALDH) Superfamily 
 
 The aldehyde dehydrogenases (ALDH) comprise an ubiquitous superfamily of 
enzymes found in both prokaryotes and eukaryotes.  These divergently related 
enzymes metabolize a vast array of endogenous and exogenous aldehyde compounds 
(63, 64).  Aldehyde compounds can often cause many detrimental effects to an 
organism, including cytotoxicity, mutagenicity, and carcinogenicity (65).  Thus, 
ALDHs serve an important detoxification role in many biological systems.  They also 
sometimes serve additional functions in the cell, including metabolism, hormone 
binding, nuclear restoration, and stress response (67-71).  ALDHs are ~500 amino 
acids in size and associate as homodimers or homotetramers.  They require either 
NAD+ or NADP+ for activity.  Most ALDHs exhibit a strong preference, in terms of 
Km, for one over the other.  The mechanism of catalysis is thought to involve the 
formation of a thiohemiacetal intermediate followed by hydride transfer to the 
nucleotide cofactor.  Broadly speaking, aldehyde dehydrogenases can be divided into 
seven categories:  semialdehyde dehydrogenases, non-specifc ALDHs, betaine 
dehydrogenases, non-phosphorylating glyceraldehyde 3-phosphate dehydrogenases, 
phenylacetaldehyde dehydrogenases, lactaldehyde dehydrogenases, and ALDH-like 
proteins (72).   
 A number of crystal structures for aldehyde dehydrogenases have been 
determined to date (73-78).  Although the enzymes crystallized do not share a great 
deal of sequence identity (~20%), their structures show certain common features.  
Overall, the structural folds appear similar despite the differences in primary and 
quaternary structure among enzymes.  Differences are more apparent in the active site 
features, particularly in how ALDHs bind either substrate (73) or the nucleotide 
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cofactor (74-76).  The Rossmann fold, a nucleotide binding domain commonly found 
among enzymes that use NAD(P)+ or FAD, is present but possesses a slightly 
different structure than that found in most other dehydrogenases (74).  In a typical 
NAD+-dependent dehydrogenase, the Rossman fold contains six β-strands and five α-
helices  (the β-α-β motif) (79), but in ALDHs, the Rossmann fold is made of five β-
strands connected by four α-helices (74).   
 
2-Hydroxymuconate Semialdehyde Dehydrogenase (2-HMSD) 
 
2-Hydroxymuconate semialdehyde dehydrogenase (2-HMSD), which is a 
member of the semialdehyde ALDH family, is the first enzyme of the multi-enzyme 
branch in the meta-fission pathway.  A sequence alignment of five ALDH sequences 
whose structures have been solved with 2-HMSD (generated using CLUSTAL-W) is 
illustrated in Figure 13.  Although the crystal structure of 2-HMSD has not yet been 
elucidated, the sequence identity shown allows a number of predictions to be made 
about the enzyme.   
Due to both sequence identity and crystallographic studies, a general 
mechanism has been proposed for aldehyde dehydrogenases (Figure 14).  In this 
mechanism, an active site cysteine (Cys-287 in 2-HMSD) attacks the aldehyde group, 
forming a thiohemiacetal intermediate.  Other residues conserved in the active site are 
an asparagine residue, thought to stablilize the thiohemiacetal through hydrogen 
bonding (80, 81), and one of two conserved glutamate residues believed to act as a 
general base that deprotonates the active site cysteine (80, 82).  The active site 
residues, denoted by (*), are depicted in Figure 15.  This effect is thought to be 
mediated via a water molecule or a conformational change since structural work 
suggests that the glutamates are too far from the cysteine to directly deprotonate (82).  
Subsequently, hydride transfer to the nucleotide cofactor occurs, followed by release 
of the oxidized acid product.  Despite the presence of the conserved glutamate 
residues in the Vibrio harveyi aldehyde dehydrogenase, His-450 (denoted by ‡) is 
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involved with the deprotonation (82).  This was determined through site-directed 
mutagenesis of His-450 coupled with structural determination.  This particular 
residue is not found in 2-HMSD, nor is it conserved among any of the other ALDHs 
whose structures have been solved.  However, an active site histidine has also been 
implicated in the mechanism of aspartate β-semialdehyde dehydrogenase (78). 
 In addition to evolutionary questions, our interest in 2-HMSD involves a 
number of mechanistic questions.  We were interested in determining whether the 
product of 2-HMSD is 2-hydroxymuconate.  2-HMS can exist as three isomers, the 
enol, the β, γ-unsaturated ketone, or its α, β-isomer.  Assuming the three isomeras are 
present in aqueous solution, it would be interesting to determine which isomer is 
processed by the dehydrogenase, and which isomer is formed.  If 2-HMSD accepts 
the conjugated aldehyde, in which the aldehyde is more electrophilic, and produces 
the conjugated form of 2-HM, 4-OT serves no apparent function.  2-HMSD has been 
studied previously (84-86).  Only the native enzyme was studied; the enzyme was not 
cloned for over-expression.  Moreover, its activities with various substrates were 
assessed only by UV-visible spectroscopy and not by NMR spectroscopy, which 
would provide more information.  Although potential active site residues were 
identified, no mutagenesis or inactivation experiments were performed.  In our 
studies, we cloned and overexpressed 2-HMSD, verified its kinetic parameters for 2-
HMSD, characterized the reaction by NMR, obtained further insight as to its substrate 
specificity, and investigated the role of the putative catalytic cysteine in the 
mechanism (Cys-287). 
 
4-OT, the 4-OT Family, and the Tautomerase Superfamily 
 
 4-OT follows 2-HMSD in the multi-enzyme branch of the catechol meta-
fission pathway (Figure 12).  This enzyme has been a subject of research in the 
Whitman laboratory for the past fifteen years.  4-OT is a homohexamer (trimer of 
homodimers) of 6810 Da subunits.  It catalyzes a 1,3-keto-enol tautomerization (2-
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hydroxymuconate to the β, γ-unsaturated ketone) as well as a 1,5-keto-enol 
tautomerization (2-hydroxymuconate to the α,β-unsaturated ketone) (Figure 16).  The 
overall reaction is the conversion of the β, γ-unsaturated ketone to its α, β-isomer via 
a dienol intermediate.  4-OT is an ideal system for the of study structure-function 
relationships in enzymes for two major reasons.  First, it catalyzes a proton transfer 
without the assistance of a metal ion or a cofactor, making it a relatively simple 
enzyme to study.  Second, its small size (62 amino acids) facilitates its study using 
chemical synthesis and NMR spectroscopy, which would be difficult, if not 
impossible, for much larger proteins. 
 The current mechanism for the 4-OT-catalyzed reaction is illustrated in 
Figure 17.  Pro-1 was established as the general base, primarily as a result of affinity-
labeling studies, crystallography, chemical synthesis, and NMR studies (86-93).  
Although the N-terminal proline would not normally be thought of as a general base 
at physiological pH because its pKa is approximately 9.4, direct NMR titration of 
uniformly labeled 15N-enzyme has shown that the pKa is ~6.4.  The 1000-fold 
decrease in pKa thus allows Pro-1 to function as a base. 
In Figure 17, a single prime (′) indicates that the residue is found in the 
neighboring monomer within the same dimer, relative to Pro-1.  A double prime (′′) 
indicates that the residue is found in an adjacent dimer relative to Pro-1.  Thus, the 
arginine-11 from a neighboring monomer was shown to be important in both binding 
and catalysis through site-directed mutagenesis (94, 95).  Changing Arg-11 to an 
alanine increased Km ~9-fold and decreased kcat ~90 fold.  Arg-11 likely acts as an 
electron sink, drawing electron density towards C-5 of the substrate and facilitating 
protonation. 
 Arginine-39, from a neighboring dimer, is important both for catalytic and 
structural reasons.  Mutation to an alanine or a glutamine affects catalysis, the pKa of 
the N-terminal proline, and the overall structure of the enzyme (94, 95).  Small 
changes are observed for Km, but larger decreases (125-fold and ~400-fold for R39A 
and R39Q, respectively) are observed for kcat.  Arg-39 is involved in hydrogen 
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bonding with both the C-1 carboxylate and the C-2 oxygen, thus facilitating 
deprotonation at C-3.  Mutation of this residue probably eliminates one of these 
hydrogen bonds, making deprotonation less favorable.  Additionally, a slight increase 
of the pKa of Pro-1 is observed in the R39Q mutant.  NMR titration indicates that the 
pKa is increased to 7.1.  In this mutant, a larger proportion of Pro-1 is protonated and 
cannot function as a base in catalysis at cellular pH.  Moreover, the R39Q mutant 
shows structural disruption, possibly allowing water into the largely hydrophobic 
active site. 
 Another critical residue in 4-OT is Phe-50 (96).  The F50A mutant shows 
large changes in Km and kcat (11-fold increase and 175-fold decrease, respectively).  
Moreover, the F50A mutant shows large structural damage, suggesting that the 
phenylalanine residue is crucial for maintaining the hydrophobicity of the active site.  
The dielectric constant of the wild-type active site is estimated to be 14.7 ± 0.7, while 
that of the F50A mutant is estimated to be 21.6 ± 2.6.  The active site of F50A 4-OT 
is more accessible to water than that of the wild-type, which may decrease the 
interactions between the polar active site residues and the substrate.  The phenyl ring 
of Phe-50 may also interact with the diene functional group of 2-HM. 
The 4-OT family of enzymes is the best characterized family in the 
tautomerase superfamily.  Three members of this family are major subjects of this 
dissertation.  Overall, the tautomerase superfamily is comprised of three families of 
enzymes.  The title enzymes of these families are MIF (macrophage migration 
inhibitory factor), CHMI (5-carboxy-2-hydroxymuconate isomerase), and 4-OT (97).  
These enzymes share little sequence identity (~7%) but share structural homology.  
The common structural unit among these proteins is a β-α-β motif.  In CHMI and 
MIF, each monomer consists of two β-α-β motifs that resemble the 4-OT dimer.  
Although 4-OT possesses six active sites, MIF and CHMI each contain three – one 
per monomer.  Despite their low sequence identity, each protein contains an N-
terminal proline that functions as a catalytic base.   The reactions catalyzed by these 
enzymes are diagrammed in Figure 18. 
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 MIF exists as a trimer of ~14 kD subunits.  This protein acts as part of the 
inflammatory response (98).  It also catalyzes two enzymatic reactions; the 
tautomerization of phenylpyruvate between its enol and keto forms (Figure 18), and 
the tautomerization of D-dopachrome to 5,6-dihydroxyindole-2-carboxylic acid, an 
intermediate in the biosynthesis of melanin (99, 100).  Although the enzymatic 
properties of MIF have been extensively studied, they have not been correlated with 
MIF’s anti-inflammatory activities (101). 
 CHMI catalyzes an isomerization in the homoprotocatechuate (HPC) pathway 
of Escherichia coli C.  This pathway (Figure 19) allows E. coli C to use aromatic 
amino acids as its sole sources of carbon and energy (102).  The HPC pathway 
closely parallels the meta-fission pathway (Figure 13).  Unlike the MF pathway, 
which is found on a plasmid, the HPC pathway is chromosomally encoded (103).  
Like MIF, CHMI exists as a homotrimer of ~14 kD amino acid subunits.  CHMI 
converts 5-carboxymethyl-2-hydroxymuconate (CHM) to 5-carboxymethyl-2-oxo-3-
hexene-1,6-dioate (Figure 18), analogous to the 4-OT-catalyzed reaction.   
 
Homologues of 4-OT:  YwhB from Bacillus subtilis and CaaD from Pseudomonas 
pavonceae 170 
 
 The fact that 4-OT is part of a plasmid-encoded pathway is suggestive of its 
evolutionary origin.  4-OT might have evolved from a chromosomal enzyme 
possessing tautomerase or isomerase activities.  It may also have arisen from an 
enzyme that possessed one of these activities in a low-level form (63).  When 4-OT 
was first cloned in 1992, the only known homologues were isozymes from other 
species (104).  With the successful completion of many genome sequencing projects, 
however, many chromosomal homologues of 4-OT have been identified (104).  These 
homologues, all of small size (61-79 amino acids), are ubiquitous among the 
eubacteria and archaea.  Most of these proteins are found in organisms that are not 
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known to degrade aromatic compounds, suggesting that they serve some other 
function. 
 A multiple sequence alignment among the three members of the 4-OT family 
that are at the crux of the work in this dissertation is shown in Figure 20.  The 
conserved (and likely active site) residues include Pro-1, Arg-11, and Phe-50. 
 YwhB from Bacillus subtilis has been identified only as a putative 
tautomerase (106).  Its true biological role remains unknown.  When it was first 
discovered in 1998, it was the most closely related homologue to 4-OT, sharing 36% 
sequence identity.  In solution, it exists as a homohexamer of 61 amino acids per 
subunit.  YwhB contains Pro-1, Arg-11, and a tyrosine in place of Phe-50.  Arg-39 is 
not present, but a lysine (Lys-37) is nearby.  Experiments in our laboratory have 
shown that YwhB functions as both a tautomerase and an isomerase, although not 
with the same catalytic efficiency as 4-OT (63).  As is the case for the characterized 
members of the tautomerase superfamily, Pro-1 is believe to act as a general base.  A 
crystal structure of YwhB has been obtained, demonstrating that the active sites of 
YwhB and 4-OT are nearly superimposable (Figure 21) (63).  The structural and 
sequence homology shared by these enzymes suggests a common evolutionary link, 
much like that shown earlier between mandelate racemase and muconate-lactonizing 
enzyme.   
 trans-3-Chloroacrylic acid dehalogenase (CaaD) from Pseudomonas 
pavonceae 170 catalyzes the conversion of trans-3-chloroacrylic acid to malonate 
semialdehyde via the addition of water (Figure 22).  It also processes trans-3-
bromoacrylic acid in the same fashion.  This enzyme is part of a chromosomally-
encoded pathway that allows P. pavonceae and other soil bacteria to utilize 1, 3-
dichloropropene as a sole source of carbon (107-109).  The degradation pathway is 
illustrated in Figure 23.  
1, 3-dichloropropene is the active ingredient in the commercial fumigants 
Telone II, Telone C17, and Telone C35 (110).  These xenobiotic compounds are often 
used to treat soil to kill nematode parasites prior to planting.  1, 3-dichloropropene 
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has only been in use for a few decades, so bacteria that process this compound likely 
evolved to do so very recently.  CaaD is made up of two subunits (denoted the α- and 
β-subunits), both of which show sequence identity with 4-OT and YwhB (111).  
CaaD is reportedly a heterohexamer (a trimer of heterodimers) in solution, rather than 
a homohexamer like 4-OT and YwhB (111).  Both subunits of CaaD contain the 
conserved N-terminal proline.   Site-directed mutagenesis experiments indicate that 
the β-Pro-1 is essential for activity, but the α-Pro-1 is not (111).  Arg-11 and Phe-50, 
conserved from 4-OT, are present in the α-subunit of the enzyme.  Like YwhB, 
however, Arg-39 is not present in either subunit.  In the absence of a crystal structure, 
no definite statements can be made about the active site of CaaD. 
 The sequence identity shown between these three enzymes raises some 
interesting evolutionary and mechanistic questions.  What is the nature of the 
relationship between 4-OT, YwhB, and CaaD?  It is reasonable to infer that all three 
enzymes shared a common ancestor.  Since CaaD presumably evolved more recently, 
could one (or both) of the other enzymes have been recruited for the 1, 3-
dichloropropene degradation pathway?  If recruitment did occur, is it simply because 
the active-site structure is convenient for the task?  Perhaps the active site structure 
was not designed to perform the dehalogenation reaction but evolved through a series 
of mutations to do so.  Do any of the three enzymes exhibit catalytic promiscuity?  
Does YwhB or 4-OT show low levels of dehalogenase activity?  Alternatively, can 
CaaD act as a tautomerase or an isomerase?  Does Pro-1 of the β-subunit of CaaD 
function as a general base as in the other members of the tautomerase superfamily?  
These questions will be addressed in the following chapters. 
 The studies that follow have both functional and intellectual significance.  The 
characterization of 2-HMSD will expand our understanding of aldehyde 
dehydrogenases in general, and the category of semialdehyde dehydrogenases in 
particular.  The only present structure of a semialdehyde dehydrogenase is that of 
aspartate β-semialdehyde dehydrogenase (78).  This particular enzyme is much 
smaller (367 amino acids) than and does not align well with 2-HMSD (486 amino 
 19
 
acids).  Additionally, aspartate β-semialdehyde dehydrogenase binds NADP/H, not 
NAD/H.  The work described here thus sets the stage for the determination of a 
crystal structure for 2-HMSD, which would be the first NAD+-dependent 
semialdehyde dehydrogenase structure available.  Although studies thus far have 
indicated that conserved cysteine, glutamate, and asparagine residues are “required” 
for catalysis, the elucidation of more recent structures has implicated unconserved 
residues such as histidine in catalysis.  Further investigation of 2-HMSD and other 
ALDHs may identify other residues, conserved or not, that are important in catalysis 
and substrate specificity.  Since ALDHs serve essential detoxification roles, among 
others in cells, such scrutiny is clinically and practically important.  The capabilities 
of these enzymes may also be exploited for bioremediation purposes.  Although there 
has been hesitation about releasing genetically modified organisms into the 
environment, it might be possible to engineer, for instance, Pseudomonas putida to 
overexpress the meta-fission pathway.  The engineered bacteria – which does not 
express any foreign proteins – might then be used to detoxify locations contaminated 
with toluene or other aromatic compounds.   
 Studies of the relationships and mechanisms of 4-OT, YwhB, and CaaD 
contribute to the understanding of enzyme evolution.  With the escalating abundance 
of antibiotic-resistant bacteria, the way in which enzymes evolve merits intensive 
study.  It is clear that over a fairly brief period of exposure to a particular compound, 
bacterial enzymes and even entire pathways will evolve to utilize it if beneficial or 
avoid it if detrimental.  The hardiness of bacteria, coupled with their high mutation, 
recombination, and growth rates, allows them to adapt much more quickly than other 
organisms with the exception of viruses.  The determination of factors that influence 
enzyme evolution and/or an indication of the manner in which enzymes evolve may 
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Figure 1.  Depiction of a single enzyme evolving via Horowitz’s retrograde 










Figure 2.  Depiction of two enzymes evolving via Horowitz’s retrograde hypothesis.  












Figure 3.  Catalysis by two enzymes involved in consecutive reactions of histidine 
biosynthesis.  Top, phosphoribosyl-formimino-5-aminoimidazole carboxamide 
ribonucleotide isomerase (PFACRI; HisA).  Bottom, imidazole-3-glycerol phosphate 

















































Figure 4.  Pathway for degradation of pentachlorophenol.  Abbreviations:  PcpB, 
















































Figure 5.  Proposed evolution of the pentachlorophenol degradation pathway.  
Abbreviations:  PcpB, pentachlorophenol hydroxylase; TCHQ DH, tetrahydroquinone 










































Figure 6.  Top: pathway for mandelate degradation.  Bottom:  pathway for 
homoprotocatechuate degradation.  Abbreviations:  MR, mandelate racemase; MDH, 
S-mandelate dehydrogenase; BFD, benzoylformate decarboxylase; BADH, 
benzaldehyde dehydrogenase; BDO, benzoate dioxygenase; DH/DC, 
dehydrogenase/decarboxylase; C1,2O, catechol 1,2-dioxygenase; MLE, muconate-
lactonizing enzyme; MLI, muconolactone isomerase; ELH, enol lactone hydrolase; 







































Figure 7.  Top, reaction catalyzed by mandelate racemase (MR).  Bottom, reaction 


















Figure 8.  Reactions catalyzed by enolase superfamily members (32).  Abbrevations:  
MR, mandelate racemase; MLE I, muconate-lactonizing enzyme; GalD, (D)-


























































Figure 10.  Reactions catalyzed by crotonase superfamily members (32).  






Figure 11.  Reactions catalyzed by radical SAM superfamily members.  
































Figure 12.  The catechol meta-fission pathway.  Abbreviations:  C2,3O, catechol 2,3-
dioxygenase; 2-HMSD, 2-hydroxymuconate semialdehyde dehydrogenase; 4-OT, 4-
oxalocrotonate tautomerase; 4-OD, 4-oxalocrotonate decarboxylase; VPH, 





























Figure 13.  Sequence alignment of aldehyde dehydrogenases (ALDHs) generated 
using CLUSTAL-W.  From top to bottom, betaine dehydrogenase, retinal 
dehydrogenase, 2-hydroxymuconate semialdehyde dehydrogenase, Streptococcus 
mutans ALDH, rat ALDH, Vibrio harveyi ALDH.   
 
(*) indicates conserved residues. (-) indicates the Rossman fold.  (+) and (¶) 
indicate residues for nucleotide binding.  (‡) indicates an unconserved histidine 
implicated in catalysis.  Symbols are located above the appropriate residue(s). 
 
 
betaine  AQLVDSMPSASTGSV VVTDDLNYWGGRRIK SKDGATTEPVFEPAT GRVLCQMVPCGAEEV DQAVQSAQAAYLK-- -WSKMAGIERSRVML     87 
retinal  -ASLQLLPSPTPN-- LEIKYTKIFINNEWQ NSESGRVFPVCNPAT GEQVCEVQEADKVDI DKAVQAARLAFSLGS VWRRMDASERGRLLD     88 
hmsd     --------------- ---KEIKHFISGELV GSASGKLFDNVSPAN GQVIGRVHEAGRAEV DAAVRAARAALKG-- PWGKMTVAERAEILH     71 
Strep    --------------- --TKQYKNYVNGEWK LSENE--IKIYEPAS GAELGSVPAMSTEEV DYVYASAKKAQPA-- -WRALSYIERAAYLH     69 
rat      --------------- --------------- --------------- ------------SSI SDTVKRAREAFNS-- -GKTRSLQFRIQQLE     31 
vibrio   --------------- NPQTDNVFYATNAFT GEALPLAFPVHTEVE VNQAATAAAKVARDF RRLNNSKRASLLR-- ------TIAS-ELEA     67 
            β1 
           ---- * ---  
betaine  EAARIIRERRDNIAK LEVINNGK-TITEAE YDIDAAWQCIEYYAG LAPTLSGQHIQLPG- -----GAFAYTRREP LGVCAGILAWNYPFM    170 
retinal  KLADLVERDRATLAT MESLNGGKPFLQAFY IDLQGVIKTLRYYAG WADKIHGMTIPVDG- -----DYFTFTRHEP IGVCGQIIPWNFPLL    172 
hmsd     RVADGITARFGEFLE ARMPGHRQAEVAGQP HRHSARRANFKVFAD LLKNVANEAFEMATP DGA--GALNYGVRRP KGVIGVISPWNLPLL    159 
Strep    KVADILMRDKEKIGA ILSKEVAK-GYKSAV SEVVRTAEIINYAAE EGLRMEGEVLEGGSF EAASKKKIAVVRREP VGLVLAISPFNYPVN    158 
rat      ALQRMINENLKSISG ALASDLGKNEWTSYY EEVAHVLEELDTTIK ELPDWAEDEPVAKTR QTQ--QDDLYIHSEP LGVVLVIGAWNYPFN    119 
vibrio   RSDDIIARAHLETAL PEVRLTGEIARTANQ LRLFADVVNSGSYHQ AILDTPNPTRAPLP- -----KPDIRRQQIA LGPVAVFGASNFPLA    151 
    a1                     β2       α2           β3                α3                    β4  α4 
          ----------        ---+  ¶  ---------------   -----     -------      -----    --------- 
betaine  IAAWK--CAPALACG NAVVFKPSPMTPVTG VILAEIFHEAG---- VPVGLVNVVQG--GA ETGSLLCHHPNVAKV SFTGSVPTGKKVMEM    252 
retinal  MFTWK--IAPALCCG NTVVIKPAEQTPLSA LYMGALIKEAG---- FPPGVVNILPGY-GP TAGAAIASHIGIDKI AFTGSTEVGKLIQEA    255 
hmsd     LMTWK--VGPALACG NCVVVKPSEETPLTA TLLGEVMQAAG---- VPAGVYNVVHGFGGD SAGAFLTEHPDVDAY TFTGETGTGETIMRA    243 
Strep    LAGSK--IAPALIAG NVIAFKPPTQGSISG LLLAEAFAEAG---- LPAGVFNTITGR-GS EIGDYIVEHQAVNFI NFTGSTGIGERIGKM    241 
rat      LTIQP--MVGAVAAG NAVILKPSEVSGHMA DLLATLIPQYM---- DQNLYLVVKGG---- VPETTELLKERFDHI MYTGSTAVGKIVMAA    199 
vibrio   FSAAGGDTASALAAG CPVIVKGHTAHPGTS QIVAECIEQALKQEQ LPQAIFTLLQGN-QR ALGQALVSHPEIKAV GFTGSVGGGRALFNL    240 
   β5 
 ---      ---*-     * 
betaine  SAKT--VKHVTLELG GKSPLLIFKDCELEN AVRGALMANFLTQ-- GQVCTNGTRVFVQRE IMPQFLEEVVKRTKA IVVGDPLLT----ET    334 
retinal  AGRSN-LKRVTLELG GKSPNIIFADADLDY AVEQAHQGVFFNQ-- GQCCTAGSRIFVEES IYEEFVKRSVERAKR RIVGSPFDP----TT    338 
hmsd     AAKG--VRQVSLELG GKNAGIVFADCDMDK AIEGTLRSAFANC-- GQVCLGTERVYVERP IFDAFVARLKAGAEA LKIGEPNDP----EA    325 
Strep    AGMR----PIMLELG GKDSAIVLEDADLEL TAKNIIAGAFGYS-- GQRCTAVKRVLVMES VADELVEKIREKVLA LTIGNPED-----DA    320 
rat      AAKH--LTPVTLELG GKSPCYVDKDCDLDV ACRRIAWGKFMNS-- GQTCVAPDYILCDPS IQNQIVEKLKKSLKD FYGEDAKQ-----SR    280 
vibrio   AHERPEPIPFYGELG AINPTFIFPSAMRAK ADLADQFVASMTMGC GQFCTKPGVVFALNT PETQAFIETAQSLIR QQSPSTLLTPGIRDS    330 
            * 
betaine  RMGGLISKPQLDKVL GFVAQAKK-----EG ARVLCGGEPLTPSDP KLKNGYFMSPCVLDN CRDDMTCVKEEIFGP VMSVLPFDTEEEVLQ    419 
retinal  EQGPQIDKKQYNKIL ELIQSGVA-----EG AKLECGGKGLG---- --RKGFFIEPTVFSN VTDDMRIAKEEIFGP VQEILRFKTMDEVIE    417 
hmsd     NFGPLISHKPREKVP SYYQQAVD-----DG ATVVTGGGVPEMP-A HLAGGAWVQPTIWTG LADDSAVVTEEIFGP CCHIRPFDSEEEAIE    409 
Strep    DITPLIDTKSADYVE GLINDAND-----KG ATALTEIKREG---- -----NLICPILFDK VTTDMRLAWEEPFGP VLPIIRVTSVEEAIE    396 
rat      DYGRIINDRHFQRVK GLIDNQ--------- -KVAHGGTWDQ---- ---SSRYIAPTILVD VDPQSPVMQEEIFGP VMPIVCVRSLEEAIQ    353 
vibrio   YQSQVVSRGSDDGID VTFSQAESPCVASAL FVTSSENWRKHPAWE EEIFGPQSLIVVCEN VADMLSLSEMEAGSL TATIHATEEDYPQVS    420 
    ‡ 
betaine  RANNTTFGLASGVFT RDISRAHRVAANLEA GTCYINTYSIS--PV EVPFGGYKMSGFGRE NGQATVDYYSQLKTV IVEMGDVDSLF----    503 
retinal  RANNSDFGLVAAVFT NDINKALMVSSAMQA GTVWINCYNAL--NA QSPFGGFKMSGNGRE MGEFGLREYSEVKTV TVKIPQKNS------    499 
hmsd     LANSLPYGLASAIWT ENVRRAHRVAGQIEA GIVWVNSWFLR--DL RTAFGGSKQSGIGRE GGVHSLEFYTELKNI CVKL-----------    486 
Strep    ISNKSEYGLQASIFT NDFPRAFGIAEQLEV GTVHINNKTQRG-TD NFPFLGAKKSGAGIQ GVKYSIEAMTTVKSV VFDIK----------    475 
rat      FINQREKPLALYVFS NNEKVIKKMIAETSS GGVTANDVIVHITVP TLPFGGVGNSGMGAY HGKKSFETFSHRRSC LVKSL----------    433 























Figure 15.  Active site residues of ALDHs (83).  Abbreviations:  Vh-ALDH, Vibrio 

















































































Figure 18.  Reactions catalyzed by tautomerase superfamily members.  
Abbreviations, 4-OT, 4-oxalocrotonate tautomerase; MIF, macrophage migration 



































Figure 19.  The homoprotocatechuate pathway for the degradation of aromatic amino 
acids.  Abbreviations:  HPCO, homoprotocatechuate (homogentisate) dioxygenase; 
CHMSD, 5-carboxy-2-hydroxymuconate semialdehyde dehydrogenase; CHMI, 5-
carboxy-2-hydroxymuconate isomerase; COHED, 5-(carboxymethyl)-2-oxo-3-









































Figure 20.  Sequence alignment of 4-oxalocrotonate tautomerase (4-OT), YwhB, and 






1          11         21         31         41 
4-OT   PIAQIHILEG RSDEQKETLI REVSEAISRS LDAPLTSVRV IITEMAKGHF 
ywhB        PYVTVKMLEG RTDEQKRNLV EKVTEAVKET TGASEEKIVV FIEEMRKDHY 
CaaDα       PMISCDMRYG RTDEQKRALS AGLLRVISEA TGEPRENIFF VIREGSGINF 
CaaDβ       PFIECHIATG RSVARKQQLI RDVIDVTNKS IGSDPKIINV LLVEHAEANM 
 
            51      61         71 
4-OT   GIGGELASKV RR 
ywhB      AVAGKRLSDM E 
CaaDα       VEHGEHLPDY VPGNANDKAL IAKLK 






















































2-Hydroxymuconate semialdehyde dehydrogenase (E.C. 1.2.1.32, 2-HMSD) 
from Pseudomonas putida mt-2 catalyzes a reaction in the catechol meta-fission 
pathway (Scheme 1), oxidizing 2-hydroxymuconate semialdehyde (2-HMS, 1) to 2-
hydroxymuconate (2-HM, 2, Scheme 2), requiring NAD+ as a coenzyme (1).  The 
enzymes of this pathway, encoded by the TOL plasmid pWW0, allow soil bacteria to 
use toluene, xylenes, and other substituted aromatics as their sole sources of carbon 
and energy.  2-HMSD is reportedly a homodimer of ~52 kDa subunits (2).   
2-HMSD is a member of the semialdehyde dehydrogenase family within the 
aldehyde dehydrogenase (ALDH) superfamily of enzymes.  ALDHs are ubiquitous 
among both prokaryotes and eukaryotes.  They usually consist of ~500 amino acid 
monomers which assemble into homodimers or homotetramers in solution (3).  
ALDHs metabolize a vast array of aldehyde compounds which are often detrimental, 
causing cytotoxic reactions, cancer, and mutations (3).  Thus, these enzymes serve an 
important detoxification role in biological systems.  ALDHs also function in other 
cellular pathways such as glycolysis.  A nucleotide coenzyme is an absolute 
requirement for activity, with most ALDHs exhibiting a strong preference (as 
assessed by Km ) for either NAD+ or NADP+.   
On the basis of sequence alignment and crystallographic studies, a general 
catalytic mechanism can be formulated for ALDHs (Scheme 3).  An active site 
cysteine attacks the aldehyde group, forming a thiohemiacetal intermediate.  
Subsequent hydride transfer to the nucleotide coenzyme occurs, resulting in oxidation 
of the thiohemiacetal and concomitant reduction of the NAD(P)+ coenzyme.  
Deacylation of the enzyme leads to release of the carboxylate product.  Cysteine is far 
more reactive as the thiolate ion; the corresponding pKa in the enzyme active site is 
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typically ~8.5 (4).  Thus, another residue is thought to activate the cysteine by 
deprotonation.  In the Vibrio harveyi ALDH, this residue is a histidine (5), while in 
others, such as rat ALDH, it is a glutamate (6-8).  A conserved asparagine residue in 
the active site is thought to stablilize the thiohemiacetal intermediate through 
hydrogen bonding with the aldehyde oxygen (6, 9). 
The sequence alignment of 2-HMSD with several ALDHs whose crystal 
structures have been solved is illustrated in Figure 24.  The sequences shown 
represent the range of coenzyme and substrate specificity as well as a variety of host 
organisms.  Four of these ALDHs, including 2-HMSD, are NAD+-dependent.  The 
first structure determined in the superfamily was that of class 3 rat liver ALDH, 
which is analogous to the human enzyme involved in alcohol metabolism.  Betaine 
ALDH, found in humans and animals, converts betaine aldehyde to betaine, which 
can serve as a methyl donor in the biosynthesis of methionine and may also defend 
against osmotic stress (10, 11).  Retinal dehydrogenase, found in various animal 
tissues, catalyzes the conversion of retinal to retinoic acid.  Retinoic acid plays a 
variety of roles in differentiation and development, which are mediated through 
retinoid receptors.  The two remaining ALDHs in the alignment are NADP+-
dependent.  The ALDH from Streptococcus mutans catalyzes the irreversible 
oxidation of glyceraldehyde-3-phosphate into 3-phosphoglycerate, generating the 
NADPH necessary for growth and other biosynthetic pathways (12).  Lastly, the 
ALDH from Vibrio harveyi catalyzes the oxidation of long-chain aliphatic aldehydes, 
substrates for this bacterium’s chemiluminescence reaction (13). 
 Overall, the folds among the solved structures are quite similar despite 
differences in overall quaternary structure and the lack of a high degree of sequence 
identity.  This alignment suggests the identities of potential catalytic residues in 2-
HMSD.  Putative active site residues in 2-HMSD include Asn-155, Cys-287, Glu-
254, and Glu-390, indicated with an (*).  The histidine in Vibrio harveyi, His-450, 
that deprotonates the cysteine is denoted with a (‡) (5).  This residue is not conserved 
among the other ALDHs shown.  In 2-HMSD, the corresponding residue is Ala-439.  
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A non-classical α/β Rossman fold, the canonical binding motif for nucleotide 
coenzymes, is shared by aldehyde dehydrogenases (Figure 24).  The typical β-α-β 
Rossman fold (14) consists of six β-strands interconnected by five α-helices.  In the 
ALDH Rossman fold, the α5 helix and the β6 strand are missing (8).  The structure of 
the Rossman fold in 2-HMSD has not been determined. 
Only one structure from the semialdehyde dehydrogenase family has been 
determined to date, that of aspartate β-semialdehyde dehydrogenase (ASADH) (15).  
However, ASADH catalyzes a reductive dephosphorylation that can be considered 
analogous to the reverse reaction of 2-HMSD (Scheme 4).  Additionally, ASADH is 
an NADPH-dependent enzyme rather than an NADH-dependent one.  Thus, it is 
likely that at least the nucleotide-binding domain of ASADH differs from that of 2-
HMSD.  ASADH and 2-HMSD do not share a high degree of sequence identity due 
to the much shorter length of the former enzyme (367 vs. 486 amino acids) and a 
disparity in the locations of the catalytic cysteines (Cys-135 in ASADH, Cys-287 in 
2-HMSD).  It would thus be of great interest to determine the structure of 2-HMSD, 
which would be the first NAD+-dependent bacterial dehydrogenase structure 
available. 
4-Oxalocrotonate tautomerase (4-OT) follows 2-HMSD in the meta-fission 
pathway (Scheme 1).  It catalyzes a 1,3-keto-enol tautomerization as well as a 1,5-
keto-enol tautomerization (Scheme 5).  The overall reaction is the conversion of 2-
oxo-4-hexenedioate (3) to 2-oxo-3-hexenedioate (4) via the dienol intermediate 2 
(16).  Since 2 exists in an equilibrium with two keto isomers in solution, it is likely 
that 2-HMS does as well (Scheme 6).  The next enzyme in the pathway, 4-
oxalocrotonate decarboxylase (4-OD) uses 4 as its substrate (Scheme 7) (Thanuja’s 
17).  If 2-HMSD were to use the corresponding isomer of 2-HMS (i.e., 6) as 
substrate, yielding 4 as product, 4-OT would be unnecessary in the pathway.  Thus, it 
would be interesting to determine the isomeric equilibrium for 1 and to identify which 
isomer 2-HMSD processes. 
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The determination of the isomer of 2-HM generated by 2-HMSD would also 
identify the physiological substrate for 4-OT.  This issue has been of interest in the 
Whitman laboratory for several years.  Previous work has demonstrated that rapid 
equilibration occurs between 2 and 3, followed by a slower conversion to 4 in 
aqueous solution (16).  Kinetic and stereochemical studies indicate that both 2 and 3 
are substrates for 4-OT, with 2 being the preferred substrate, as determined by kcat/Km 
(16).  Although 2 is stable in the crystalline form, a direct determination of the true 
substrate for 4-OT has been precluded by the instability of 3, which cannot be 
synthesized or isolated. 
In order to gain a better mechanistic understanding of 2-HMSD and to shed 
light upon its relationship to 4-OT, we first cloned the gene, then expressed and 
purified the protein.  The gene for catechol 2,3-dioxygnease (C2,3O) was also cloned 
and the protein partially purified.  C2,3O was used to generate 2-HMS from catechol 
via enzymatic synthesis (Scheme 8).  The solution behavior of 2-HMS was examined 
by 1H and 13C NMR spectroscopy.  Subsequently, we conducted a kinetic analysis of 
2-HMSD with a variety of substrates (1, 8-11, Figure 25) and examined a potential 
inhibitor, the monoethyl ester of 2-HM (12, Figure 25).  The role of the putative 
catalytic cysteine (Cys-287), identified through sequence analysis, was also 
investigated by irreversible inactivation experiments and site-directed mutagenesis.   
In the course of this investigation, we determined that 2-HMS is a cyclic 
acetal when isolated by acidification and extraction (Scheme 9).  NMR experiments 
indicate the resulting 6-membered ring (14) is stable in organic solvents but opens in 
aqueous solution to give 1.  The 2-HMSD-catalyzed physiological reaction (Scheme 
2) yields 2 as product, suggesting that 2 is the cellular substrate for 4-OT.  2-HMSD 
also shows broad substrate specificity.  Among the compounds investigated, 2-HMSD 
prefers 4-carboxybenzaldehyde (11), perhaps because its structure mimics the 
conformation of 1 that the enzyme requires (Figure 26).  We also found that 12 is a 
competitive inhibitor of 2-HMSD, making it a useful ligand for future 
crystallographic studies.  Furthermore, mutation of Cys-287 yielded inactive (C287A) 
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or insoluble (C287S) protein.  These results, coupled with time-dependent irreversible 
inactivation using iodoacetamide (15), indicate that Cys-287 is required for activity, 




MATERIALS AND METHODS 
 
 Materials.  Tryptone, yeast extract, and agar were obtained from Difco 
(Detroit, MI) or Fisher Scientific (Pittsburgh, PA).  Restriction enzymes, PCR 
reagents, Taq DNA polymerase, Platinum Taq High Fidelity DNA polymerase and 
T4 DNA ligase were obtained from F. Hoffmann-La Roche, Ltd. (Basel, Switzerland) 
or Promega Corp. (Madison, WI).  Pfu DNA polymerase was obtained from 
Stratagene (La Jolla, CA).  Thin-walled PCR tubes were obtained from Ambion 
(Austin, TX).  Oligonucleotides for DNA amplification and sequencing were 
synthesized by either Genosys (The Woodlands, TX) or Oligos Etc. (Wilsonville, 
OR).  The Wizard Plus Minipreps and PCR Preps DNA Purification Systems were 
obtained from Promega.  The remaining molecular biology reagents including 
agarose, DNA ladders, and protein molecular weight standards, were obtained from 
Invitrogen Corporation (Carlsbad, CA).  The 0.2 µM PES syringe filters were 
obtained from Nalge Nunc International (Rochester, NY).  The Amicon stirred cells 
and ultrafiltration membranes were obtained from Millipore Corp. (Billerica, MA).  
The pET-24a(+) plasmid was obtained from Novagen (Madison, WI).  All other 
reagents were obtained from Sigma-Aldrich, Inc. (St. Louis, MO).   
 Strains.  Escherichia coli strain DH5α (Invitrogen) was used for cloning and 
isolation of plasmids.  E. coli strains BL21(DE3)pLysS (Novagen) and BL21-
Gold(DE3)pLysS (Stratagene) were used for recombinant protein expression.   
Methods.  Techniques for restriction enzyme digestions, ligation, 
transformation, and other standard molecular biology manipulations were based on 
methods described elsewhere (18), or as suggested by the manufacturer.  Plasmid 
DNA was introduced into cells by electroporation using a Cell-Porator 
Electroporation System (Whatman Biometra, Göttingen, Germany).  The PCR was 
performed in a DNA thermal cycler (Model 480) obtained from PerkinElmer Inc. 
(Wellesley, MA).  Colony screening by the PCR is based on methods described in the 
pET System Manual (Novagen).  DNA sequencing was done at the DNA Core 
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Facility in the Institute for Cellular and Molecular Biology at the University of Texas 
(Austin).  Kinetic data were obtained on a Hewlett Packard 8452A or an Agilent 8453 
Diode Array spectrophotometer.  Solutions in cuvettes were mixed using a stir/add 
cuvette mixer (Bel-Art Products, Pequannock, NJ).  The kinetic data were fitted by 
nonlinear regression data analysis using the Grafit program (Erithacus Software Ltd., 
Horley, U. K.) obtained from Sigma Chemical Co.  HPLC was performed on a 
Waters (Milford, MA) 501/510 system or a Beckman System Gold HPLC (Fullerton, 
CA) using a TSKgel Phenyl-5PW hydrophobic column or a TSKgel DEAE-5PW 
anion exchange column (Tosoh Biosciences, Montgomeryville, PA).  Protein was 
analyzed by Tris glycine sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) under denaturing conditions on 10-17.5% gels using either the Mini-
Protean II or III vertical gel electrophoresis apparatus obtained from Bio-Rad 
(Hercules, CA) (19).  Protein concentrations were determined using the method of 
Waddell (20).  The NMR spectra were recorded in 100% H2O on a Varian Unity 
INOVA-500 spectrometer using selective pre-saturation of the water signal with a 2-s 
pre-saturation interval.  The lock signal is dimethyl-d6 sulfoxide.  Chemical shifts are 
standardized to the dimethyl-d6 sulfoxide signal at 2.49 ppm.   
Construction of the C2,3O expression vector.  Catechol 2,3-dioxygenase has 
previously been cloned from Pseudomonas putida mt-2, and its structure has been 
determined (21, 22).    In order to synthesize 1, the xylE gene was cloned from 
Pseudomonas putida mt-2 using overlap extension PCR (23) to remove an internal 
NdeI restriction site.  The TOL plasmid was prepared as described elsewhere (17).  
The external primers were oligonucleotides 5'-GGT ATT CCA TAT GAA CAA 
AGG TGT AAT G-3' (primer A) and 5'-CGG AAT TCT CAG GTC AGC ACG GT-
3' (primer D).  Primer A contains 7 bases (to facilitate digestion), an NdeI restriction 
site (underlined), and 15 bases corresponding to the nucleotide sequence of the first 
five amino acids of C2,3O.  Primer D contains 9 bases (to facilitate digestion), an 
EcoRI restriction site (underlined), and 8 bases corresponding to the reverse 
complement of the C2,3O nucleotide sequence.  The internal primers were 5'-ACA 
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GCC ATA AGC CAT CAG ATC-3' (primer B) and 5'-GAT CTG ATG GCT TAT 
GGC TGT-3' (primer C).  In each internal primer, the mutation (a single base) is 
underlined and remaining bases correspond to the coding sequence (primer C) or the 
complementary sequence (primer B) of the gene. 
  For the construction of the AB and CD fragments, each PCR reaction 
contained 5 µL of 20 µM solutions of primers A and B or C and D, 2 µL of a 10 mM 
stock of dNTPs, 10 µL of 10x Taq reaction buffer, 6 µL of 25 mM MgCl2, 8 µL of 
template, 1 µL of Taq, and a sufficient quantity of sterile water to make a final 
volume of 100 µL.  The PCR protocol consisted of a 2-min incubation period at 94 
°C, followed by 20 cycles of the PCR where each cycle contained a denaturation step 
at 94 °C for 2 min, an annealing step at 50 °C for 2 min, and an elongation step at 72 
°C for 3 min, and a final 5-min incubation period at 72 °C.  The amplified products 
were analyzed by electrophoresis on 0.8% agarose gels and purified using the Wizard 
PCR Preps system.  For the construction of the AD fragment, each PCR reaction was 
assembled similarly except that 5 µL of each of the AB and CD fragments were used 
as template.  The PCR protocol consisted of a 2-min incubation period at 94 °C, 
followed by 25 cycles of the PCR where each cycle contained a denaturation step at 
94 °C for 1 min, an annealing step at 55 °C for 75 s, and an elongation step at 72 °C 
for 75 s, and a final 10-min incubation period at 72 °C.  The AD fragment was 
electrophoresed.  Two bands (~850 and ~950 bp) were observed, which were both 
excised and purified using the Wizard PCR Preps system.  
Subsequently, the purified PCR products and the pET-24a(+) vector were  
treated with the NdeI and EcoRI restriction enzymes for 3 hrs at 37° C.  The digestion 
products were electrophoresed on a 0.8% agarose gel.  Further purification was 
achieved by use of the Wizard PCR Preps system.  The resulting fragments were 
ligated using T4 ligase (0.1 µL of 10 units/µL) at room temperature overnight.  The 
DNA was precipitated from the mixture and re-suspended in sterile water (5 µL), 
which was used to transform E. coli strain DH5α cells by electroporation according 
to the manufacturer’s instructions.  The transformed cells were treated as previously 
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described (21), plated on LB/Kn (50 µg/mL) agar plates, and grown overnight at 37 
°C.  Growth resulted on plates containing the larger (i.e., ~950 bp) C2,3O fragment.  
Colony screening was performed on 20 colonies to detect the presence of insert.  Four 
colonies were selected for plasmid isolation and sequencing.  Only one of the four 
plasmids contained the correct sequence.  This plasmid was designated pET-24a(+)-
C2,3OA.   
Aliquots (0.5-1 µL) of pET-24a(+)-C2,3OA were used to transform either E. 
coli strain BL21(DE3)pLysS or E. coli strain BL21-Gold(DE3)pLysS cells by 
electroporation following the manufacturer’s directions.  An aliquot (50 µL) was 
plated on LB/Kn (50 µg/mL) agar plates, and grown overnight at 37 °C.  In the 
presence of IPTG (0.5 mM) and catechol (µM), cells expressing C2,3O gave rise to a 
yellow color, indicating the production of 2-HMS (24).   
Overexpression and Partial Purification of C2,3O.  A 50 mL culture of LB 
containing kanamycin (50 µg/mL) was inoculated with a single colony of the 
expression strain and grown overnight at 37° C.  Subsequently, a sufficient quantity 
of the overnight culture was used to inoculate 500 mL of LB/Kn medium in a 2 L 
Erlenmeyer flask to give an OD600nm reading of ~0.05.  Cultures (6-2L flasks) were 
grown at 37° C to an OD600nm of ~0.6-0.8 with vigorous shaking and induced with 0.5 
mM IPTG.  Cells were harvested after three hours of growth and stored at -80° C 
until use.  Typically, 2 L of culture yields 5 g cells. 
C2,3O was partially purified using a published protocol modified as follows 
(25).  The cells (5 g) were thawed, resuspended in 3 volumes (14 mL) of 10 mM 
ethylenediamine buffer containing 10% isopropanol (pH 7.4), placed on ice, and 
initially disrupted by sonication at 50% output for 30 s.  Phenylmethylsulfonyl 
fluoride (0.5 mM) and 6-aminocaproic acid (1 mM) were added to the cell 
suspension.  Subsequently, the cell suspension was subjected to further sonication for 
four 5-min intervals using 5-s pulses with a cycle time of 50%.  After each 5-min 
interval, the cells were allowed to sit for 5 minutes.  Protamine sulfate (2% of the cell 
weight, 96 mg) was added to the lysate, and the resulting mixture was stirred for 10 
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min at 4 °C and centrifuged at 19,000 rpm for 30 min at 4 °C.  The supernatant was 
filtered through a 0.2 µM PES syringe filter.  
The filtered supernatant was loaded onto a DEAE-5PW anion-exchange 
column (21.5 mm x 15 cm) previously equilibrated in 10 mM ethylenediamine buffer, 
pH 7.4 (Buffer A).  Protein was eluted using a 10 min wash of 100% Buffer A, 
followed by 2-25 min linear sodium sulfate gradients (0-0.15 M, 0.15-0.25 M), and a 
final 10-min wash with 0.5 M sodium sulfate.  The flow rate was 5 mL/min.  
Fractions (7.5-10 mL) were collected and assayed for activity.  Fractions were 
assayed for activity using a mixture containing 2 µL catechol (165 mM in EtOH), 5 
µL of the fraction, and 1 mL of 100 mM sodium phosphate buffer, pH 7.3.  The 
increase in absorbance at 375 nM, due to the formation of 1, was monitored.  
Typically, the C2,3O activity elutes at ~0.17 M sodium sulfate.  The most active 
fractions were pooled (~70 mL), concentrated, and exchanged into 20 mM sodium 
phosphate (pH 7.3) using an Amicon stirred cell containing a YM-10 membrane.  
This purification resulted in ~150 mg of ~75% pure protein as assessed by SDS-
PAGE.   
Construction of the 2-HMSD expression vector.  The xylG gene from 
Pseudomonas putida mt-2 was cloned in two stages using a modification of overlap 
extension PCR (23).  DNA from the TOL plasmid was isolated using the Wizard Plus 
Minipreps.  The external primers used were 5'-AGA GAT TGT GCA TAT GAA 
AGA AAT CAA GCA T-3' (primer A) and 5'-GTT CAT GAG CGG CCG CCT CAA 
AGT TTC ACA CAG AT-3' (primer D).  Primer A contains 10 bases (to facilitate 
digestion), an NdeI restriction site (underlined), and 15 bases corresponding to the 
coding nucleotide sequence of the first five amino acids.  Primer D contains 7 bases 
(to facilitate digestion), a NotI restriction site, 1 additional base, and 18 bases 
corresponding to the reverse complement of a stop codon and the nucleotide sequence 
for the last five amino acids of 2-HMSD.  The internal primers were 5'-GCC TGC 
ATC ACC TCG CCG A-3' (primer B) and 5'-GGT CAA ACC ATC CGA GGA A-3' 
(primer C).  These primers correspond to the nucleotide coding sequence of 2-HMSD 
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including the last base of Val-177 through Glu-183, and the reverse complement of 
the sequence including the last base of Leu-189 through Gln-195, respectively. 
For the construction of the AB and CD fragments, each PCR reaction 
contained 2 µL of 20 µM solutions of primers A and B or C and D, 2 µL of a 10 mM 
stock of dNTPs, 10 µL of Pfu reaction buffer, 15 µL of the TOL plasmid, 2 µL of Pfu, 
and a sufficient quantity of sterile water to make a final volume of 100 µL.  The PCR 
protocol consisted of a 45-s incubation period at 94 °C, followed by 25 cycles of the 
PCR in which each cycle contained a denaturation step at 94 °C for 45 s, an annealing 
step at 55 °C for 45 s, and an elongation step at 72° C for 3.5 min, and a final 10 min 
incubation period at 72 °C.  The amplified products were analyzed by electrophoresis 
on 0.8% agarose gels and purified using the Wizard PCR Preps system.  The AD 
fragment was constructed similarly except that the AB and CD fragments (5 µL of 
each) were used as template, and the 72 °C elongation step for each cycle was 
increased to 4 min.  A band of the anticipated size (~1500 bp) was excised after 
analysis by gel electrophoresis and purified using the Wizard PCR Preps.   
The purified AD fragment and the pET-24a(+) vector were treated with NdeI 
and NotI overnight at 37 °C.  The digestion products were electrophoresed and 
purified using the Wizard PCR Preps.  Ligation and precipitation of the DNA were 
carried out as described previously.  The purified DNA was used to transform E. coli 
strain DH5α by electroporation following the manufacturer’s instructions.  The 
transformed cells were treated and incubated as described above.  Colony screening 
was performed on four colonies to detect the presence of insert.  Subsequent 
sequencing of one plasmid, designated pET-24a-2-HMSD 8, indicated differences 
from the published sequence (Genbank Accession No. CAC86805).  This plasmid 
was used for all further studies.  Preparation of the expression strain 
(BL21(DE3)pLysS or BL21-Gold(DE3)pLysS) was performed as described above. 
Overexpression and Purification of 2-HMSD.  The expression strain was 
grown under the conditions described above.  Typically 3L of culture yields 6-7 g of 
cells.  2-HMSD was purified by modifying a series of previously published 
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procedures (1, 2, 26).  The buffers used in this purification are Buffer A:  50 mM 
KH2PO4 buffer containing 10% isopropanol, pH 8.2; Buffer B:  50 mM KH2PO4 
buffer made 1 M in (NH4)2SO4, pH 7.4; and Buffer C:  50 mM KH2PO4 buffer, pH 
7.4.  The cells (6 g) were thawed, resuspended in 3 volumes (18 mL) of buffer A, 
placed on ice, and initially disrupted by sonication at 50% output for 30 s.  
Phenylmethylsulfonyl fluoride (0.5 mM) and 6-aminocaproic acid (1 mM) were 
added to the cell suspension.  Subsequently, the cell suspension was subjected to 
further sonication for three 5-min intervals using 5-s pulses with a cycle time of 50%.  
After each 5-min interval, the cells were allowed to sit for 5 minutes.  Protamine 
sulfate (2% of the cell weight, 0.12 g) was added to the lysate.  The mixture was 
stirred for 10 min at 4 °C and centrifuged at 17,000 rpm for 30 min at 4 °C.  
The resulting supernatant was filtered through a 0.2 µm syringe filter and 
loaded onto a DEAE-5PW anion-exchange column previously equilibrated in Buffer 
A.  Protein was eluted using a 10-min wash of 100% Buffer A, followed by a 50 min 
linear gradient (0-1 M) in sodium chloride, and a final 10-min wash with 1 M NaCl.  
The flow rate was 5 mL/min.  Fractions (7.5-10 mL) were collected and assayed for 
activity.  Typically, 2-HMSD elutes at ~0.25 M NaCl.  The most active fractions were 
pooled (~60 mL) and concentrated using an Amicon stirred cell equipped with a YM-
30 membrane.  The resulting concentrate (~10 mL) was made 1 M in (NH4)2SO4 and 
allowed to stir for 1 hr at 4 °C.  After centrifugation at 15,000 rpm for 30 min, the 
supernatant was removed and loaded onto a Phenyl-5PW hydrophobic column (21.5 
mm x 15 cm) equilibrated in Buffer B.  Protein was eluted using a 10 min wash of 
100% Buffer B, followed by a 30 min linear gradient (1-0 M) using Buffer C, and a 
final 20-min wash with 100% Buffer C.  Fractions were assayed and concentrated as 
before.  2-HMSD elutes during the final wash.  The purity was judged to be ~99% as 
assessed by SDS-PAGE.  The overall yield is approximately 15-30 mg of 
homogenous protein per liter of culture.  For this preparation, a 3-L culture gave 90 
mg of protein.  
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Construction of the C287A and C287S 2-HMSD Mutants.  Two mutants were 
constructed by overlap extension PCR as described elsewhere (23). Sequence 
alignment shows that a single cysteine is conserved at position 287.  Thus, Cys-287 
was mutated to an alanine and a serine.  The external primers for the construction of 
the alanine mutant were primers A and D as described in the construction of the 2-
HMSD expression vector.  The internal primers were 5′ - TCG GTG CCC AGT GCG 
ACC TGT CC - 3′ (primer B) and 5′ - GGA CAG GTC GCA CTG GGC ACC GA - 
3′ (primer C).  In each internal primer, the mutation is underlined and the remaining 
bases correspond to the coding sequence (primer C) or the complementary sequence 
(primer B) of 2-HMSD.   
For the construction of the AB and CD fragments for the C287A mutant, each 
PCR reaction contained 1 µL of 20 µM solutions of primers A and B or C and D, 1 µL 
of a 10 mM stock of dNTPs, 5 µL of 10 × Platinum Taq reaction buffer, 2 µL of 50 
mM MgSO4, 1 µL of pET-24a-2-HMSD8, 0.4 µL Platinum Taq High Fidelity, and a 
sufficient quantity of sterile water to make a final volume of 50 µL.  The PCR 
protocol consisted of a 45-s incubation period at 94 °C, followed by 35 cycles of the 
PCR where each cycle contained a denaturation step at 94 °C for 30 s, an annealing 
step at 50 °C for 45 s, and an elongation step at 68 °C for 2 min, and a final 10-min 
incubation period at 68 °C.   The amplified products were analyzed by electrophoresis 
on 0.8% agarose gels and purified using the Wizard PCR Preps DNA purification 
system.   
The AD fragment was constructed similarly except that the AB and CD 
fragments (2 µL of each) were used as template.  The AD fragment was 
electrophoresed, excised, and purified using the Wizard PCR Preps system.  
Restriction digests and subsequent DNA purification were performed as described 
previously.  The resulting fragments were ligated using T4 ligase (0.1 µL of 10 
units/µL) at room temperature for 1 hr.  An aliquot (1 µL) of the ligation was diluted 
five-fold with sterile water and used to transform E. coli strain DH5α cells by 
electroporation.  The transformed cells were treated as previously described (21), 
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plated on LB/Kn (50 µg/mL) agar plates, and grown overnight at 37 °C.  Plasmid 
DNA was isolated from the single colony that resulted.  Sequencing of the 
surrounding bases (~400 bp) indicated that the mutation was present, and that no 
other mutations had been introduced in that section of the gene.  This plasmid was 
designated pET-24a-2-HMSD-C287A. 
The external primers for the C287S mutant were oligonucleotides 5'-GCG 
GAT AAC AAT TCC CCT CT-3' (primer A) and 5'-CTC AGC TTC CTT TCG GGC 
TT-3' (primer D).  Primer A corresponds to a region 36 bases upstream of the NdeI 
restriction site in the pET-24a(+) plasmid, while primer D corresponds to the 
complementary sequence of a region 20 bases downstream of the His-tag region in 
the pET-24a(+) plasmid.  The internal primers were primer B from the C287A mutant 
and oligonucleotide 5′ - GGA CAG GTC AGT CTG GGC ACC GA - 3′ (primer C).  
In primer C, the mutation is underlined and the remaining bases correspond to the 
coding sequence of the gene. 
For the construction of the AB and CD fragments for the C287S mutant, each 
PCR reaction contained 1 µL of 20 µM solutions of primers A and B or C and D, 1 µL 
of a 10 mM stock of dNTPs, 5 µL of 10 × Pfu  buffer, 1 µL of pET-24a-2-HMSD8, 1 
µL of Pfu DNA Polymerase, and a sufficient quantity of sterile water to make a final 
volume of 50 µL.  The PCR protocol used was the same as that used for the synthesis 
of the AB and CD fragments for wild-type 2-HMSD. The amplified products were 
analyzed by electrophoresis on 0.8% agarose gels.  Two bands (~1 kb) were observed 
from the AB reaction; a single band (~500 bp) was observed from the CD reaction.  
Each band was purified using the Wizard PCR Preps DNA purification system.  The 
AD fragment was constructed similarly except that the AB and CD fragments (2.5 µL 
of each) were used as template, and the same PCR protocol was followed.  A single 
band (~1500 bp) was observed after electrophoresis, which was excised and purified 
using the Wizard PCR Preps system.   
Restriction digests and subsequent purification of the pET-24a(+) vector and 
the AD fragment were performed as described previously.  The resulting fragments 
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were ligated using T4 ligase (0.1 µL of 10 units/µL) at room temperature for 2 hr.  An 
aliquot (2 µL) of the ligation mixture was diluted five-fold with sterile water and used 
to transform E. coli strain DH5α cells by electroporation.  The transformed cells were 
treated as previously described (21), plated on LB/Kn (50 µg/mL) agar plates, and 
grown overnight at 37 °C.  Two colonies resulted, from which plasmid DNA was 
isolated.  Sequencing of the surrounding bases (~400 bp) indicated that the mutation 
was present in both plasmids, and that no other mutations had been introduced in that 
portion of the gene.  These plasmids were designated pET-24a-2-HMSD C287S 1 and 
pET-24a-2-HMSD C287S 2. 
Overexpression of the C287A and C287S 2-HMSD Mutants.  For expression, 
each mutant plasmid was transformed into BL21(DE3)pLysS by electroporation.  
Cells were selected for as described previously and grown using the protocol 
described for wild-type 2-HMSD.  Subsequently, the C287A mutant was purified 
using the procedure used for wild-type 2-HMSD.  One liter of culture yields 2 g of 
cells and 15 mg of protein.  Approximately half of the induced protein is found in the 
initial pellet after cell lysis.  One liter of C287S HMSD culture yields 2 g of cells.  
However, all of the induced protein was found in the cell pellet.  Therefore, no further 
attempt at purification was pursued. 
Synthesis of 2-HMS (1).  Compound 1 was generated enzymatically using 
C2,3O as follows.  Catechol (200 mg, 1.8 mmol) was dissolved in 20 mM sodium 
phosphate buffer (30 mL, pH 7.5).  To this mixture was added a 100 µL aliquot of 
C2,3O (11.5 mg/mL).  Pure oxygen gas was bubbled directly into the reaction as it 
stirred.  Subsequently, aliquots (50 µL) of C2,3O were added every 15 min (4x) and 
the pH adjusted to 7.3-7.6 with aliquots of 1 M NaOH.  When the pH no longer 
required adjustment, indicating that the acid was no longer being generated, the 
reaction was complete.  As the reaction progressed, a yellow color appeared which 
turned to deep red, indicative of the formation of 1.  The solution was acidified to pH 
~2 with 8.5% phosphoric acid and extracted with ethyl acetate (3x30 mL).  The 
organic layers were pooled, dried over anhydrous Na2SO4, filtered, and evaporated to 
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dryness at room temperature.  The resulting solid was dissolved in ethyl acetate and 
recrystallized.  The compound is stable at room temperature as a solid.  A 1H NMR 
spectrum taken in deuterated methanol indicates that compound 14 is isolated.  
However, the 1H NMR spectrum indicates that compound 1 exists in aqueous 
solution.  The yield of 14 was 48 mg (0.3 mmol, 17%).   
Enzymatic Assays and Kinetic Studies of 2-HMSD.  The kinetic assays were 
performed in 50 mM KH2PO4 buffer, pH 8.5 using 1 or 8-11 and NAD+.  Stock 
solutions of NAD+ (0.1 M) were made in buffer (50 mM KH2PO4, pH 8.5) and stored 
at 4 °C.  The solutions were stable for a week under these conditions.  Solutions of 
NAD+ (5, 25, and 50 mM) were made by diluting the stock solution appropriately into 
50 mM KH2PO4 buffer, pH 8.5.  Stock solutions of 1 (20 mM), 9 (200 mM), 10 (200 
mM), and 11 (20 mM) were prepared in ethanol.  Solutions of 1 and 11 (2 mM) and 
10 (100 mM) were made by appropriate dilution of stock solutions with ethanol.  
Stock solutions (154 mM) of 8 were prepared in 50% DMSO/50% water (v/v).    
 To measure the kinetic parameters for compounds 1 and 8-11, a sufficient 
quantity of 2-HMSD was diluted into buffer (40 mL).  NAD+ was added to the 
incubation mix at a saturating condition (1 mM, 10 µL of a 0.1 M solution) as 
described elsewhere (1, 2, 26).  The enzyme/coenzyme mixture was equilibrated at 23 
°C for at least 15 min prior to assaying.  The quantities of enzyme used with the 
indicated compounds are as follows, diluted from a 3.0 mg/mL solution of 2-HMSD:  
1, 80 µL/40 mL; 8 and 9, 120 µL/40 mL; 10, 800 µL/40 mL; 11, 80 µL/40 mL.  The 
final concentrations of enzyme ranged from 10-8-10-6 M.  Subsequently, a 1 mL-
portion of the mixture was transferred to a cuvette and assayed by the addition of a 
small quantity of substrate.  For 1, the decrease in absorbance at 375 nm (ε2-HMS = 
33,000 M-1 cm-1), corresponding to the decrease in the concentration of substrate, was 
monitored.  For all other substrates, the increase in absorbance at 340 nm (εNADH = 
6220 M-1 cm-1), corresponding to the formation of NADH, was monitored.  The 
concentrations of substrate were as follows:  1, 2-40 µM; 8, 200-1600 µM, 9, 200 
µM, 10, 100-1000µM, 11, 2-50 µM.   
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To measure the kinetic parameters for NAD+ as substrate, a sufficient quantity 
of 2-HMSD (120 µL of a 3.0 mg/mL solution) was diluted into buffer (40 mL) and 
equilibrated at 23 °C for at least 15 min prior to assaying.  After transfer of an aliquot 
(1 mL) to a cuvette, varying amounts of NAD+ (12.5-200 µM) were added by 
appropriate dilutions of 5, 25, or 50 mM solutions of the coenzyme.  Reactions were 
initiated by the addition of 11 at a saturating condition (200 µM, 10 µL of a 20 mM 
solution).  The increase in absorbance at 340 nm, corresponding to the formation of 
NADH, was monitored. 
Kinetics of Irreversible Inhibition with Iodoacetamide (15).  2-HMSD (3.0 
mg/mL, 58 µM based on the monomer molecular weight) was divided into 100 µL 
quantities and placed in dark eppendorf tubes at room temperature prior to the 
addition of inhibitor.  Subsequently, varying amounts of 15 (nine concentrations 
ranging from 75-1000 µM) were added to the incubation mixtures.  The volume of 
inhibitor added did not exceed 10% of the final volume.  Aliquots (4 µL) were 
removed immediately after the addition of inhibitor at 10-s intervals, diluted into 50 
mM potassium phosphate buffer (1 mL, pH 8.5) containing 1 mM NAD+, and assayed 
for residual activity.  The assay was initiated by the addition of 11 (200-250 µM).  
Stock solutions of 15 (50 mM) were made up in 50 mM potassium phosphate buffer 
(pH 7.4), resulting in a final pH of ~7.  The stock solutions were diluted with a 
sufficient volume of 50 mM potassium phosphate buffer (pH 7.4) to make 0.5 mM 
and 5 mM solutions.  Rates of inactivation (kobs) were determined from a least-
squares fit of the data obtained from the initial linear portion of the decrease in 
activity to the equation for a first-order decay using Microsoft Excel.  The rate 
constants (KI and kinact) were determined by fitting the data as previously described 
(27).  Typically, 2-3 experiments were performed at each inhibitor concentration. 
Competitive Inhibition of 2-HMSD.  The reversible competitive inhibition of 
2-HMSD was examined using 12.  For these experiments, a quantity of 2-HMSD (95 
µL of a 22.8 mg/mL solution) was added to 95 mL of assay buffer [50 mM potassium 
phosphate buffer (pH 8.5), 1 mM NAD+] and incubated at 22 °C for ~15 min.  
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Subsequently, the diluted enzyme solution was separated into portions (13 mL) and 
stored at 22 °C.  An aliquot of 12 was added to a portion of the solution to yield the 
approximate final inhibitor concentration.  After ~5 min, aliquots (1 mL) were 
removed and assayed using eleven concentrations of 1 (2-40 µM).  The final 
concentrations of 12 were 0-100 µM, which were diluted from a stock solution (50 
mM) made up in ethanol.  The final pH of the enzyme solution was ~8.1 after 
addition of the inhibitor in all cases.  The kinetic data were fitted using the equation 






Cloning, Expression, and Purification of C2,3O and 2-HMSD.  The gene for 
C2,3O has been cloned from a variety of sources.  The enzyme from P. putida mt-2 
has been overexpressed, purified, and crystallized (21, 22).  2-HMSD has previously 
been purified from P. putida mt-2, using either the TOL plasmid pWW0 as the source 
of the gene or using a constitutively expressed subclone of the TOL plasmid (1, 2).  
The yield of protein using these sources of protein was not reported.  Thus, 2-HMSD 
has not previously been overexpressed.    
In this study, the genes for both C2,3O (xylE) and 2-HMSD (xylG) were 
amplified from the TOL plasmid pWW0.  C2,3O was required for the synthesis of the 
compound 1, the substrate for 2-HMSD.  Accordingly, both enzymes were cloned 
into the T7 expression system for overexpression in E. coli strains BL21(DE3)pLysS 
or BL21-Gold(DE3)pLysS.  C2,3O was partially purified (~75% pure as assessed by 
SDS-PAGE) using a DEAE-5PW anion-exchange column.  Further purification was 
not necessary because the enzyme was used only for the synthesis of 1. 
Purification of 2-HMSD using anion-exchange and hydrophobic interaction 
chromatography yielded 15-30 mg protein per liter of culture that was essentially 
(~99%) pure as assessed by SDS-PAGE.  DNA sequencing revealed several 
differences between the published sequence and the sequence from our expression 
plasmid, pET-24a-2-HMSD, raising a question about the accuracy of either or both 
sequences.  Since the apparent mutations observed in pET-24a-2-HMSD were 
observed in other clones that had been isolated, and the polymerase used for cloning 
was a low-error polymerase, the reported sequence is likely not correct.  Moreover, 
the measured kinetic parameters for 1 suggested that the protein generated by this 
clone was the correct one.  Neither the quaternary structure nor the molecular mass of 
2-HMSD was determined.  The expression systems for both C2,3O and 2-HMSD 
have yielded high levels of active protein, setting the stage for future studies, 
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including x-ray crystallography or stopped-flow kinetics, that require large amounts 
of protein. 
 Cloning, Expression, and Purification of the C287A and C287S 2-HMSD 
Mutants.  Sequence alignment with other aldehyde dehydrogenases (Figure 24) 
identified several conserved residues that could be involved in the catalytic 
mechanism of 2-HMSD, including a cysteine, two glutamates, and an asparagine.  
Cys-287, which aligns with Cys-297 of betaine ALDH, Cys-302 of retinal 
dehydrogenase, and Cys-243 of rat liver ALDH (Figure 24) was mutated to an alanine 
and a serine residue to determine whether it was essential for activity.  Both mutants 
were constructed using overlap extension PCR using pET-24a-2-HMSD as template.  
The resulting plasmids were transformed into BL21(DE3)pLysS for expression and 
purification.  The sequences immediately surrounding the mutations (~400 bp) were 
confirmed, suggesting that nearby residues have not been changed.  Expression of the 
C287S resulted in insoluble protein.  This suggested a disruption in the overall 
structure of the mutant protein.  In light of this finding, further purification of the 
C287S mutant was not pursued.  Expression of the C287A mutant yielded ~50% 
soluble protein after cell lysis.  The soluble protein was purified following the wild-
type procedure.  The overall yield was 15 mg/L protein. 
Synthesis of 2-HMS.  2-HMS (1) was synthesized using C2,3O, which 
converts catechol to 2-HMS.  It has been previously reported that C2,3O undergoes 
suicide inactivation by the substrate (25).  Thus, pure oxygen was bubbled into the 
reaction in order to enhance the enzyme’s activity.  Additionally, the enzyme was 
added in aliquots over time to reduce the amount of inactivation that might occur.  
Conversion of catechol to 1 resulted in a decrease in pH, which was adjusted with 
aliquots of NaOH to maintain neutrality.  When the pH no longer decreased, the 
reaction was considered complete.  Extraction and re-crystallization with ethyl acetate 
resulted in 14 as determined by 1H and 13C NMR spectroscopy.  No further 
purification was carried out.   
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Kinetic Properties of 2-HMSD and C287A-2-HMSD.  In previous studies on 
2-HMSD, buffers such as Tris (pH 8.5), glycine-NaOH (pH 9.2-9.6), and CAPS (pH 
9.6) were used for enzymatic assays (1, 2, 26).  Amine buffers can react with the 
aldehyde substrates, forming a Schiff base, and thereby affect the results of kinetic 
studies.  Phosphate buffer, however, is inert towards aldehydes.  Another reason for 
investigating the reaction of 2-HMSD in phosphate buffer was to facilitate NMR 
studies, since the organic buffers would show signals in the NMR spectra, 
complicating their interpretation.  Thus, the activity of 2-HMSD was determined in 
50 mM potassium phosphate buffer, pH 8.5, by UV-Vis spectroscopy.  The pH was 
chosen on the basis of published pH rate work, suggesting that 2-HMSD functioned 
optimally at pH ~8.3 (2).   
Initially, 2-HMSD was mistakenly identified as benzaldehyde dehydrogenase 
from P. putida (2, 26). To determine the substrate specificity of the “benzaldehyde 
dehydrogenase,” Harayama and co-workers tested 8 as well as several 
monosubstituted benzaldehydes with 2-HMSD (2, 26).  The substituents included 
methyl-, methoxy-, halo-, and nitro-groups as well as p-carboxybenzaldehyde (11).    
For some of substrates, kinetic parameters were determined.  For others, including 11, 
only a specific activity in units/mg was described.  These determinations were 
performed at a single substrate concentration, so that no kinetic parameters were 
reported.  Additionally, the initial kinetic parameters for NAD+ were determined 
using benzaldehyde under conditions that did not saturate the enzyme (10 µM).  
Later, after correctly identifying the enzyme, 2-HMSD was characterized with 1, but 
new parameters for NAD+ were not determined. 
In this investigation, 1, 8, 11, and NAD+ were examined, and the previously 
unstudied carboxy-substituted benzaldehydes (9, 10, Table 1) were also assessed as 
substrates.  Kinetic parameters were obtained for all compounds that showed activity.   
The kinetic parameters determined among substrates investigated in both this work 
and in previous work differ to some extent.  The kinetic parameters for NAD+ are not 
comparable because the previous values were not determined under saturating 
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conditions.  Interestingly, the kcat values obtained here for 1 (13.4 s-1) and 8 (4.2 s-1) 
are ~10 s-1 less than the published values (27.2 and 14.7 s-1, respectively).  These 
differences may indicate the non-enzymatic reaction in organic buffers that do not 
occur in phosphate buffer.  The Km value obtained here for 8 (457 µM) is equal to the 
reported value (460 µM), while the Km for 1 (5.7 µM) is three-fold lower than 
reported (17 µM).  Compared to the kcat/Km value obtained for 1, 8 shows a 260-fold 
decrease in activity.  The high Km value observed for 8 is likely due to the absence of 
a carboxylate, which may be bound by a residue in the active site. 
Compounds 9-11 were of interest because they each possess an aldehyde and 
a carboxylate group.  Although 11 was investigated earlier (2), the authors did not 
recognize the potential similarities between 1 and 11.  Compound 11 is the preferred 
substrate for 2-HMSD as determined by its kcat/Km value.  The Km for 1 is 2.6 times 
greater than that of 11, while the kcat values are comparable.  This results in an overall 
two-fold increase in kcat/Km.  The difference in Km values may reflect the greater 
flexibility of 1 in solution, compared to the rigid structure of 11.  Compounds 9 and 
10 were poor substrates for 2-HMSD.  No activity is observed using 9 as substrate, 
which may be a result of the adjacent positions of the substituents.  Compound 10 is a 
very poor substrate in comparison to 1 and 11, with the kcat/Km values differing 428-
fold and 893-fold, respectively.  Both Km (22 to 57-fold) and kcat (16 to 20-fold) also 
show significant decreases.  Although 10 contains both an aldehyde and a carboxylate 
substituent, the meta-positioning of these groups is not the optimal alignment for 
binding or turnover in the active site.   
The kinetic values for NAD+ were not determined using 1 due to the presence 
of an isobestic point at 340 nm.  Compound 11 is the preferred substrate for 2-HMSD 
as assessed by kcat/Km.  Thus, 11 was used at a saturating condition (200 µM, 100x 
Km) to determine the kinetic parameters for NAD+.  The observed kcat is 4 s-1, while 
the Km is 27 µM.  These values cannot be compared to published values because the 
previous values were determined under non-saturating conditions with a poor 
substrate (8) (1, 26). 
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C287A 2-HMSD showed no detectable activity by UV-Vis spectroscopy upon 
incubation with 1 under the conditions used for the wild-type for 30 s.  This result 
was consistent with the sequence analysis implicating Cys-287 in catalysis.  The fact 
that the purified mutant protein eluted under the same conditions as the wild-type 
suggested that it retained the correct structure despite the mutation.  The quaternary 
structure of the mutant enzyme was not determined. 
Inactivation of 2-HMSD by Iodoacetamide.  Incubation of 2-HMSD with 
iodoacetamide results in time-dependent inactivation of the enzyme.  The decrease in 
activity is linear for approximately 4 half-lives (Figure 27).  The kobs values measured 
in 26 experiments were plotted versus the inhibitor concentration and fit to a 
rectangular hyperbola (Figure 28).  The values of kinact and KI obtained from this plot 
are 0.032 ± 0.007 s-1 and 820 ± 290 µM.  The hyperbolic inactivation is consistent 
with the formation of a dissociable complex between the enzyme and iodoacetamide 
before covalent attachment and inactivation.   
Competitive Inhibition of 2-HMSD by 12. On the basis of the structures of the 
1 and 2, and the previous report that 2-HMSD possesses esterase activity 
(Shaw/Harayama), 12 was examined as a potential inhibitor of 2-HMSD.  However, 
compound 12 did not show evidence of time-dependent inactivation.  When an 
aliquot of 2-HMSD (44.2 µM with respect to the monomer) was incubated with an 
excess (1 mM) of 12, the enzyme retained full activity after 13 hr incubation at 4 °C.  
Subsequently, 12 was examined as a reversible competitive inhibitor.  It was found to 
be a competitive inhibitor with a Ki value of 40 ± 8 µM.  This value is 7-fold and 18-





 Enzymes of the aldehyde dehydrogenase superfamily catalyze the oxidation of 
an aldehyde as well as the reduction of an acid.  While this general reaction has been 
investigated in many contexts, the ALDH mechanism has not been completely 
characterized.  Human liver aldehyde dehydrogenase is the most notable ALDH, as it 
is partially responsible for the metabolism of ethanol.  Moreover, a mutation in the 
enzyme gives rise to alcohol intolerance, and drugs such as disulfiram, which are 
used to treat alcoholics, are known to inhibit this enzyme.  A variety of ALDHs have 
been investigated due to interest in their roles in growth, metabolic and biosynthetic 
pathways, and detoxification.  A sample of the functions that these enzymes serve is 
demonstrated by the enzymes of Figure 24. 
The variety of roles that ALDHs play, as well as the substrates that they 
accept, suggest reasons for their apparent divergent evolution.  Some similarities are 
shared among members in the superfamily, such as the active-site cysteine.  However, 
differences in structure are to be expected due to differences in substrate and 
coenzyme specificity.  For example, most ALDHs use either NAD+ or NADP+, but 
not both.  It was believed that the binding of the coenzymes would be different in 
NAD+ or NADP+-dependent enzymes.  This was verified by crystallography.  In 
NAD+-dependent ALDHs, a conserved lysine [indicated by a (+) in Figure 24] or a 
glutamate [indicated by a (¶) in Figure 24] have been reported to interact with the 2′ 
and 3′ oxygen atoms of the ribose ring of the adenine moiety (8, 10).  In NADP+-
dependent ALDHs, the conserved lysine interacts with two oxygens of the NADP+ 2′-
phosphate.  A threonine residue (¶) replaces the glutamate in these enzymes, 
providing a pocket for the phosphate group of NADP+ (12, 28).  Steric hindrance 
from surrounding residues as well as negative electrostatic interactions are thought to 
prevent the phosphate group of NADP+ from binding in NAD+-dependent ALDHs 
(12).  Furthermore, differences in accessibility to the active site appear to influence 
substrate specificity among ALDHs.  Enzymes, such as the rat liver ALDH, that 
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readily oxidize acetaldehyde have channels for diffusion of the substrate.  However, 
retinal dehydrogenase has a disordered substrate channel that may bind long-chain 
aldehydes using a “hand-in-glove” fit (29). 
2-HMSD, which catalyzes the oxidation of 2-HMS (1) to the corresponding 
acid 2, has not been rigorously examined.  The enzyme was initially identified 
incorrectly as the benzaldehyde dehydrogenase from P. putida (2).  Although the 
gene was identified, it was not cloned into a vector for overexpression.  The protein 
was purified to homogeneity using a four-step procedure, and its quaternary structure, 
corresponding to homodimerization, was determined by gel filtration.  Other physical 
properties were also determined, such as stability, isoelectric point, and stoichiometry 
with NAD+.  Due to its incorrect identification, the enzyme was characterized with 
benzaldehyde (8), mono-substituted analogs possessing methyl-, methoxy-, nitro, 
chloro-, and fluoro- groups at various positions around the ring, and 11.  For some 
compounds including 11, a single substrate concentration was assessed for specific 
activity, and kinetic parameters were not determined.  Kinetic parameters for NAD+ 
were determined using non-saturating concentrations of a poor substrate (8).  Assays 
were performed in organic buffers including Tris, glycine-NaOH, and CAPS, which 
are amines that could react with the aldehyde moiety.  Upon correct identification of 
the enzyme, the kinetic parameters for 1 were determined, but those for NAD+ were 
not recalculated using the physiological substrate.   
In previous studies, compound 1 was synthesized enzymatically (1), but the 
procedure used was not reported.  A characterization of the compound has not been 
reported either, apart from the characteristic λmax of 375 nm.  In addition, 1 is not 
likely to be stable under aqueous conditions.  Compound 1 may undergo ketonization 
to 5 and 6 in aqueous buffer (Scheme 6).  The solution chemistry of 1, the presumed 
physiological substrate, has not been characterized.   
Mechanistic and structural questions regarding this enzyme have not been 
addressed.  Among these questions are the mechanics of how the reaction is carried 
out, the identities and functions of crucial residues in catalysis, and the structure of 
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the enzyme.  Although two potential residues in catalysis, Cys-287 and Glu-254, have 
been identified in previous work, no mutagenesis work was performed (1).  In the 
most recent investigation by Inoue et al., crystals of 2-HMSD diffracting to 2.5 Å 
were obtained (1).  However, the corresponding structure has not been published.  
Identification of the product of the 2-HMSD-catalyzed reaction would suggest the 
physiological substrate for 4-OT, the next enzyme in the meta-fission pathway.  The 
identity of this substrate, either 2 or 3, has not been directly addressed.  Studies to 
address these many questions require copious amounts of enzyme as well as rigorous 
characterization of the solution chemistry of a compound (1) that is most easily 
generated by enzymatic synthesis.  The results of this investigation represent a 
significant step forward in addressing these issues and suggest directions for future 
mechanistic and structural studies. 
 Our strategy relied on expressing 2-HMSD under control of the T7 promoter, 
which resulted in large amounts of active protein.  2-HMSD was purified to 
homogeneity using anion-exchange chromatography followed by hydrophobic 
interaction chromatography.  Due to its apparent highly hydrophobic nature, 2-HMSD 
eluted from the hydrophobic column during the final buffer wash, resulting in highly 
concentrated, pure protein.  The recombinant protein showed comparable kinetic 
values to those previously reported for 1, suggesting that recombinant 2-HMSD is 
properly folded.  Verification of the molecular mass or the quaternary structure of the 
protein were not performed to further confirm the identity of 2-HMSD due to 
equipment constraints.   
A similar approach was used for the expression of C2,3O, which was required 
for the synthesis of 2-HMS (1), the substrate for 2-HMSD.  Although C2,3O was only 
partially purified (~75%), the expression system generates large amounts of protein, 
which is useful for the synthesis of 2-HMS.  Enzymatic synthesis of 2-HMS yielded 
only 2-HMS as product.  The finding that the isolated compound was 14 was not 
surprising, since acetals result under acidic conditions and the product is a stable six-
membered ring.  Compound 14 is stable for at least three years at room temperature.  
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As a result of the acidification and extraction process, the starting material 13 is 
readily separated from 2-HMS. Thus, although the yield of 2-HMS (17%) was rather 
low, 13 could easily be recycled for further synthesis.  This property is particularly 
useful for the generation of isotopically-labelled 1.  Organic synthesis of 2-HMS from 
commercially available reagents would require considerably more effort and time.  
C2,3O may be used to oxidize substituted catechols as well, allowing analogs of 2-
HMS to be easily synthesized. 
We examined several substrates for 2-HMSD in order to probe its structural 
requirements and to gain insight into potential active site features.  Compound 1 is a 
flexible molecule with many possible conformations, two of which (s-trans and s-cis) 
are illustrated in Figure 26.  Thus the aldehyde and carboxylate moieties can assume 
various positions in aqueous solution.  To investigate the preferred positioning of 
these substituents within the enzyme, a series of carboxy-substituted benzaldehydes 
(9-11) were tested as substrates.  Benzaldehyde (8) was also investigated to provide a 
reference point, apart from 1, with which the obtained kinetic parameters could be 
compared. 
The results presented in Table 1 indicated that 2-HMSD is able to oxidize 
compounds 8, 10, and 11.  A discrepancy is observed between the published (14.7 s-1) 
and observed (4.2 s-1) kcat values for 8.  Since a similar discrepancy of 10 s-1 is also 
observed with 1, this may be attributable to a non-enzymatic reaction in buffer.  
However, the observed Km of 457 µM using 8 agrees with the published Km.  It is not 
surprising that benzaldehyde is a very poor substrate for 2-HMSD, as evidenced by its 
higher Km.  2-HMS is a long, linear molecule with polar substituents, while 
benzaldehyde is a cyclic compound that lacks the carboxylate and hydroxyl groups 
found in 2-HMS.  These groups are likely to be important in binding.  Indeed, the 
presence of a carboxylate group in 1 and 11 results in 260-fold and 540-fold rate 
enhancements, respectively, compared to 8.  This suggests that the carboxylate is 
important for binding. 
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The presence of both functional groups alone is not sufficient for catalysis, 
however.  These results also show that the carboxylate group must be properly 
aligned with respect to the aldehyde.  For example, 2-HMSD is not able to process 9.  
Although 9 has both functional groups, their ortho-positions apparently do not allow 
9 to fit correctly into the active site.  2-HMSD processes 10, in which the two 
substituents are meta- to each other, although poorly.  The observed kcat and kcat/Km 
values for 10 are the lowest among the investigated substrates.  The 3-fold decrease in 
Km for 10 compared to 8 again indicates that a carboxylate group improves binding. 
Compound 11 is the best substrate for 2-HMSD, as evidenced by its kinetic 
parameters, probably because its fixed conformation optimally positions the 
carboxylate and aldehyde groups.  In 11, the carboxylic acid group is maintained 
para- to the aldehyde substituent.  This structure mimics one of the possible s-cis 
conformations of 1 in solution (Figure 26).  In solution, the s-trans conformation is 
favored due to a decrease in steric hindrance.  However, the active site of the enzyme 
may bind 1 in the s-cis conformation that resembles 11 as a result of particular 
structural residues.  The observation that compound 11 is preferred over 1, the 
physiological substrate, suggests that the active site may form a channel that 
preferentially binds molecules in which the carboxylate and aldehyde functional 
groups are aligned as far apart as possible.  A positively charged residue, such as a 
lysine or an arginine, may reside within the active site, binding the carboxylate group.   
The kinetic parameters of 2-HMSD (using 1) were compared with those of 
other aldehyde dehydrogenases.  Succinic semialdehyde dehydrogenase (SSADH) 
and aspartate β-semialdehyde dehydrogenase (ASADH) are two other members of the 
semialdehyde dehydrogenase family (30-32).  Although these enzymes prefer 
different substrates (succinic semialdehyde and NAD+ and β-aspartyl phosphate and 
NADP+, respectively), general comparisons can be made.  For SSADH, the Km values 
are 4-15 µM for the aldehyde and 31-130 µM for the nucleotide, and for ASADH, the 
Km values are 14 µM for the phosphate and 42 µM for the nucleotide.  Thus, these 
semialdehyde dehydrogenases each have lower Km values for their aldehyde 
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substrates compared to the nucleotide coenzymes.  Unfortunately, kcat values have not 
reported, so neither kcat nor kcat/Km can be compared.   
Interestingly, the TOL plasmid of P. putida mt-2 encodes a benzaldehyde 
dehydrogenase.  The reported parameters for 8 as a substrate for this enzyme were a 
Km of 2.5 µM and a kcat/Km of 1.7 x 107 (1).  These values are similar to the 
corresponding parameters for 2-HMSD using 1 as a substrate, although there is a 7-
fold difference in kcat/Km.  Furthermore, although 2-HMSD accepts 8 as a substrate, 
benzaldehyde dehydrogenase reportedly does not accept 1.  Thus, these enzymes 
appear to have evolved to fulfill specific roles in the organism which apparently do 
not overlap in function. 
Sequence analysis permitted the identification of putative active site residues.  
These residues included Asn-155, Cys-287, Glu-254, and Glu-390.  Cys-287 is likely 
the catalytic base as illustrated in Scheme 3.  Asn-155 may stabilize the 
thiohemiacetal intermediate through hydrogen bonding to the oxygen atom.  One of 
the two glutamate residues may deprotonate the cysteine.  Crystal structures suggest 
that the effect of the glutamate may be mediated via a water molecule or a 
conformational change, since the residue itself seems to be too far (~8 Å) from the 
aldehyde substrate to directly deprotonate (6, 9).   
The role of the cysteine was investigated by affinity labeling and site-directed 
mutagenesis.  Cys-287 was mutated to an alanine and a serine.  The C287A mutant 
retained no apparent activity, which was consistent with a possible role in catalysis.  
Since the mutant purified in a manner similar to the wild-type, it is likely that it did 
not suffer from a major change in structure.  Additional study is necessary to verify 
this assumption.  It was anticipated that the C287S mutant would exhibit decreased 
activity due to the presence of a hydroxyl rather than a thiol group.  Unfortunately, 
the C287S mutant resulted in completely insoluble protein, which suggested that the 
protein was improperly folded.  This may have been due to the C287S mutation, or 
perhaps to the inadvertent mutation of unknown amino acids outside the area that was 
sequenced were.  Further purification and analysis of this mutant was not attempted. 
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Iodoacetamide is one reagent commonly used in the detection of catalytic 
cysteines (33).  The mechanism of iodoacetamide is illustrated in Scheme 10.  In this 
process, the activated cysteine directly attacks the iodide-substituted methyl group.  
Iodide is readily displaced because it is a good leaving group.  This results in covalent 
modification of the enzyme, yielding a carboxyamidated cysteine.  2-HMSD was 
inactivated by iodoacetamide.  The inactivation of the enzyme appears to follow 
saturation kinetics, which is indicative of the formation of a dissociable active site 
complex prior to inactivation.  The precise target for modification was not determined 
but is currently under investigation. 
The results of the site-directed mutagenesis and irreversible inhibition studies 
clearly implicate C287 in catalysis.  Another way to explicitly assign Cys-287 in 
catalysis is through x-ray crystallography.  It would be useful to have either an 
irreversible or a reversible inhibitor as a ligand in the active site, around which the 
active site residues could align.  Iodoacetamide is not a good potential ligand due to 
its small size compared to the substrate, 1, and its potential reactivity over the time 
required to generate crystals (~2-3 weeks in some cases).  Thus the ethyl ester of 2-
HM (12) was examined as a potential ligand.  ALDHs, including 2-HMSD, have been 
shown to possess esterase activity (2, 34, 35).  If 2-HMSD has esterase activity, it 
might be irreversibly modified (Scheme 11) by 12.  Over time, the enzyme might be 
re-activated upon exposure to protons in solution.  However, time-dependent 
inactivation was not demonstrated using 12, indicating that it was not an irreversible 
inhibitor.  However, 12 did prove to be a good competitive inhibitor of 2-HMSD.  
The Ki, although approximately 7 to 18-fold higher than the Km values for the best 
substrates, suggests that this compound may be useful as a ligand for structural 
studies. 
UV-Vis and NMR data suggest that the substrate for 2-HMSD is 1 and not 5 
or 6.  These data also indicate that the product of 2-HMSD is 2.  Thus, 4-OT, the next 
enzyme in the pathway, is required for the processing of 2 to afford 4, which is 
processed by 4-OD as substrate.  These data may be further verified by obtaining the 
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structure of 2-HMSD with 12.  It would be interesting to determine whether or not 1 
and/or 2 tautomerize within the active site of 2-HMSD.   
The results presented herein set the stage for further analysis of 2-HMSD.  A 
number of experiments can still be done to delineate the roles of active site residues.  
The three other putative active site residues identified by sequence alignment (Asn-
155, Glu-254, and Glu-390) were not analyzed in this work, but they could be 
mutated to determine the effects on the activity of the protein.  An x-ray structure of 
2-HMSD can be pursued because both an efficient expression and purification 
procedure have been developed.  The characterization of a potent reversible 
competitive inhibitor, 12, makes a ligand for such studies available.  Stopped-flow or 
rapid quench experiments may be used to “trap” the thiohemiacetal intermediate, 
which has been observed.  Future studies of 2-HMSD will not only shed light on its 
mechanism, but also provide insight as to this enzyme’s evolutionary relationship to 
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Figure 24.  Sequence alignment of aldehyde dehydrogenases (ALDHs) generated 
using CLUSTAL-W.  From top to bottom, betaine dehydrogenase, retinal 
dehydrogenase, 2-hydroxymuconate semialdehyde dehydrogenase, Streptococcus 
mutans ALDH, rat ALDH, Vibrio harveyi ALDH.   
 
(*) indicates conserved residues. (-) indicates the Rossman fold.  (+) and (¶) indicate 
residues for nucleotide binding.  (‡) indicates an unconserved histidine implicated in 
catalysis.  Symbols are located above the appropriate residue(s). 
 
betaine  AQLVDSMPSASTGSV VVTDDLNYWGGRRIK SKDGATTEPVFEPAT GRVLCQMVPCGAEEV DQAVQSAQAAYLK-- -WSKMAGIERSRVML     87 
retinal  -ASLQLLPSPTPN-- LEIKYTKIFINNEWQ NSESGRVFPVCNPAT GEQVCEVQEADKVDI DKAVQAARLAFSLGS VWRRMDASERGRLLD     88 
hmsd     --------------- ---KEIKHFISGELV GSASGKLFDNVSPAN GQVIGRVHEAGRAEV DAAVRAARAALKG-- PWGKMTVAERAEILH     71 
Strep    --------------- --TKQYKNYVNGEWK LSENE--IKIYEPAS GAELGSVPAMSTEEV DYVYASAKKAQPA-- -WRALSYIERAAYLH     69 
rat      --------------- --------------- --------------- ------------SSI SDTVKRAREAFNS-- -GKTRSLQFRIQQLE     31 
vibrio   --------------- NPQTDNVFYATNAFT GEALPLAFPVHTEVE VNQAATAAAKVARDF RRLNNSKRASLLR-- ------TIAS-ELEA     67 
            β1 
           ---- * ---  
betaine  EAARIIRERRDNIAK LEVINNGK-TITEAE YDIDAAWQCIEYYAG LAPTLSGQHIQLPG- -----GAFAYTRREP LGVCAGILAWNYPFM    170 
retinal  KLADLVERDRATLAT MESLNGGKPFLQAFY IDLQGVIKTLRYYAG WADKIHGMTIPVDG- -----DYFTFTRHEP IGVCGQIIPWNFPLL    172 
hmsd     RVADGITARFGEFLE ARMPGHRQAEVAGQP HRHSARRANFKVFAD LLKNVANEAFEMATP DGA--GALNYGVRRP KGVIGVISPWNLPLL    159 
Strep    KVADILMRDKEKIGA ILSKEVAK-GYKSAV SEVVRTAEIINYAAE EGLRMEGEVLEGGSF EAASKKKIAVVRREP VGLVLAISPFNYPVN    158 
rat      ALQRMINENLKSISG ALASDLGKNEWTSYY EEVAHVLEELDTTIK ELPDWAEDEPVAKTR QTQ--QDDLYIHSEP LGVVLVIGAWNYPFN    119 
vibrio   RSDDIIARAHLETAL PEVRLTGEIARTANQ LRLFADVVNSGSYHQ AILDTPNPTRAPLP- -----KPDIRRQQIA LGPVAVFGASNFPLA    151 
    a1                     β2       α2           β3                α3                    β4  α4 
          ----------        ---+  ¶  ---------------   -----     -------      -----    --------- 
betaine  IAAWK--CAPALACG NAVVFKPSPMTPVTG VILAEIFHEAG---- VPVGLVNVVQG--GA ETGSLLCHHPNVAKV SFTGSVPTGKKVMEM    252 
retinal  MFTWK--IAPALCCG NTVVIKPAEQTPLSA LYMGALIKEAG---- FPPGVVNILPGY-GP TAGAAIASHIGIDKI AFTGSTEVGKLIQEA    255 
hmsd     LMTWK--VGPALACG NCVVVKPSEETPLTA TLLGEVMQAAG---- VPAGVYNVVHGFGGD SAGAFLTEHPDVDAY TFTGETGTGETIMRA    243 
Strep    LAGSK--IAPALIAG NVIAFKPPTQGSISG LLLAEAFAEAG---- LPAGVFNTITGR-GS EIGDYIVEHQAVNFI NFTGSTGIGERIGKM    241 
rat      LTIQP--MVGAVAAG NAVILKPSEVSGHMA DLLATLIPQYM---- DQNLYLVVKGG---- VPETTELLKERFDHI MYTGSTAVGKIVMAA    199 
vibrio   FSAAGGDTASALAAG CPVIVKGHTAHPGTS QIVAECIEQALKQEQ LPQAIFTLLQGN-QR ALGQALVSHPEIKAV GFTGSVGGGRALFNL    240 
   β5 
 ---      ---*- 
betaine  SAKT--VKHVTLELG GKSPLLIFKDCELEN AVRGALMANFLTQ-- GQVCTNGTRVFVQRE IMPQFLEEVVKRTKA IVVGDPLLT----ET    334 
retinal  AGRSN-LKRVTLELG GKSPNIIFADADLDY AVEQAHQGVFFNQ-- GQCCTAGSRIFVEES IYEEFVKRSVERAKR RIVGSPFDP----TT    338 
hmsd     AAKG--VRQVSLELG GKNAGIVFADCDMDK AIEGTLRSAFANC-- GQVCLGTERVYVERP IFDAFVARLKAGAEA LKIGEPNDP----EA    325 
Strep    AGMR----PIMLELG GKDSAIVLEDADLEL TAKNIIAGAFGYS-- GQRCTAVKRVLVMES VADELVEKIREKVLA LTIGNPED-----DA    320 
rat      AAKH--LTPVTLELG GKSPCYVDKDCDLDV ACRRIAWGKFMNS-- GQTCVAPDYILCDPS IQNQIVEKLKKSLKD FYGEDAKQ-----SR    280 
vibrio   AHERPEPIPFYGELG AINPTFIFPSAMRAK ADLADQFVASMTMGC GQFCTKPGVVFALNT PETQAFIETAQSLIR QQSPSTLLTPGIRDS    330 
            * 
betaine  RMGGLISKPQLDKVL GFVAQAKK-----EG ARVLCGGEPLTPSDP KLKNGYFMSPCVLDN CRDDMTCVKEEIFGP VMSVLPFDTEEEVLQ    419 
retinal  EQGPQIDKKQYNKIL ELIQSGVA-----EG AKLECGGKGLG---- --RKGFFIEPTVFSN VTDDMRIAKEEIFGP VQEILRFKTMDEVIE    417 
hmsd     NFGPLISHKPREKVP SYYQQAVD-----DG ATVVTGGGVPEMP-A HLAGGAWVQPTIWTG LADDSAVVTEEIFGP CCHIRPFDSEEEAIE    409 
Strep    DITPLIDTKSADYVE GLINDAND-----KG ATALTEIKREG---- -----NLICPILFDK VTTDMRLAWEEPFGP VLPIIRVTSVEEAIE    396 
rat      DYGRIINDRHFQRVK GLIDNQ--------- -KVAHGGTWDQ---- ---SSRYIAPTILVD VDPQSPVMQEEIFGP VMPIVCVRSLEEAIQ    353 
vibrio   YQSQVVSRGSDDGID VTFSQAESPCVASAL FVTSSENWRKHPAWE EEIFGPQSLIVVCEN VADMLSLSEMEAGSL TATIHATEEDYPQVS    420 
    ‡ 
betaine  RANNTTFGLASGVFT RDISRAHRVAANLEA GTCYINTYSIS--PV EVPFGGYKMSGFGRE NGQATVDYYSQLKTV IVEMGDVDSLF----    503 
retinal  RANNSDFGLVAAVFT NDINKALMVSSAMQA GTVWINCYNAL--NA QSPFGGFKMSGNGRE MGEFGLREYSEVKTV TVKIPQKNS------    499 
hmsd     LANSLPYGLASAIWT ENVRRAHRVAGQIEA GIVWVNSWFLR--DL RTAFGGSKQSGIGRE GGVHSLEFYTELKNI CVKL-----------    486 
Strep    ISNKSEYGLQASIFT NDFPRAFGIAEQLEV GTVHINNKTQRG-TD NFPFLGAKKSGAGIQ GVKYSIEAMTTVKSV VFDIK----------    475 
rat      FINQREKPLALYVFS NNEKVIKKMIAETSS GGVTANDVIVHITVP TLPFGGVGNSGMGAY HGKKSFETFSHRRSC LVKSL----------    433 




Figure 25.  Top, potential substrates for 2-HMSD: 8, benzaldehyde, 9, 2-
carboxylbenzaldehyde, 10, 3-carboxybenzaldehyde, 11, 4-carboxybenzaldehyde.  























Figure 26.  Top, two possible conformations of 2-HMS (1).  Left, s-trans, right, s-cis.  




















Figure 27.  The inactivation of 2-HMSD after incubation with varying amounts of 15 
(filled triangles, 75 µM; empty triangles, 100 µM; empty diamonds, 150 µM; filled 
diamonds, 250 µM; empty squares, 400 µM; filled squares, 800 µM; empty circles, 


























Figure 28.  Determination of the kinact and KI values for 15. A plot of the kobsd values 
for inactivation measured in 26 experiments as a function of varying amounts of 7 
(75-1000 µM). The values of kinact and KI obtained from this plot are 0.032 ± 0.007 s-1 








































13.4 ± 1.1 
 
 
5.7 ± 1.1 
 
2.4 x 106 
8 4.2 ± 0.5 
 
457.2 ± 142.6 9.2 x 103 
9 No activity 
 
No activity No activity 
10 0.7 ± 0.02 
 
124.3 ± 13.9 5.6 x 103 
11 11.1 ± 0.4 
 
2.2 ± 0.4 5.0 x 106 
NAD+ 4.2 ± 0.2 
 




aThe steady-state kinetic parameters were determined in 50 mM potassium phosphate  
buffer (pH 8.5) at 23 °C.  Errors are standard deviations.  
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REACTIONS OF TRANS-3-CHLOROACRYLIC ACID DEHALOGENASE 
WITH ACETYLENE SUBSTRATES:  CONSEQUENCES OF AND 





  The enzyme trans-3-chloroacrylic acid dehalogenase (CaaD) converts the 
trans-isomers of 3-bromo- and 3-chloroacrylates (1, Scheme 12) to malonate 
semialdehyde (3) (1-3).  CaaD has been isolated from Pseudomonas pavonaceae 
strain 170 and is part of a pathway that enables the bacterium to use either 3-
chloroacrylate or 1,3-dichloropropene as sources of carbon and energy (4).  The latter 
compound is one of the active ingredients in the commercial products Shell D-D and 
Telone II, which are mixed in with the soil and used to control plant-parasitic 
nematodes (5).   
  The genes for the dehalogenase were recently cloned from the P. pavonaceae 
strain, the gene expressed, and the enzyme purified and characterized (3).  The 
enzyme is a heterohexamer, consisting of 3 α-subunits, each having 75 amino acid 
residues, and 3 β-subunits, each having 70 amino acid residues.  Sequence analysis 
revealed similarities between the α-subunit of CaaD and a bacterial isomerase, 4-
oxalocrotonate tautomerase (4-OT), and the β-subunit of CaaD and a 4-OT 
homologue found in Bacillus subtilis and designated YwhB.  Both 4-OT and YwhB 
are homohexamers, with monomers that consist of 62 and 61 amino acids, 
respectively (6, 7).   
  The mechanism of 4-OT has been studied extensively over the past decade 
(7).  The amino-terminal proline functions as a general base, converting 2-oxo-4-
hexenedioate (4, Scheme 13) to 2-oxo-3-hexenedioate (6) through a dienol 
intermediate, known commonly as 2-hydroxymuconate (5) (7).  Arg-39 and an 
ordered water molecule provide hydrogen bonds to the carbonyl oxygen of 4, thereby 
facilitating deprotonation at C-3 (8, 9).  Arg-11 interacts with the C-6 carboxylate 
group and functions as an electron sink to draw electron density to the C-5 position 
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for protonation.  Phe-50 plays a role in maintaining the hydrophobicity of the active 
site, which assists in catalysis and contributes to the lowered pKa of Pro-1 (10).  
Significantly, both the α− and β− subunits of CaaD have an amino-terminal proline 
while the α-subunit has Arg-11 (3).   
  These similarities and the results of mutagenesis experiments prompted 
Janssen and co-workers to suggest a mechanism involving the addition of water to the 
double bond of 1 to form the unstable chlorohydrin intermediate, 2 (3).  Subsequent 
collapse to 3 can occur by either the direct expulsion of the chloride or by the α,β-
elimination of HCl, followed by ketonization (11).  Pro-1 of the β-subunit was 
identified as a critical mechanistic residue because the P1A mutant had no activity 
while mutation of Pro-1 in the α-subunit (to an alanine) had little effect on activity 
(3).  Two possible roles were proposed for Pro-1 (3).  It could function as a general 
base to activate the water molecule for attack at C-3 of 1 (as shown in Scheme 14) or 
it could function as a general acid to protonate C-2 of 1 while the water molecule is 
activated in some other manner.  Arg-11 of the α-subunit was also identified as a 
critical residue because the R11A mutant was inactive.  It is proposed that Arg-11 
interacts with the C-1 carboxylate group of the 3-haloacrylate.   
  The mechanism of CaaD and the parallels between it and 4-OT are intriguing 
and raise several questions.  One of the more exciting questions concerns how the two 
enzymes evolved and diverged to catalyze such different reactions.  In order to gain a 
better mechanistic understanding of CaaD, and to ultimately address this evolutionary 
question, we conducted a kinetic analysis of CaaD and examined its behavior with 
three acetylene substrates.  In the course of this investigation, we developed an 
efficient expression system for CaaD as well as a direct UV spectrophotometric assay 
to monitor its activity, and verified that 3 is the product of the reaction.  We further 
determined that CaaD converts 2-oxo-3-pentynoate (7, Scheme 15) to acetopyruvate 
(8), suggesting that 3-bromo- and 3-chloropropiolioate (9 and 10, respectively) might 
function as mechanism-based inhibitors of CaaD.  Both compounds were found to be 
potent irreversible inhibitors of CaaD with the sole target of modification by 9 being 
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Pro-1 in the β-subunit.  Thus, CaaD hydrated the three acetylene compounds, but the 
resulting products had different consequences for the enzyme.  These observations are 
consistent with an enzyme-catalyzed hydration reaction and indicate that the 3-
halopropiolic acids are promising candidates for further mechanistic and structural 




MATERIALS AND METHODS 
 
  Materials.  All reagents, buffers, and solvents were obtained from Aldrich 
Chemical Co. (Milwaukee, WI), Sigma Chemical Co. (St. Louis, MO), Fisher 
Scientific Inc. (Pittsburgh, PA), Spectrum Laboratory Products, Inc (New Brunswick, 
NJ), or EM Science (Cincinnati, OH) with the following exceptions.  The trans-3-
chloroacrylate was obtained from Fluka Chemical Corp. (Milwaukee, WI).  Literature 
procedures were used for the syntheses of 2-oxo-3-pentynoate (7) (12), 3-bromo- and 
3-chloropropiolic acids (9 and 10), and the trans-isomer of 3-bromoacrylate (11) (13, 
14).  Tryptone, yeast extract, and agar were obtained from Becton, Dickerson, and 
Company (Franklin Lakes, NJ).  The Ultrafree DA centrifugal filter units, the YM-3 
ultrafiltration membranes, and the Amicon concentrators were obtained from 
Millipore Corp. (Billerica, MA).  The thin-walled PCR tubes were obtained from 
Ambion, Inc. (Austin, TX).  Restriction enzymes, PCR reagents, and T4 DNA ligase 
were obtained from F. Hoffmann-La Roche, Ltd. (Basel, Switzerland), Promega 
Corp. (Madison, WI), or New England Biolabs (Beverly, MA).  The Wizard PCR 
Preps DNA purification system was purchased from Promega Corp.  The QIAprep 
Spin Miniprep kit was obtained from Qiagen, Inc. (Valencia, CA).  The remaining 
molecular biology reagents including agarose, DNA ladders, and protein molecular 
weight standards, were obtained from Invitrogen Corporation (Carlsbad, CA).  
Oligonucleotides for DNA amplification and sequencing were synthesized by either 
Oligos Etc. (Wilsonville, OR) or Genosys (The Woodlands, TX).   
  Strains.  Escherichia coli strains DH5α (Invitrogen) and JM109 (Promega) 
were used for cloning and isolation of plasmids.  E. coli strains BL21(DE3)pLysS 
from Novagen and BL21-Gold(DE3)pLysS from Stratagene (La Jolla, CA) were used 
for recombinant protein expression.   
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  Methods.  Techniques for restriction enzyme digestions, ligation, 
transformation, and other standard molecular biology manipulations were based on 
methods described elsewhere (15), or as suggested by the manufacturer.  Plasmid 
DNA was introduced into cells by electroporation using a Cell-Porator 
 
Electroporation System (Whatman Biometra, Göttingen, Germany).  The PCR was 
performed in a DNA thermal cycler (Model 480) obtained from PerkinElmer Inc 
(Wellesley, MA).  Colony screening by the PCR is based on methods described in the 
pET System Manual (Novagen).  DNA sequencing was done at the DNA Core 
Facility in the Institute for Cellular and Molecular Biology at the University of Texas 
(Austin).  Kinetic data were obtained on a Hewlett Packard 8452A or an Agilent 8453 
Diode Array spectrophotometer.  The cuvettes were mixed using a stir/add cuvette 
mixer (Bel-Art Products, Pequannock, NJ).  The kinetic data were fitted by nonlinear 
regression data analysis using the Grafit program (Erithacus Software Ltd., Horley, 
U. K.) obtained from Sigma Chemical Co.  HPLC was performed on a Waters 
(Milford, MA) 501/510 system or a Beckman System Gold HPLC (Fullerton, CA) 
using a TSKgel Phenyl-5PW hydrophobic column (TosoHaas, Montgomeryville, PA) 
or a Superose 12 gel filtration column (Amersham Biosciences, Piscataway, NJ).  
Protein was analyzed by Tris glycine sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) under denaturing conditions on 17.5% gels using either 
the Mini-Protean II or III vertical gel electrophoresis apparatus obtained from Bio-
Rad (Hercules, CA) (16).  Protein concentrations were determined using the method 
of Waddell (17).  The NMR spectra were recorded in 100% H2O on a Varian Unity 
INOVA-500 spectrometer using selective pre-saturation of the water signal with a 2-s 
pre-saturation interval.  The lock signal is dimethyl-d6 sulfoxide.  Chemical shifts are 
standardized to the dimethyl-d6 sulfoxide signal at 2.49 ppm.   
  Synthesis of the α- and β-Subunit Genes and Construction of the Expression 
Vectors.  In separate reactions, the genes for the α- and β-subunit of CaaD were 
synthesized in two stages in a Perkin Elmer DNA Thermocycler using either five (for 
the α-subunit) or four (for the β-subunit) long oligonucleotides, two external 
oligonucleotide primers, and the PCR reagents (18-20).  The five long 
oligonucleotides (designated α1-α5) used for the synthesis of the α-subunit along with 
the two external oligonucleotide primers (designated primers A and B) used for 
amplification of the synthesized gene are listed in Table S1.  Primer A consists of 
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nine bases to facilitate digestion by NdeI, the NdeI restriction site (underlined), and 
15 bases corresponding to the coding sequence of the first five amino acids of the α-
subunit.  Primer B consists of nine bases to facilitate digestion by NotI, the NotI 
restriction site (underlined), the complementary sequence for a stop codon, and 18 
bases corresponding to the complementary sequence of the last six amino acids of the 
α-subunit.  Oligonucleotides α1, α3, and α5 represent the coding base sequences for 
17-, 24-, and 14-amino acid segments, respectively, of the α-subunit.  These segments 
correspond to the initiating methionine (designated as the first amino acid) to Arg-18, 
Ala-31 to His-54, and Pro-63 to the stop codon, respectively.  Oligonucleotides α2 
and α4 represent the complementary base sequences coding for 24- and 20-amino 
acid segments, respectively, of the α-subunit.  These segments correspond to Thr-13 
to Arg-36 and Ile-49 to Asp-68, respectively.  Adjacent oligonucleotides overlap by 
18 bases.  The first 18 bases of oligonucleotide α1 are identical to the last 18 bases of 
primer A, while the last 18 bases of oligonucleotide α5 correspond to the 
complementary sequence for the last 18 bases of primer B.   
  The four long oligonucleotides (designated β1-β4) used for the synthesis of the 
β-subunit along with the two external oligonucleotide primers (designated primers C 
and D) used for amplification of the synthesized gene are listed in Table S2.  Primer 
C was designed so that the gene for the β-subunit could either be co-expressed with 
the α−subunit on the same plasmid or expressed separately from its own plasmid.  
Thus, it contains an initial eight bases (to facilitate digestion) followed by sites for 
both the NotI and NdeI (underlined) restriction enzymes.  Separating the two sites are 
a stop codon, the sequence for a ribosomal binding site (GAAGGA), and six bases 
(GATATA), which correspond to the sequence found in the pET-21a(+) vector.  
Primer D contains a NotI restriction site (underlined) followed by the complementary 
sequence for a stop codon and 17 bases corresponding to the complementary 
sequence of the last six amino acids of the β-subunit.  Oligonucleotides β1 and β3 
represent the coding sequences for 18- and 24-amino acid segments, respectively, and 
correspond to Met-1 to Gln-18 and Ser-31 to Ser-54.  Oligonucleotides β2 and β4 
 106
 
represent the complementary base sequences for 24- and 23-amino acid segments, 
which correspond to Ser-13 to Pro-36 and Ala-49 to the stop codon, respectively.  
The only bases shared by both primer C and oligonucleotide β1 are those 
corresponding to the start codon (i.e., ATG).  The last 18 bases of primer D are the 
same as the first 18 bases of oligonucleotide β4.  Again, adjacent oligonucleotides 
overlap by 18 bases. 
  In stage 1 of the PCR for the synthesis of the α-subunit, a 50-µL reaction 
mixture consisted of the 10× PCR reaction buffer (5 µL), the five long 
oligonucleotides (2 µl each from 1 µM solutions), primers A and B (2.5 µL each from 
20 µM solutions), dNTPs (1 µL from a 10 mM stock solution containing the four 
dNTPs), 25mM MgCl2 (3 µL), Taq polymerase (1 µL), and sterile de-ionized water 
(26 µL).  The reaction mixture was contained in a thin-walled reaction tube and 
layered with sterile paraffin oil.  The PCR protocol was made up of an initial 5-min 
denaturation cycle at 94 °C, 25 cycles of PCR, and a final 5-min elongation period at 
72 °C.  Each cycle consisted of three steps: denaturation at 94 °C for 1 min, annealing 
at 55 °C for 75 s, and elongation at 72 °C for 2 min.  The amplified PCR products 
were analyzed by electrophoresis on 1% agarose gels.  Two distinct bands were 
observed, one at approximately 200 bp and one at approximately 300 bp.  The bands 
were separately excised and purified using the Wizard PCR Preps DNA purification 
system.   
  In the second stage of PCR, these purified PCR products were used as 
templates in individual PCRs.  Accordingly, each reaction contained 10× PCR 
reaction buffer (5 µL), a purified PCR product (1 µL), primers A and B (2.5 µL each 
from 20 µM solutions), dNTPs (1 µL from a 10 mM stock solution containing the four 
dNTPs), 25mM MgCl2 (3 µL), Taq polymerase (1 µL), and sterile de-ionized water 
(34 µL).  After subjecting the reaction mixtures to the PCR protocol described above, 
the amplified PCR products were analyzed by electrophoresis on 1% agarose gels.  
Both PCRs gave rise to similar sets of bands.  The most intense band, observed at 
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approximately 250 bp, was excised and purified using an Ultrafree-DA centrifugal 
unit.   
  Subsequently, the purified PCR product and the pET-24a(+) vector were 
treated with the NdeI and NotI restriction enzymes overnight at 37 °C, and the 
digestion products were electrophoresed on a 1% agarose gel.  Further purification 
was achieved by use of the Ultrafree-DA centrifugal units.  The resulting fragments 
were ligated using T4 ligase (0.1 units) at room temperature overnight.  The DNA 
was precipitated from the mixture and re-suspended in sterile water (5 µL), which was 
used to transform E. coli strain DH5α cells by electroporation.  The transformed cells 
were plated on LB/Kn (50 µg/mL) agar plates, and grown overnight at 37 °C.  Four 
colonies were chosen at random and the plasmids purified using the Qiaprep Spin 
Miniprep Kit.  Each of the four plasmids was digested with the NdeI and NotI 
restriction enzymes to screen for the presence of insert (i.e., the α-subunit) as 
indicated by the appropriate size band (250 bp) upon electrophoresis on a 1% agarose 
gel.  Only one of the four plasmids contained the α-subunit.  The plasmid was 
designated pET-24a(+)-CaaDα.  Sequencing of the insert and the adjacent sequence 
verified that no mutations had been introduced.   
  The β-subunit was synthesized in two stages of PCR in a comparable manner 
using the oligonucleotides shown in Table S2.  The most intense band (~250 bp in 
size) observed after the second stage was excised and purified using an Ultrafree-DA 
centrifugal unit.  The PCR product and the pET-21a(+) vector were treated with the 
NdeI and NotI restriction enzymes and the products of these reactions purified and 
ligated as described above.  The ligated DNA was precipitated and used to transform 
E. coli strain DH5α as described above.  An aliquot of the transformed cells, after 
being treated as described above, was plated on LB/Ap (100 µg/mL) agar plates, and 
grown overnight at 37 °C.  A total of 18 colonies were chosen at random and 
screened for the presence of a plasmid having the β-subunit insert, as indicated by the 
appropriate size band (~250 bp) upon electrophoresis on a 1% agarose gel.  Four 
plasmids were identified that contained the insert.  Sequencing of all four inserts (and 
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the adjacent sequences) uncovered two constructs (designated pET-21a-CaaDβ4 and 
pET-21a-CaaDβ6) without mutations.  
  Aliquots (0.5-1 µL) of each plasmid (pET-24a-CaaDα and pET-21a-CaaDβ4) 
were used to transform either E. coli strain BL21(DE3)pLysS or E. coli strain BL21-
Gold(DE3)pLysS cells by electroporation following the manufacturer’s directions.  
An aliquot (50-100 µL) was plated on LB/Kn (50 µg/mL)/Ap (100 µg/mL)/Cm (25 
µg/mL) agar plates, and grown overnight at 37 °C.  Only those colonies containing 
the two expression plasmids and the pLysS plasmid will grow on the triple antibiotic 
media (21).   
  Overexpression and Purification of CaaD.  A 25 mL culture of LB containing 
both ampicillin (100 µg/mL) and kanamycin (50 µg/mL) was inoculated with a single 
colony of the expression strain and grown overnight at 37° C.  Subsequently, a 
sufficient quantity of the overnight culture was used to inoculate 500 mL of 
LB/Kn/Ap medium in a 2 L Erlenmeyer flask to give an OD600nm reading of ~0.05.  
Cultures (6-2L flasks) were grown at 37° C to an OD600nm of ~0.6-0.8 with vigorous 
shaking and then induced with 0.5 mM IPTG.  Additional aliquots of ampicillin (50 
µg/mL) and kanamycin (25 µg/mL) were added to each culture upon induction in 
order to promote the retention of both expression plasmids (pET-21a-CaaDβ4 and 
pET-24a(+)-CaaDα).  Cells were harvested after four hours of growth and stored at -
80° C until use.  Typically, 3 L of culture yields 12 g cells.   
  The purification of recombinant CaaD to near homogeneity was carried out by 
the following procedure.  The buffers used in this purification are Buffer A:  50 mM 
Tris-SO4, pH 8.0; Buffer B: 50 mM Tris-SO4, 1 M (NH4)2SO4, pH 8.0;  and Buffer C: 
20 mM NaH2PO4, pH 7.3.  The cells (23.6 g) were thawed, resuspended in 3 volumes 
(71 mL) of buffer A, placed on ice, and initially disrupted by sonication at 50% 
output for one minute.  Phenylmethylsulfonyl fluoride (0.5 mM) and 6-aminocaproic 
acid (1 mM) were added to the cell suspension.  Subsequently, the cell suspension 
was subjected to further sonication for six 5-min intervals using 5-s pulses with a 
cycle time of 50%.  After each 5-min interval, the cells were allowed to sit for 5 
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minutes.  Protamine sulfate (0.47 g) was added to the lysate and the resulting mixture 
was stirred for 10 min at 4 °C, and then centrifuged at 19, 000 rpm for 30 min at 4 °C.  
The supernatant was removed, made 1 M in (NH4)2SO4, and allowed to stir for 60 
min at 4 °C.   
  After centrifugation at 17, 000 rpm for 30 min, the supernatant was loaded 
onto a Phenyl-5PW column, previously equilibrated in Buffer B.  Protein was eluted 
using a 20-min wash of 100% Buffer B, followed by a 60 min linear (NH4)2SO4 
gradient (1.0-0.0 M) using Buffer A, and a final 10-min wash with 100% Buffer A.  
The flow rate was 5 mL/min.  Fractions (7.5 mL) were collected and assayed for 
activity.  Typically, the CaaD activity elutes 25 min after the initial wash.  The most 
active fractions were pooled (~200 mL), concentrated, and exchanged into Buffer A 
using an Amicon stirred cell containing a YM-3 membrane.  The resulting 
concentrate (~29 mL) was made 1 M in (NH4)2SO4, and allowed to stir for 60 min at 
4 °C.  After centrifugation at 17, 000 rpm for 30 min, the supernatant was removed 
and passed through the Phenyl column using the conditions described above.  The 
most pure and active fractions were pooled (~ 80 mL), concentrated to ~ 6 mL, and 
loaded onto a Sephadex G-200 column (2.5 × 100 cm), equilibrated with Buffer C.  
The flow rate was about 0.4 mL/min.  Fractions were collected for 25 min each and 
contained about 10 mL.  Typically, CaaD elutes after about 12 hours.  The most 
active fractions were pooled and concentrated.  The purity was judged to be >95% as 
assessed by SDS-PAGE.  The overall yield of CaaD is typically 15-20 mg of 
homogenous protein per liter of culture.  For this preparation, a 4-L culture gave 70 
mg of protein.   
  The native molecular mass of CaaD was estimated by size exclusion 
chromatography on a Superose 12 column.  The enzyme was chromatographed in 200 
µL portions (1.3 mg/mL) on the gel filtration column equilibrated with 20 mM 
sodium phosphate buffer, pH 7.3, at a flow rate of 0.4 mL/min.  The protein eluted at 
~31 min.   
  Construction of the β-P1A- and α−R11A-CaaD Mutants.  Two mutants of 
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CaaD were constructed by overlap extension PCR as described elsewhere (22).  In the 
β-P1A mutant of CaaD, Pro-1 in the β-subunit was changed to an alanine, while the α-
subunit remained unchanged.  In the α−R11A mutant of CaaD, Arg-11 in the α-
subunit was changed to an alanine, while the β-subunit was unchanged.  The external 
primers for each mutant were oligonucleotides 5'-GCG GAT AAC AAT TCC CCT 
CT-3' (primer Am) and 5'-CTC AGC TTC CTT TCG GGC TT-3' (primer Dm).  
Primer Am corresponds to a region 36 bases upstream of the NdeI restriction site in 
both the pET-21a(+) and pET-24a(+) plasmids.  Primer Dm corresponds to the 
complementary sequence of a region 20 bases downstream of the His-tag region in 
both the pET-21a(+) and pET-24a(+) plasmids.  The internal primers for the β-P1A 
mutant were 5'-ATA CAT ATG GCC TTC ATC GAA-3' (primer Bm) and 5'-TTC 
GAT GAA GGC CAT ATG TAT-3' (primer Cm).  The internal primers for the α-
R11A mutant were 5'-CGT TAT GGG GCA ACA GAC GAA-3' (primer Bm) and 5'-
TTC GTC TGT TGC CCC ATA ACG-3' (primer Cm).  In each internal primer, the 
mutation is underlined and the remaining bases correspond to the coding sequence 
(primers Cm) or the complementary sequence (primer Bm) for the appropriate CaaD 
subunit gene.   
  For the construction of the AmBm and CmDm fragments for the β-P1A mutant, 
each PCR reaction contained 2.5 µL of 20 µM solutions of primers Am and Bm or Cm 
and Dm, 1 µL of a 10 mM stock of dNTPs, 5 µL of 10 × Taq reaction buffer, 3 µL of 
25 mM MgCl2, 5 µL of a 1:500 dilution of the pET-21a(+)-CaaDβ4 plasmid miniprep, 
0.5 µL of Taq DNA polymerase, and a sufficient quantity of sterile water to make a 
final volume of 50 µL.  The PCR protocol consisted of a 5-min incubation period at 
94 °C, followed by 25 cycles of the PCR where each cycle contained a denaturation 
step at 94 °C for 60 s, an annealing step at 55 °C for 75 s, and an elongation step at 72 
°C for 75 s, and a final 5-min incubation period at 72 °C.  The amplified products 
were analyzed by electrophoresis on 1% agarose gels and purified using the Wizard 
PCR Preps DNA purification system.  The AmDm fragment was constructed similarly 
except that the AmBm and CmDm fragments (1 µL of each) were used as template.  The 
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AmDm fragment was electrophoresed, excised, and purified using the Ultrafree-DA 
centrifugal filter units.  Digestion and purification of the AmDm fragment and the 
pET-21a(+) vector were carried out as described above.  Ligation was performed 
using the Quick Ligation Kit (New England Biolabs, Inc., Beverly, MA).  The 
purified DNA was used to transform E. coli strain BL21-Gold(DE3) pLysS by 
electroporation.  Transformed cells were plated onto LB/Ap (50 µg/mL)/Cm (25 
µg/mL) and incubated overnight at 37 °C.  Four colonies were selected at random and 
their plasmids were isolated for sequence analysis.  Only one colony possessed the 
correct sequence for the desired mutant and was designated pET-21a(+)-CaaDβ-P1A.   
  For construction of the α-R11A mutant, Herculase DNA polymerase 
(Stratagene) replaced Taq DNA polymerase in the PCR reactions and MgCl2 was not 
added.  The PCR protocol consisted of a 2-min incubation period at 92 °C, followed 
by 30 cycles of the PCR where each cycle had a 30-sec denaturation step at 92 °C, a 
30-sec annealing step at 60 °C, and a 60-sec elongation step at 72 °C, and a final 10-
min incubation period at 72 °C.  Purification of the AmBm and CmDm fragments and 
construction of the AmDm fragment was carried out as described above.  
Subsequently, the pET-24a(+) vector and the AmDm fragment were treated with the 
appropriate restriction enzymes at 37 °C for 6 hr and purified using gel 
electrophoresis and the Ultrafree-DA centrifugal filter units.  Ligation and 
transformations were carried out as described for the construction of the β-P1A 
mutant.  The purified DNA was used to transform E. coli DH5α by electroporation.  
Transformed cells were plated onto LB/Kn (50 µg/mL) and incubated overnight at 37 
°C.  Two colonies were selected at random for sequencing.  One colony, designated 
pET-24a(+)-CaaDα-R11A2, had only the desired mutation.   
  Overexpression and Purification of the β-P1A- and the α-R11A CaaD 
Mutants.  For expression, each mutant plasmid was transformed into E. coli strain 
BL21-Gold(DE3) pLysS by electroporation along with the appropriate wild-type 
partner plasmid.  Thus, for expression of the β-P1A mutant, both the pET-21a(+)-
CaaDβ-P1A and pET-24a(+)-CaaDα vectors were used to transform cells.  For 
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expression of the α-R11A mutant, both the pET-21a(+)-CaaDβ4 and pET-24a(+)-
CaaDα-R11A2 vectors were used to transform cells.  Cells were selected for the 
presence of the two plasmids by growth on LB plates containing the triple antibiotics 
as described above.  Cells expressing the mutant proteins were grown using the 
protocol described for the wild type enzyme.  Subsequently, the mutant proteins were 
purified following the procedure used for the wild type CaaD.  Typically, a 3L culture 
of the β-P1A mutant yields 10 g of cells and 50 mg of ~95% pure protein as assessed 
by SDS-PAGE.  A 3L culture of the α-R11A mutant yields 10 g of cells and 40 mg of 
~90% pure protein as assessed by SDS-PAGE.   
  The native molecular masses of the two mutants were estimated by size 
exclusion chromatography on a Superose 12 column.  Both enzymes were 
chromatographed in 200 µL portions (0.7 mg/mL) on the gel filtration column 
equilibrated with 20 mM sodium phosphate buffer, pH 7.3, at a flow rate of 0.4 
mL/min.  The β-P1A CaaD mutant eluted at ~32 min, while the α-R11A CaaD mutant 
eluted at ~31 min.   
  Mass Spectrometric Characterization of CaaD and the Mutants.  The subunit 
masses of CaaD and the two mutants were determined using an LCQ electrospray ion 
trap mass spectrometer (ThermoFinnigan, San Jose, CA), housed in the Analytical 
Instrumentation Facility Core in the College of Pharmacy at the University of Texas 
at Austin.  The protein samples (~1 mg/ml in 100 mM (NH4)2CO3 buffer, pH 8.0) 
were mixed in a 1:10 ratio with a solution of 50% (v/v) methanol in water containing 
5% acetic acid.  The samples were infused into the mass spectrometer at 20 µl/min 
and spectra were acquired continuously in the centroid mode over the mass range of 
m/z 350-2000.  The deconvoluted masses were calculated using ThermoFinnigan’s 
Xcalibur 1.3 BioWorks 3.0 software with approximately 40 spectra averaged.   
  The observed monomer masses for the α- and β-subunits of CaaD were 8342 
(calc. 8344) and 7505 (calc. 7507), respectively.  The observed monomer masses for 
the α- and β-subunits of β−P1A-CaaD were 8342 (calc. 8344) and 7479 (calc. 7481), 
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respectively.  The observed monomer masses for the α- and β-subunits of α−R11A-
CaaD were 8257 (calc. 8258) and 7506 (calc. 7507), respectively.   
  Enzymatic Assay and Kinetic Studies of CaaD.  The kinetic assays were 
performed in 20 mM Na2HPO4 buffer, pH 9.0, observing the decrease in absorbance 
at 224 nm corresponding to the hydration of trans-3-chloroacrylate (1, ε = 4900 M-1 
cm-1) and trans-3-bromoacrylate (11, ε = 9700 M-1 cm-1).  An aliquot of CaaD (100 
µL of a 13.2 mg/mL solution) was diluted into buffer (40 mL) and incubated for 1 h.  
Subsequently, a 1 mL-portion of the enzyme was transferred to a cuvette and assayed 
by the addition of a small quantity of substrate (1 or 11) from a 5 mM or 50 mM 
stock solution (in 100 mM Na2HPO4 buffer, pH 9.2).  The addition of 1 or 11 (as their 
free acids) to the 100 mM phosphate buffer adjusted the pH of the stock solution to 
about 7.0.  The 5 mM stock solution was made by dilution of an aliquot of the 50 mM 
stock solution into 100 mM NaH2PO4 buffer, pH 7.3.  The concentrations of substrate 
used in the assay ranged from 10-150 µM.   
  The hydration of 2-oxo-3-pentynoate (7) by CaaD was monitored by 
following the formation of acetopyruvate (8) at 294 nm (ε = 7,000 M-1 cm-1) in 20 
mM sodium phosphate buffer (pH 9.0) (23).  An aliquot of CaaD (500 µL of a 2.9 
mg/mL solution) was diluted into buffer (50 mL) and incubated for 1 h.  The assay 
was initiated by the addition of a small quantity of 7 from either a 5.95 mM or 59.5 
mM stock solution.  The stock solution (59.5 mM) was made by dissolving the 
appropriate amount of 2-oxo-3-pentynoate in 100 mM Na2HPO4 buffer, pH 9.2.  The 
addition of 7 (as the free acid) adjusted the pH of the buffer to about 7.  The 5.95 mM 
stock solution was made by dilution of an aliquot of the 59.5 mM into 100 mM 
NaH2PO4 buffer, pH 7.3.  The concentrations of 7 used in the assay ranged from 6-
595 µM.   
  1H NMR Spectroscopic Detection of 3.  An NMR tube contained 100 mM 
Na2HPO4 buffer (0.54 mL, pH ~9.2) and a solution of 1 (4 mg, 0.04 mmol) dissolved 
in DMSO-d6 (30 µL).  The final pH of the solution was 6.8.  Subsequently, an aliquot 
of CaaD (60 µL of a 6.7 mg/mL solution in 20 mM sodium phosphate buffer, pH 7.3) 
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was added to the reaction mixture.  The concentration of 1 in the NMR tube was 62 
mM.  The first 1NMR spectrum was recorded 5 min after the addition of the enzyme 
and every 5 min thereafter until the reaction was completed (30 min).  3:  1H NMR 
(H2O, 500 MHz) δ 3.20 (2H, d, J = 3 Hz, H-2), 9.50 (1H, t, H-3).  The spectra also 
showed signals corresponding to acetaldehyde (resulting from the non-enzymatic 
decarboxylation of 3), and to the hydrates of 3 [1H NMR (H2O, 500 MHz) δ 2.34 (2H, 
d, J = 5.4 Hz, H-2), 5.15 (1H, t, H-3)] and acetaldehyde (24).   
  13C NMR Spectroscopic Detection of 3.  An NMR tube contained 200 mM 
Na2HPO4 buffer (0.3 mL, pH ~8.5), 1M NaOH (175 µL), H2O (10 µL), and a solution 
of 1 (20 mg, 0.19 mmol) dissolved in DMSO-d6 (30 µL).  The final pH of the solution 
was 6.8.  After sitting at 4 °C overnight, an aliquot of CaaD (115 µL of a 6.7 mg/mL 
solution in 20 mM sodium phosphate buffer, pH 7.3) was added to the reaction 
mixture.  The concentration of 1 in the NMR tube was 310 mM.  The initial 13C NMR 
spectrum was obtained 25 min after the addition of CaaD.  3:  13C NMR (H2O, 500 
MHz) δ 46.2 (C-2), 175.4 (C-1), 204.2 (C-3).  The spectra also showed evidence for 
the presence of acetaldehyde (resulting from the non-enzymatic decarboxylation of 
3), and the hydrates of 3 [13C NMR (H2O, 500 MHz) δ 53.6 (C-2), 90.3 (C-3), 178.5 
(C-1)] and acetaldehyde (24).   
  UV and 1H NMR Spectroscopic Detection of Acetopyruvate (8) in the CaaD-
catalyzed Hydration of 2-Oxo-3-pentynoate (7).  In the UV spectrophotometric 
experiment, the conversion of 7 to 8 was performed by adding a quantity of CaaD (5 
µL of a 7.9 mg/mL solution) to a cuvette containing buffer (1 mL of 20 mM Na2HPO4 
buffer, pH 9) and an aliquot of 7 (2 µL from a 59.5 mM solution in 100 mM Na2HPO4 
buffer, pH 9.2).  Spectra were recorded every 30 s until the reaction neared 
completion (approx. 15 min).  The region from 200-350 nm was examined using the 
Agilent 8453 Diode Array spectrophotometer at 27 °C.  For the 1H NMR experiment, 
7 (4 mg, 36 mmol) dissolved in DMSO-d6 (30 µL), was added to 100 mM Na2HPO4 
buffer, pH 9.2 (0.6 mL) in an NMR tube.  The addition of 7 adjusted the pH of the 
buffer to 6.5.  Subsequently, an aliquot of CaaD (200 µL of a 11 mg/mL solution) was 
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added to the mixture to initiate the reaction.  NMR spectra were recorded at 3.5 min 
and 10 min after the addition of enzyme, when the reaction was completed.  The 1H 
NMR spectra show the presence of signals corresponding to 8, its hydrate 12 (25), 
and the enol isomer, 13 (26).  1H NMR (100 mM Na2HPO4, 500 MHz) δ 2.02 (s, 3H, 
CH3 of 12), 2.05 (s, 3H, CH3 of 13), 2.12 (s, 3H, CH3 of 8), 2.88 (s, 2H, CH2 of 12), 
3.79 (s, 2H, CH2 of 8), 5.94 (s, 1H, enol proton of 13).   
  Detection of the β-P1A- and α−R11A-CaaD Mutant Activity.  Activities for the 
β-P1A- and α−R11A-CaaD mutants could not be determined by UV spectroscopy 
because the large amount of protein required interfered with the UV absorbance of 
substrate.  Hence, activity was detected using 1H NMR spectroscopy as follows.  To 
an NMR tube containing 100 mM Na2HPO4 buffer (0.6 mL, pH ~9.2) was added a 
solution of 3-chloroacrylic acid (1, 4 mg, 0.04 mmol) dissolved in DMSO-d6 (30 µL).  
The addition of 1 to the buffer lowered the pH to ~6.8.  Subsequently, an aliquot of β-
P1A-CaaD or α−R11A-CaaD (100 µL of a 7.4 mg/mL solution) was added to separate 
NMR tubes.  The reaction mixture was allowed to incubate for 24 hrs.  The final pH 
was 6.65 (β-P1A-CaaD) or 6.53 (α−R11A-CaaD).  A 1H NMR spectrum revealed the 
presence of acetaldehyde (resulting from the non-enzymatic decarboxylation of 3) 
and its hydrate in the NMR tube containing α−R11A-CaaD, but no products in the 
NMR tube containing β-P1A-CaaD.   
  Kinetics of Irreversible Inhibition.  A quantity (100 µL) of CaaD (5.7 mg/mL) 
was diluted 10-fold into 20 mM sodium phosphate buffer (pH 7.3) to give a final 
concentration of 36 µM (based on dimer molecular mass).  The diluted enzyme was 
divided into 150 µL quantities, placed in 1.5 mL eppendorf micro test tubes, and 
equilibrated at 23 °C for 1 hr before the addition of inhibitor.  A 20 µL-aliquot was 
removed just prior to the addition of inhibitor and assayed for activity.  This activity 
represents 100% activity at time zero.  Subsequently, varying amounts of 9 or 10 (0–
40 µM) and a sufficient quantity of buffer (100 mM Na2HPO4 buffer, pH 7.3) were 
added to the incubation mixtures to make a final total volume of 140.4 µL.  Aliquots 
(20 µL) were removed from these mixtures immediately after the addition of inhibitor 
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(~ 5 s) and at 5-s intervals thereafter, diluted into 20 mM sodium phosphate buffer (1 
mL, pH 9.0), and assayed for residual activity.  The assay was initiated by the 
addition of 11 (150 µM).  Each time point (shown in Figure 31) represents the 
average of three different runs.  Stock solutions (50 mM) of 9 and 10 were made up in 
100 mM Na2HPO4 buffer (pH 9.2).  The addition of the inhibitor resulted in a final 
pH of ~7.  The stock solutions were diluted with a sufficient volume of 100 mM 
sodium phosphate buffer (pH 7.3) to make 5 mM and 0.5 mM solutions of inhibitor.   
  Protection of CaaD from Inhibition by 9 and 10.  The protection of CaaD 
from inactivation by 9 and 10 was carried out as follows.  Quantities of CaaD (150 
µL) were placed in 1.5 mL eppendorf micro test tubes and the initial time point was 
obtained as described above.  Aliquots (10.4 µL) of a solution containing either 9 
(0.25 mM or 0.5 mM) and 11 (14 mM, 65 mM, and 138 mM) or 10 (0.25 or 0.5 mM) 
and 11 (14 mM, 65 mM, and 138 mM) were then added to the eppendorf tubes.  This 
resulted in final concentrations of either 9 (20 µM or 40 µM) or 10 (20 µM or 40 µM) 
and 11 (1 mM, 5 mM, and 10 mM).  Aliquots (20 µL) were removed from these 
mixtures as described above, diluted into 20 mM sodium phosphate buffer (1 mL, pH 
9.0, a 50-fold dilution), and assayed for residual activity using the quantity of 11 
present in the incubation mixture.   
  Bromide Elimination from 9 in the Presence of CaaD.  The release of bromide 
ion was monitored using an Accumet AP63 pH/millivolt/ion meter equipped with an 
Accumet bromide combination ion selective electrode (Fisher Scientific Inc.).  The 
amount of bromide in solution was determined from a standard curve following the 
manufacturer’s directions.  The reaction mixtures (total volume of 3 mL) contained 
varying amounts of 9 (0 µM, 25 µM, 150 µM, or 300 µM) made up as described above 
and CaaD (297 µL from a 21.5 mg/mL solution resulting in a final concentration of 
127 µM).  The reactions were initiated by the addition of inhibitor.  An aliquot (60 
µL) of a 5M NaNO3 solution was added to each reaction mixture to maintain a 
constant ionic strength.   
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  In order to determine the response time of the electrode, the amount of 
bromide ion was monitored in a reaction mixture containing 20 mM NaH2PO4 buffer, 
pH 9.0, (1.5 mL), NaNO3 (30 µL of a 5 M solution), and NaBr (30 µL of a 5 mM 
solution) under the conditions described above.  The final concentration of bromide 
ion in solution (50 µM) was determined from a standard curve to be present in 
solution after ~3 min.   
  Irreversibility of the Inactivation.  The irreversibility of the reaction was 
established using both 9 and 10.  CaaD (1.53 µM based on the molecular weight of 
the dimer) was incubated with an excess of 9 or 10 (50 µM) in 5 mL of 20 mM 
Na2HPO4 buffer (pH ~9) for 20 min at 23 °C.  The final pH of the solution was 8.0.  
In a separate control reaction, an identical quantity of enzyme was incubated without 
inhibitor under identical conditions.  The treated samples had no activity after 20 min.  
The three samples were dialyzed against 20 mM Na2HPO4 buffer, pH 9.0 at 22 °C.  
After 63 h, the control sample lost ~40% of its original activity, while the treated 
samples did not regain any activity.   
  Trypsin Digestion of CaaD and CaaD-modified by 9.  Each sample contained 
~1 mg of CaaD (125 µl of a 7.9 mg/mL solution) and a sufficient quantity of 20 mM 
sodium phosphate buffer, pH 7.3, to give a final volume of ~0.5 mL.  One sample 
was treated with 9 (13 µL from a 44.8 mM stock solution of 9 in 100 mM Na2HPO4 
buffer).  Both samples were incubated at 4 °C for ~12 hrs and passed through separate 
PD-10 Sephadex columns equilibrated in 100 mM (NH4)2CO3 buffer, pH 8.  Fractions 
(~0.5 mL) were collected, and protein was identified by the Waddell method (17).  
Subsequently, both samples were treated with sequencing grade trypsin by a 
modification of a literature procedure (26).  Accordingly, aliquots (300 µL) of CaaD 
and modified CaaD were made 1M in guanidine hydrochloride, 5 mM in CaCl2, and 1 
mM in dithiothreitol (DTT).  The sequencing grade trypsin (100 µg) was reconstituted 
according to the manufacturer’s instructions in 1 mM HCl (10 µL) and a 2-µL aliquot 
was added to each protein sample.  The samples were incubated at 37 °C overnight.  
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Subsequently, the mixtures were subjected to matrix assisted laser desorption-
ionization (MALDI) mass spectral analysis as described below.   
  Mass Spectrometry of the Digested Proteins.  The trypsin-digested CaaD 
samples were analyzed on the delayed extraction Voyager-DE PRO MALDI-TOF 
instrument (PerSeptive Biosystems, Framingham, MA) operating in the positive ion 
mode.  The instrument is equipped with a 337 nm nitrogen laser with a 20 Hz firing 
rate.  The matrix consisted of α-cyano-4-hydroxycinnamic acid from the Sequazyme 
Peptide Mass Standards Kit (PerSeptive Biosystems) dissolved in 50% (v/v) 
acetonitrile in water with 0.1 % trifluoroacetic acid (TFA).  Samples (1 mg/mL in 100 
mM (NH4)2CO3 buffer, pH 8) were mixed with the matrix in a 1:10 ratio.  A 1 µl 
aliquot was removed and drop dried on a stainless steel target.  Close external 
calibration was performed using Calibration Mixture 1 (Sequazyme Peptide Mass 
Standards Kit) made up according to the manufacturer’s directions.  The 2.0 m 
reflector detector was used with the low mass gate set at m/z 500, and spectra were 
acquired over the range of m/z 500-3500.  The instrument parameter file 
“angiotensin_reflector” was used for data acquisition, with 20 kV accelerating 
voltage, 74% grid voltage, 0.002% guide wire voltage and 75 nsec delay time.  Up to 
400 shots were averaged for the spectrum with typical resolution of 8000.  MALDI-
Post Source Decay (PSD) spectra were composite spectra generated from a set of 11 
mirror ratios acquired with the instrument parameter file “angiotensin_PSD”.  Up to 
400 shots were averaged for each segment.  Air was used for collision induced 





  Construction, Expression, and Characterization of CaaD.  CaaD has been 
constitutively expressed in both E. coli and Pseudomonas sp. strain GJ1 (3).  In order 
to optimize expression of the unlabeled enzyme as well as isotopically labeled 
enzyme for NMR studies, and to facilitate mutagenesis, the genes for the α− and β− 
subunits of CaaD from Pseudomonas pavonaceae strain 170 were synthesized in 
separate reactions using a PCR-based gene synthesis strategy (18-20), and cloned into 
the T7 expression system.  Accordingly, the gene for the α-subunit was divided into 
five long oligonucleotides with short overlapping regions, while the gene for the β-
subunit was divided into four long oligonucleotides with short overlapping regions.  
These overlaps serve as primers for the extension of the long oligonucleotides, 
resulting in their fusion in the course of the PCR.  The full-length genes are then 
amplified by the inclusion of short primers (corresponding to the termini).  
Subsequently, the two gene fragments were cloned into separate plasmids, which 
were, in turn, transformed into the expression strain.  The sequences of the subunits 
were confirmed by DNA sequencing.  CaaD was purified to near homogeneity by 
hydrophobic interaction chromatography followed by gel filtration.  Typically, the 
expression system yielded 17-20 mg of homogeneous protein (~95% pure as 
estimated by SDS-PAGE) per liter of culture.   
  The purified CaaD was analyzed by electrospray ionization mass spectrometry 
(ESI-MS) and gel filtration chromatography.  A sample generates two major peaks in 
the mass spectrum (after deconvolution) that correspond to the expected masses of the 
α− and β− subunits.  The observed masses of the two peaks indicate that the amino-
terminal proline is not blocked in either subunit by the initiating methionine.  The 
native molecular mass (as estimated on a gel filtration column) is comparable to the 
previously reported mass, suggesting that CaaD is a heterohexamer in solution (3).   
  Construction, Expression, and Characterization of CaaD Mutants.  The β-
P1A and the α-R11A mutants of CaaD were constructed by overlap extension PCR 
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using the appropriate synthetic gene (in either the pET-21a or pET-24a plasmid) as 
template (22).  The resulting plasmid containing the mutant gene was co-transformed 
into the E. coli strain BL21-Gold(DE3)pLysS along with the appropriate wild type 
plasmid.  The sequence of each mutant was confirmed by DNA sequencing.  
Subsequently, the mutant proteins were expressed and purified following the protocol 
developed for the wild type enzyme.  The expression system yielded 10-15 mg for the 
β-P1A mutant and 15-20 mg for the α-R11A mutant (per liter of culture).  Analysis of 
the mutant proteins by ESI-MS and gel filtration chromatography indicated that the 
α− and β−subunits of the mutants had the expected masses (and were not blocked by 
the initiating methionine) and that the mutants were heterohexamers in solution.   
  Kinetic Properties of CaaD, β-P1A-CaaD, and the α-R11A-CaaD.  The 
activity of CaaD was previously determined by a colorimetric assay that monitored 
the release of the halide (3).  It was necessary to have a more direct assay for CaaD 
activity in order to facilitate inhibition studies, pH rate studies, and kinetic studies of 
CaaD mutants.  Hence, the activity of CaaD was monitored by following the decrease 
in the absorbance of the substrate at 224 nm.  This assay was used to measure kinetic 
parameters for CaaD using 1 and 11 (Table 2).  The two substrates have comparable 
Km values, while the kcat value for 11 is 1.3-fold greater than that for 1.  The increase 
in kcat may reflect the fact that bromide is a better leaving group than chloride (if the 
loss of halide reflects the rate-determining step).  The overall effect of the increase in 
kcat is a slightly higher (~1.2-fold) kcat/Km value for 11 (compared to 1).  A Km of 0.19 
mM and a kcat of 6.4 s-1 were previously reported for CaaD using 1 (3).  The 
differences (most notably in Km) are likely a function of the two different assays.   
  Both the β-P1A and the α-R11A mutants of CaaD were reported to be inactive 
using 1 (3).  The β-P1A mutant showed a small amount of activity using 11, but the 
α-R11A mutant did not (3).  In the spectrophotometric assay, activity was not 
detected for either mutant 1 or 11.  However, a 24 hr incubation of both mutant 
proteins (in separate reactions) with 1 showed that the α-R11A mutant retained a 
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small amount of activity (as determined by the presence of the characteristic signals 
in a 1H NMR spectrum) while the β-P1A mutant had no detectable activity.   
  1H and 13C NMR Characterization of the CaaD-catalyzed Reaction.  In order 
to directly observe the product, the CaaD-catalyzed reaction was monitored by 1H and 
13C NMR spectroscopy (Figure 29).  Incubation of CaaD and 1 for 5 min resulted in 
the spectrum shown in Figure 29A.  The doublets centered at 6.09 and 6.92 ppm 
correspond to the protons at C-2 and C-3 of 1, respectively.  Malonate semialdehyde 
(3) is responsible for the doublet at 3.20 ppm and the triplet at 9.50 ppm, which 
correspond to the protons at C-2 and C-3, respectively.  In addition, signals 
corresponding to the hydrate of 3 appear as a doublet at 2.34 ppm and a triplet at 5.15 
ppm, corresponding to the protons at C-2 and C-3, respectively.  Finally, the spectrum 
shows much smaller signals readily assigned to acetaldehyde and its hydrate (25).  
After 20 min (Figure 29B), the signals corresponding to 1 have largely collapsed 
while those corresponding to 3 and its hydrate remain.  Over time, the signals 
corresponding to acetaldehyde and its hydrate grow in intensity.  In view of the 
significantly slower rate of formation of acetaldehyde, it can be reasonably concluded 
that it results from the non-enzymatic decarboxylation of 3.  The 13C NMR spectrum 
(recorded 25 min after the addition of CaaD to 1) shows signals that can be most 
reasonably assigned to 3 and its hydrate.   
  Hydration of 2-Oxo-3-pentynoate (7) by CaaD.  2-Oxo-3-pentynoate (7) was 
previously synthesized and found to be a potent active site-directed irreversible 
inhibitor of 4-OT (12).  In view of the sequence similarities between CaaD and 4-OT, 
and the importance of the β−Pro-1 to the enzyme-catalyzed reaction (3), 7 was 
initially examined as a potential affinity label of CaaD.  Incubation of 7 with CaaD 
resulted in a decrease in the absorbance corresponding to 7 (λmax = 234 nm), 
accompanied by the appearance of a new absorbance peak at 294 nm, which 
corresponds to acetopyruvate (8) (Figure 30).  In addition to the characteristic λmax, 
the identity of 8 was further confirmed by 1H NMR spectroscopy.  The 1H NMR 
spectrum showed signals consistent with the structure of 8 (26), as well as two 
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additional species, the hydrate 12 (26), and the enol 13 (26) (Scheme 15).  No 
significant inactivation of CaaD by 7 was observed in these experiments.  In the 
absence of CaaD, 7 is stable for several hours in solution and does not decompose to 
8 (12).   
  The kinetic parameters for the conversion of 7 to 8 were also determined and 
are summarized in Table 2.  The values of kcat are 5 to 7-fold lower than those 
determined for 1 and 11, respectively, while the Km is about 3-fold higher.  The net 
effect is a modest decrease (19-22-fold) in the kcat/Km (when compared with those 
determined for 1 and 11).  Presumably the additional carbonyl group as well as the sp 
hybridization of 7 is detrimental to its binding (resulting in a higher Km), which could 
misalign the substrate with respect to the catalytic groups of CaaD and cause the 
observed decrease in kcat.   
  Inactivation of CaaD by 9 or 10.  Incubation of CaaD with either 9 or 10 
results in a rapid irreversible inactivation of the enzyme (Figure 31).  The enzyme 
loses ~80 % of its activity in ~10 s when incubated with a stoichiometric excess (10% 
based on the dimer molecular mass of CaaD) of 9 (Figure 31A).  Under the same 
conditions, CaaD loses 80% of its activity in ~5 s when incubated with 10 (Figure 
31B).  The rapid loss of activity did not permit the collection of sufficiently precise 
data to assess whether the loss of activity occurs in a time-dependent manner or 
whether the observed differences in the inactivation times are meaningful.  Various 
attempts to slow the inactivation process by lowering the temperature to 4 °C or by 
varying the pH over the range of 5.5-9.0 were not successful.  Under all conditions, 
CaaD was rapidly inactivated.  Dialysis (63 h) of CaaD inactivated by either 9 or 10 
does not result in any reactivation of CaaD, consistent with the formation of a 
covalent bond between the enzyme and a species resulting from 9 (or 10).   
  Binding at the active site of CaaD was suggested by the observation that 11, if 
added with either inhibitor, protects CaaD from inactivation.  The results are 
summarized in Table 3 and show a clear trend.  A lower concentration of 11 (1 mM 
which is ~25-fold higher than the Km of 11) prolongs the enzyme’s lifetime by a few 
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seconds while higher concentrations (5 and 10 mM which are 200-250 higher than the 
Km of 11) prolong it by tens of seconds.  Presumably, when the enzyme converts all 
of substrate 11 present in the incubation mixtures to 3, the protection is lost.   
  Bromide Elimination from 9 in the Presence of CaaD.  The elimination of 
bromide ions was observed for increasing concentrations (25 µM, 150 µM, and 300 
µM) of 9, when incubated with a fixed concentration of CaaD (127 µM) (Figure 32) at 
24 °C and pH 8.0.  In all cases, the majority of bromide ion release is complete within 
3 min and is dependent on the presence of CaaD.   
  In the presence of a stoichiometric amount of 9, CaaD is completely 
inactivated under these conditions within 10 s.  This observation initially suggested 
that the observed bromide ion elimination and the inactivation of CaaD by 9 might 
not be a coupled process.  However, a control experiment indicated that the rate of 
bromide ion release cannot be accurately determined under these conditions.  In this 
experiment, the concentration of bromide ion in solution was monitored using a 50 
µM solution of NaBr.  After ~3 min, a total of 50 µM of bromide ion was achieved in 
solution (as detected by the electrode).  Thus, the rate of CaaD inactivation by 9 is too 
fast to obtain accurate data that can be correlated with the rate of bromide ion 
elimination.  Nonetheless, there is a correlation between inactivation and the release 
of bromide ion.  At sub-stoichiometric concentrations of 9 (compared with the 
concentration of CaaD), bromide ion release corresponds to the concentration of 9.  
When 9 is in a stoichiometric excess, bromide ion release corresponds to the 
concentration of CaaD.   
  Identification of the Modified Peptide by Mass Spectrometry.  ESI mass 
spectral analysis of the intact α- and β−subunits of CaaD, after its incubation with 9, 
indicated that only the β−subunit was modified by the inhibitor.  The molecular mass 
of the β−subunit increases from 7505 ± 3 Da to 7590 ± 3 Da after incubation with 9, 
while the mass of the α-subunit remains unchanged at 8342 ± 3 Da.  The increase in 
mass is due to the covalent attachment of a species with a mass of 85 ± 3 Da.   
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  In order to identify the site of attachment, CaaD was inactivated by 9, 
(designated the treated sample), incubated overnight with trypsin, and analyzed by 
MALDI-TOF mass spectrometry.  A control sample was made up similarly, but 
excluding 9 from the mixture.  The site of covalent attachment was determined by 
comparative MALDI-TOF of these tryptic digests followed by selected fragmentation 
of the peptides of interest (27).  The results (for the β-subunit) from the mass spectral 
analysis of each sample are summarized in Table 3 and show one major new peak 
appearing in the spectrum of the treated sample.   
  In the MALDI spectrum of the control sample (Figure 33A), there is a 
prominent peak at m/z 1200.63 ± 0.06, which corresponds to the calculated mass of 
the N-terminal sequence (PFIECHIATGL) of the β−subunit of CaaD2.  This peak is 
not present in the MALDI spectrum of the treated sample (Figure 33B), but there is a 
new pair of peaks at m/z 1242.68 ± 0.06 and 1244.75 ± 0.12.  These masses 
correspond to the N-terminal sequence (PFIECHIATGL) of the β−subunit of CaaD 
modified by adducts of 42 and 44 Da, respectively3.   
  The ions corresponding to the selected peaks in the spectra of the control and 
the treated samples were subjected to MALDI-PSD analysis in order to determine the 
location of the modified residue (27).  The MALDI-PSD spectrum of the peptide at 
m/z 1200 in the control sample, show a series of b ions, which have a charge on the 
N-terminal side of the fragmented peptide (Figure 34A).  The MALDI-PSD spectra of 
the peptides in the treated sample show a similar b ion series, but now each ion is 
shifted by a mass of +42 (Figure 34B)3.  Since all the b1 ions are shifted by +42, the 
modification is on the N-terminal proline.  While the b1 ion, corresponding to the 
fragmentation of Pro-1, is not normally seen in PSD spectra, a b1 +42 ion is seen at 
m/z 140.2 in the spectra of the treated sample.  In the spectrum of the intact protein, 
there was a mass shift of ~85 Da, while in the digest, a mass shift of +42/+44 is seen.  
The discrepancy is probably due to decarboxylation of the adduct during the MALDI 





  Many synthetic halogenated hydrocarbons are environmental pollutants that 
frequently cause adverse health effects in humans and animals (28).  Remarkably, 
microorganisms have evolved to use these compounds as sources of carbon and 
energy, converting them to carbon dioxide and water, thereby rendering such toxic 
substances less harmful.  In most cases, this capability stems from the presence of 
specialized enzymes known as dehalogenases, which catalyze the cleavage of the 
carbon-halogen bond.  There is much interest in the mechanisms of these enzymes 
because of their ability to catalyze a chemically difficult reaction, their potential use 
in bioremediation efforts, and their possible recent origin (28).   
  The majority of known microbial hydrolytic dehalogenases can be categorized 
into two broad groups, based on the whether the enzyme processes a halogenated 
aliphatic compound (29, 30) or a halogenated aromatic compound (31).  
Representative dehalogenases from both groups have been extensively studied, 
several crystal structures have been obtained, and a considerable body of mechanistic 
evidence has accumulated (28-31).  These enzymes proceed through a two-step 
process.  In the first step, an aspartate group attacks the substrate at the carbon to 
which the halogen is bound, resulting in loss of the halide and the formation of an 
alkyl (or aryl) enzyme intermediate.  Subsequently, this intermediate is hydrolyzed by 
water.  The catalytic aspartate is part of a catalytic triad or dyad, while the departure 
of the halide is sometimes facilitated by the presence of a halide-binding pocket (28-
31).   
  While haloaromatic and haloalkyl dehalogenases are well characterized, 
haloalkene dehalogenases are rare and the catalytic strategies used by these enzymes 
are poorly understood.  The only known haloalkene dehalogenases are CaaD and a 
cis-3-chloroacrylic acid dehalogenase (28).  The recent characterization of CaaD, 
including sequence analysis and site-directed mutagenesis studies, demonstrated clear 
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mechanistic and structural differences between it and all previously characterized 
dehalogenases, and placed CaaD in the 4-OT family of enzymes (3).   
  The 4-OT family of enzymes is one of the three known families that comprise 
the tautomerase superfamily (32, 33).  The other two families are represented by 5-
(carboxymethyl)-2-hydroxymuconate isomerase (CHMI), another bacterial 
isomerase, and macrophage migration inhibitory factor (MIF), a mammalian cytokine 
with a phenylpyruvate tautomerase activity.  The members of this superfamily are 
homologous proteins that share two major traits - they are constructed from a 
common β−α−β structural unit and they have an amino-terminal proline.  In the title 
enzyme of each family, Pro-1 serves as a general base in a keto-enol tautomerization 
reaction.  In the 4-OT family, the monomer of each known member encodes the 
characteristic β−α−β unit, and these monomers form stable hexamers (4-OT and 
YwhB) or dimers (YdcE, a 4-OT homologue found in E. coli) (33).  While the α- and 
β-subunits of CaaD are grouped within one of the five subfamilies in the 4-OT family, 
the characteristics of the subfamily are not yet well defined (33).   
  In this context, the discovery of CaaD is highly significant because it 
represents a new activity (hydratase) as well as a new quaternary structure 
(heterohexamer) in the 4-OT family.  The product of the reaction, 3, was previously 
identified (and quantified) by its phenylhydrazone (1) and formazan derivatives (2).  
Derivatization was necessary due to the facile decarboxylation of 3.  In order to 
circumvent this problem and to directly detect 3 (and other possible products), the 
reaction was monitored by 1H NMR spectroscopy.  In addition to the hydrate of 3 
(which is readily stabilized by a 6-member ring), the NMR spectrum showed a small 
amount of acetaldehyde, resulting from the facile decarboxylation of 3 (1, 2).  The 
slow rate of formation of the acetaldehyde is consistent with the non-enzymatic decay 
of 3.  No other products were present.  On the basis of these observations, it is 
concluded that CaaD catalyzes primarily a hydration reaction to produce 3, and it 
does not catalyze the decarboxylation of 3.   
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  Previous work also identified Pro-1 and Arg-11 as critical residues for the 
dehalogenation reaction and resulted in two proposals for the catalytic mechanism 
(3).  One mechanism (Scheme 14) involves the activation of water by Pro-1 (acting as 
a general base) for attack at C-3 and the subsequent protonation at C-2 by Pro-1 (now 
functioning as a general acid).  An alternate mechanism implicates an unidentified 
residue in the activation of a water molecule while the proton at C-2 is derived from 
Pro-1, functioning only as a general acid.  In both mechanisms, Arg-11 plays a role in 
binding and perhaps catalysis:  it interacts with the carboxylate group of the substrate 
and may function as an electron sink to facilitate catalysis.  Electron density is drawn 
away from C-3 by the interaction with Arg-11, which generates a partial positive 
charge.  
  Whether Pro-1 functions as a general base or acid catalyst, our mutagenesis 
results further reinforce the critical nature of Pro-1 in the CaaD-catalyzed reaction.  It 
was not possible to quantify the enzymatic activity of the β−P1A mutant (as well as 
the α−R11A mutant) using a more sensitive UV assay, which measures the depletion 
of substrate at 224 nm.  However, it was determined by NMR spectroscopy that 
incubation of 1 and the β−P1A mutant for 24 hr did not produce acetaldehyde, which 
would result from the non-enzymatic decay of 3.  In 24 h, the α−R11A mutant 
generated a small quantity of acetaldehyde, suggesting, in turn, that a small amount of 
3 had formed.  In the absence of a crystal structure, it is not clear whether the 
inactivity of the β−P1A mutant and the diminished activity of the α−R11A are due to 
structural perturbations in addition to the absence of essential catalytic groups.  
Interestingly, the R11A mutation of 4-OT is significantly more detrimental to 
catalytic activity than is the P1A mutation, primarily due to an 8.6-fold increase in Km 
(8, 34).  The mutations did not result in major structural perturbations to the 4-OT 
structure (8, 34).   
  It is noteworthy that the reaction catalyzed by CaaD is a particularly difficult 
one, as has been reported for other enzyme-catalyzed dehalogenation reactions.  In 
0.5 M aqueous NaOH at 60 °C, about 10% of the chloride is removed from 1 in 24 hr 
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(35).  The kinetic analysis indicates that CaaD accelerates this process considerably 
and that 11 is a slightly better substrate for CaaD than is 1.  This could reflect the fact 
that C-3 is more susceptible to nucleophilic attack by water due to the greater 
activation at this position by the bromide.  It is not likely due to a difference in the 
leaving group ability of the bromide ion versus the chloride ion (bromide:chloride 
1.0:0.02) (36), as the 50-fold difference suggests that there would be a more 
significant difference in the rates.   
  CaaD will also process three acetylene compounds to products, which have 
different consequences for the enzyme.  The first compound, 2-oxo-3-pentynoate (7), 
an irreversible inhibitor of 4-OT, functions as a substrate for CaaD, and is converted 
to acetopyruvate, which does not inactivate the enzyme.  The most reasonable 
scenario for the formation of 8 from 7 is shown in Scheme 16.  The CaaD-catalyzed 
addition of water to 7 results in the formation of the enol species, 14.  Subsequent 
ketonization of 14 produces 8.  It has previously been demonstrated that 8, in aqueous 
solution, will form both the hydrate, 12, and the enol, 13 (26), accounting for the 
presence of these products in the spectrum.  Interestingly, 7 is a reasonably good 
substrate for CaaD with a kcat/Km value nearing that measured for 1 and 11.   
  The observation that 7 is a substrate and not an inhibitor reflects the difference 
between the active sites of CaaD and 4-OT.  CaaD is set up to do a hydration reaction 
while 4-OT carries out an isomerization reaction.  As a result, the active site of CaaD 
is likely to be more hydrophilic in nature than the active site of 4-OT.  Pro-1 of 4-OT 
is able to function as a general base at physiological pH because its pKa is lowered to 
about 6.4.  The hydrophobic active site of 4-OT plays a major role in lowering the 
pKa of Pro-1 and in providing a favorable environment for catalysis (10).   
  The other two acetylene compounds, 9 and 10, are also substrates for the 
enzyme, but upon hydration they are converted into potent inhibitors of CaaD, with 9 
being shown to modify Pro-1 of the β-subunit.  Modification of β−Pro-1 can occur by 
a mechanism-based route to form an acyl halide (or a ketene) or by Michael addition 
of β-Pro-1 to C-3 (Scheme 17).  In the first mechanism (Scheme 17A), the enzyme 
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hydrates 9 (or 10) to generate an unstable species 15, which will readily undergo a 
rearrangement to either the acyl halide (16), or the ketene (17).  Due to their 
reactivity, both species would be lethal to the enzyme.   
  In the second mechanism (Scheme 17B), Pro-1 attacks the C-3 position of 9 in 
a Michael-type reaction.  While conjugate additions to α,β-unsaturated carboxylic 
acids are not normally known, the inhibitor would presumably be activated by an 
interaction between the carboxylate group of 9 and a residue on the enzyme (i.e., α-
Arg-11).  Subsequent rearrangement would result in the covalent attachment of the 
propargyl moiety to the enzyme and the loss of the halide ion.   
  The observation that the covalent adduct on Pro-1 has a molecular mass of 85 
Da is consistent with the attachment of a 3-oxoacetate moiety.  Moreover, this adduct, 
a β-ketoacid, is quite susceptible to facile decarboxylation upon covalent attachment, 
resulting in an acetyl group (37).  At first glance, this sequence of events seems 
consistent with the mechanism-based route.  However, the 3-oxoacetate moiety could 
also be derived from a rearrangement of the propargyl moiety as shown in Scheme 
18.  A non-enzymatic rearrangement of the propargyl moiety would result in the 
formation of an electrophilic allene-type compound (18), which would be highly 
vulnerable to attack by a water molecule.  Ketonization of the resulting enol could 
gen erate the observed 3-oxoacetate moiety.   
  The detection of the acyl halide, the ketene, or their hydrolysis products, 
malonate, would provide a key piece of evidence supporting the mechanism-based 
route to inactivation.  Thus far, they have remained elusive and are likely to remain 
so.  If either species is generated by the enzyme, it must immediately alkylate the 
enzyme as there is no evidence for its release into solution.  This premise is supported 
the observation that the inactivation of CaaD and the bromide ion release upon 
inactivation are both nearly stoichiometric.  If immediate alkylation did not occur, 
then CaaD would continue to process 9, and the concentrations of bromide ion release 
would be greater than the concentrations of enzyme.   
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  While our current data are consistent with either route, the mechanism-based 
route is favored by the observation that 7 is converted to acetopyruvate (8) and recent 
experiments indicating that β−Pro-1 has a pKa of ~9.24, making it not sufficiently 
nucleophilic to add to 9 or 10 in a Michael type reaction.  Interestingly, if Pro-1 
functions as a general acid catalyst in the reaction, the initial hydration of 9 (or 10) by 
CaaD would remove a proton from Pro-1 and render it nucleophilic and quite 
susceptible to acylation by the acyl halide or reaction with the ketene.  Further studies 
are being actively pursued to discriminate between these mechanisms and a crystal 
structure of the inactivated enzyme will soon be available.   
  Our studies with the three acetylene compounds raise an intriguing possibility 
about the biological function of CaaD as well as its evolution.  The CaaD-catalyzed 
processing of the acetylene compounds is consistent with a hydratase reaction, 
suggesting that this might be the true physiological role of CaaD in the organism (or 
perhaps the original role).  The loss of the halide from 1 or 11, after the addition of 
water, might be a fortuitous side reaction resulting from the very rapid non-enzymatic 
decay of the unstable halohydrin.  This would make CaaD an “accidental” 
dehalogenase (28), which might have been conscripted to serve in the catabolic 
pathway for 1, 3-dichloropropene.  This speculation is further supported by the 
observation that CaaD does not appear to have a halide-binding pocket (3).  
Identification of the putative physiological substrate for CaaD would further assist in 
the delineation of its evolution.   
  Whatever the original function of CaaD is in the organism, the relationships 
between its α- and β-subunits and 4-OT and YwhB are interesting and raise questions 
about their evolutionary lineage.  In one possible scenario, an ancestral 
chromosomally encoded enzyme, having a non-specific tautomerase activity as well 
as other low-level activities, could give rise to the 4-OT activity and the CaaD 
activity through a duplication event followed by a series of mutations to obtain the 
desired activity (38, 39).  Both 4-OT and CaaD retain the ability to carry out a 
common chemical step, which is the protonation of the carbon adjacent to the 
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carboxylate group, involving Pro-1 and Arg-11.  In 4-OT, the Arg-11 functions as an 
electron sink to draw electron density toward C-5 for protonation by Pro-1.  In CaaD, 
Arg-11 may also function as an electron sink to draw electron density away from C-3 
(resulting in a partial positive charge at C-3) and thereby facilitate protonation at C-2 
by Pro-1.  While the physiological function of YwhB is not yet known, we have 
recently determined that both 4-OT and YwhB have low-level CaaD activities, which 
may result from the presence of this catalytic core (7).  These observations reinforce 
the hypothesis that the β−α−β structural motif is a versatile template (7), which Nature 
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1Abbreviations:  Ap, ampicillin;  CaaD, trans-3-chloroacrylic acid dehalogenase;  
Cm, chloramphenicol; DMSO, dimethyl sulfoxide;  ESI-MS,  electrospray ionization 
mass spectrometry;  HPLC, high pressure liquid chromatography;  IPTG, isopropyl-β-
D-thiogalactoside;  Kn, kanamycin;  LB, Luria-Bertani Medium;  MALDI-PSD, 
matrix assisted laser desorption-ionization post-source decay;  MALDI-TOF, matrix 
assisted laser desorption-ionization time-of-flight;  NMR, nuclear magnetic 
resonance;  4-OT, 4-oxalocrotonate tautomerase;  PCR, polymerase chain reaction;  
SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis;  TFA,  
trifluoroacetic acid 
 
2Trypsin has cleaved at the C-terminal side of Leu-11.  We attribute this to the 
presence of chymotrypsin in the non-TPCK-treated trypsin.   
 
3While the parent peptides selected for fragmentation have masses of 1242 and 1244, 
the b ions produced show only a mass addition of +42, instead of the expected 
additions of +42 and +44.  One possibility is that a gas-phase rearrangement of the 
fragments occurred to produce only the +42 fragments.  
 
4H.F. Azurmendi, S.C. Wang, M.A. Massiah, C.P. Whitman, A.S. Mildvan, (2003) 































































































































































Figure 29.  1H NMR (500-MHz, H2O) spectra monitoring the CaaD-catalyzed 
conversion of 1 to 3.  A.  The initial spectrum is acquired 5 min after the addition of 
CaaD to a NMR tube containing 1.  The signals corresponding to protons on 1 and 3 
are labeled. The signals at 2.34 ppm and 5.15 ppm correspond to the hydrate of 3.  B.  
The spectrum acquired 30 min after the addition of enzyme.  The signal at 2.0 ppm 








Figure 30.  UV spectra (1-mm path length) following the CaaD-catalyzed conversion 
of 7 to 8.  Spectra were recorded every 30 s until the reaction neared completion (~15 
min).  The decrease in absorbance at 234 nm corresponds to the loss of 7 (12), while 






Figure 31.  The inactivation of CaaD after incubation with varying amounts of 9 or 
10 (filled diamonds, 0 µM; filled squares, 20 µM; filled triangles, 40 µM).  The 
concentration of CaaD used is these experiments was 36 µM.  The inactivation of 
CaaD by 9 is shown in panel A while the inactivation of CaaD by 10 is shown in 











































Figure 32.  Analysis of bromide ion release from various amounts of 9 (filled 
diamonds, 0 µM; filled squares, 25 µM; filled triangles, 150 µM; crosses, 300 µM) 






















Figure 33.  MALDI-TOF mass spectral analysis of the tryptic digest of A) a control 
sample containing CaaD and B) a CaaD sample treated with 9.  The signals 
corresponding to fragments of the β-subunit are labeled with open triangles while the 
filled triangle designates the signal at 1200.63 ± 0.06 Da (in panel A) and at 1242.68 ± 
0.06 and 1244.75 ± 0.12 Da (in panel B).  The calculated and observed masses for 
these signals are summarized in Table 4.  The signals corresponding to fragments of 




























































Figure 34.  MALDI-PSD fragmentation spectra of the peaks at A) 1200.63 Da in the 
control digest, corresponding to the PFIECHIATGL (1-11) fragment of the β-subunit 
of CaaD and at B) 1242.68 and 1244.75 in the treated digest, corresponding to the 
PFIECHIATGL (1-11) modified by adducts of 42 and 44 Da, respectively.  The b 
ions and the b1 ions (in panels A and B, respectively) are labeled with open triangles.  






























































Table 2.  Kinetic Parameters for CaaDa 
 
 
 substrate kcat Km kcat/Km  
 
  (s-1) (µM) (M-1s-1)  
 
 1 3.8 ± 0.1 31 ± 2 1.2 x 105  
 
 11 5.1 ± 0.1 37 ± 2 1.4 x 105  
 
 7 0.7 ± 0.02 110 ± 4 6.4 x 103 
 
 
aThe steady-state kinetic parameters were determined in 20 mM sodium phosphate 
buffer (pH 9.0) at 23 °C.  Errors are standard deviations. 
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Table 3.  Protection of CaaD by 11. 
 
    
[I] 
 
1 mM 11 
 
5 mM 11 
 
10 mM 11 
 
 
20 µM 9a 
 
35% (10 s)b 
 
35% (40 s) 
 
70% (70 s) 
 
40 µM 9 
 
20 µM 10 
 
40 µM 10 
 
40% (10 s) 
 
65% (10 s) 
 
40 % (10 s) 
 
50% (30 s) 
 
40% (35 s) 
 
45% (40 s) 
 
40% (60 s) 
 
25 % (150 s) 
 
20% (130 s) 
 
 
aCaaD was incubated with the indicated concentrations of 9 or 10 in 20 mM sodium 
phosphate buffer (pH 7.3) at 23 °C along with the indicated concentrations of 11. 
 




























785.50 785.51 785.53 
22-29 
 
903.48 Not detected 903.53 (weak) 
30-36 
 
703.36 Not detected 703.39 (weak) 
37-55 
 
2066.11 2066.16 2066.16 
56-65 
 
1070.52 1070.54 1070.58 
66-70 
 
474.26 Not detected Not detected 
 







pH RATE ANALYSES OF WILD-TYPE AND α-P1A TRANS-3-




  The recently discovered alkene dehalogenase, trans-3-chloroacrylic acid 
dehalogenase (CaaD), converts the trans isomers of 3-haloacrylates (1 or 2, Scheme 
19) to the unstable halohydrin intermediate (3) by the addition of water.  Subsequent 
collapse of 3 affords malonate semialdehyde (4) (1).  The (αβ)3 heterohexameric 
CaaD is elaborated by the soil bacterium Pseudomonas pavonaceae 170 as part of a 
degradative pathway for 1,3-dichloropropene, the active ingredient in the 
commercially available fumigants, Shell D-D and Telone II (2,3).  These compounds 
are mixed in with the soil to kill nematode parasites.  Sequence analysis placed CaaD 
in the 4-oxalocrotonate tautomerase (4-OT) family of the tautomerase superfamily 
(1).  Conserved residues include the N-terminal proline, found in both subunits, and 
an arginine at position 11, found only in the α-subunit.  Previous site-directed 
mutagenesis experiments identified Pro-1 of the β-subunit and Arg-11 of the α-
subunit as critical mechanistic residues (1).  These experiments have also suggested 
the Pro-1 of the α-subunit is not critical for catalysis, since the observed activity of 
the α-P1A mutant was comparable with those of the wild-type enzyme (1). 
  Tautomerase superfamily members are structurally homologous proteins, 
which share a common β−α−β structural fold as well as a catalytic Pro-1 (4, 5).  In the 
bacterial isomerase 4-OT, the best-characterized enzyme in the superfamily, Pro-1 
functions as a general base.  The overall reaction transforms β,γ−unsaturated enones to 
their α,β-isomers via a dienol intermediate (4).  Pro-1 of 4-OT can function 
effectively as a general base at cellular pH because it has a pKa of ~ 6.4, as 
determined by a pH rate profile and direct NMR titration (6, 7).  The pKa is lowered 
~3 pH units from that observed for the proline in the model compound, proline amide, 
and is largely the result of its presence in a hydrophobic active site.  Phe-50 plays a 
major role in maintaining the hydrophobic environment (8).  An amino acid with an 
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aromatic or hydrophobic side chain is conserved in this position in most known 4-OT 
family members.  This observation and the fact that that Pro-1 has been implicated as 
the catalytic base in superfamily members characterized to date, suggested that Pro-1 
might behave similarly in homologues such as CaaD.   
  On the basis of these observations, two potential roles have been proposed for 
the essential β-Pro-1 (Scheme 20) (1).  In one mechanism, Pro-1 is a general base that 
activates water for attack at C-3 of 1.  The proton at C-2 comes from solvent or Pro-1, 
now functioning as a general acid catalyst.  In the second mechanism, an unknown 
residue (i.e., B:, the general base) activates the water molecule for attack at C-3 while 
the proton at C-2 comes from Pro-1, a general acid catalyst.  To discriminate between 
these two mechanisms, we determined the pKa of β-Pro-1 by pH rate studies.  If the 
pKa is substantially lowered, as it is in 4-OT, it could be inferred that β-Pro-1 acts as a 
general base.  If the pKa is comparable to that of proline amide (pKa ~ 9.4), β-Pro-1 
cannot function as a general base at cellular pH.   
  To gain insight into the precise roles that the N-terminal prolines play in the 
catalytic mechanism of CaaD, we first conducted a pH rate analysis of the wild-type 
enzyme by UV spectroscopy using trans-3-bromoacrylate (1) as the substrate.  Site-
directed mutagenesis was used to construct the α-P1A-CaaD mutant, which was over-
expressed and purified to near homogeneity.  The kinetic parameters for the α-P1A 
mutant were determined under the conditions used for the wild-type enzyme.  As has 
been shown elsewhere, the α-Pro-1 did not appear to be important for catalysis 
because its kinetic parameters were similar to those of the wild-type enzyme.  A 
kinetic pH rate analysis of the mutant enzyme was also performed to distinguish the 
role of α-Pro-1.  Both the wild-type and α-P1A-CaaD show a bell-shaped dependence 
on pH, confirming the requirements for a basic and an acidic group in the mechanism. 
  These results indicate that Pro-1 of the α-subunit does not play a role as either 
an acid or a base catalyst.  Moreover, a substantial decrease is not observed for any of 
the pKa values, indicating that β-Pro-1 does not act as a general base.  Both the acidic 
and basic groups are attributable to the enzyme.  The acidic carboxylate group of 
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trans-3-bromoacrylate can be ruled out because its pKa value was measured at ~4.6.  
To assign the observed pKa values to specific peaks, literature procedures were 
modified to provide uniformly 15N-labeled protein for 15N-NMR spectroscopy (9, 10).  
A brief discussion of the NMR titration results, which were performed in 
collaboration with Dr. Albert S. Mildvan (Johns Hopkins University), is described 
here.  The NMR data assigns a pKa of ~9 to β-Pro-1, suggesting that it acts as an acid 
catalyst.  These results, taken together, identify a new role for the conserved amino-




MATERIALS AND METHODS 
 
  Materials.  All reagents, buffers, and solvents were obtained from Aldrich 
Chemical Co. (Milwaukee, WI), Sigma Chemical Co. (St. Louis, MO), Fisher 
Scientific Inc. (Pittsburgh, PA), or Spectrum Laboratory Products, Inc (New 
Brunswick, NJ) with the following exceptions.  The trans-3-chloroacrylate (2) was 
obtained from Fluka Chemical Corp. (Milwaukee, WI).  Literature procedures were 
used for the syntheses of the trans-isomer of 3-bromoacrylate (1) (11) and 2-oxo-3-
pentynoate (5) (12) and the purification of CaaD (13).  Tryptone, yeast extract, and 
agar were obtained from Becton, Dickerson, and Company (Franklin Lakes, NJ).  The 
Ultrafree DA centrifugal filter units, the YM-3 ultrafiltration membranes, and the 
Amicon concentrators were obtained from Millipore Corp. (Billerica, MA).  The thin-
walled PCR tubes were obtained from Ambion, Inc. (Austin, TX).  Restriction 
enzymes, PCR reagents, and T4 DNA ligase were obtained from Promega Corp. 
(Madison, WI) or New England Biolabs (Beverly, MA).  The Wizard PCR Preps 
DNA purification systems were purchased from Promega Corp.  The QIAprep Spin 
Miniprep kit was obtained from Qiagen, Inc. (Valencia, CA).  Herculase DNA 
Polymerase was obtained from Stratagene (La Jolla, CA).  The remaining molecular 
biology reagents including agarose, DNA ladders, and protein molecular weight 
standards, were obtained from Invitrogen Corporation (Carlsbad, CA).  
Oligonucleotides for DNA amplification and sequencing were synthesized by either 
Oligos Etc. (Wilsonville, OR) or Genosys (The Woodlands, TX).   
  Strains and Plasmids.  Escherichia coli strains DH5α (Invitrogen) and JM109 
(Promega) were used for cloning and isolation of plasmids.  E. coli strains 
BL21(DE3)pLysS from Novagen and BL21-Gold(DE3)pLysS from Stratagene (La 
Jolla, CA) were used for recombinant protein expression.  The plasmids containing 
the gene for the α-subunit of CaaD [pET-24a(+)-CaaDα] and the gene for the β-
subunit of CaaD [pET-21a(+)-CaaDβ4] were constructed as described elsewhere (13).   
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  Methods.  Techniques for restriction enzyme digestions, ligation, 
transformation, and other standard molecular biology manipulations were based on 
methods described elsewhere (8), or as suggested by the manufacturer.  Plasmid DNA 
was introduced into cells by electroporation using a Cell-Porator Electroporation 
System (Whatman Biometra, Göttingen, Germany).  The PCR was performed in a 
DNA thermal cycler (Model 480) obtained from PerkinElmer Inc (Wellesley, MA).  
DNA sequencing was done at the DNA Core Facility in the Institute for Cellular and 
Molecular Biology at the University of Texas (Austin).  Kinetic data were obtained 
on an Agilent 8453 Diode Array spectrophotometer.  Solutions in the cuvettes were 
mixed using a stir/add cuvette mixer (Bel-Art Products, Pequannock, NJ).  The 
kinetic data were fitted by nonlinear regression data analysis using the Grafit program 
(Erithacus Software Ltd., Horley, U. K.) obtained from Sigma Chemical Co.  HPLC 
was performed on a Waters (Milford, MA) 501/510 system or a Beckman System 
Gold HPLC (Fullerton, CA) using a TSKgel Phenyl-5PW hydrophobic column 
(Tosoh Bioscience, Montgomeryville, PA).  Protein was analyzed by Tris glycine 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under 
denaturing conditions on 17.5% gels using either the Mini-Protean II or III vertical 
gel electrophoresis apparatus obtained from Bio-Rad (Hercules, CA) (14).  Protein 
concentrations were determined using the method of Waddell (15).   
  Site-Directed Mutagenesis.  The α-P1A-CaaD mutant was constructed using 
the gene for the α-subunit of CaaD [in pET-24a(+)] as the template (13).  The gene is 
flanked by an NdeI restriction site and a NotI restriction site.  The mutation was 
introduced by overlap extension PCR (16). The external PCR primers were 
oligonucleotides 5'-GCG GAT AAC AAT TCC CCT CT-3' (designated primer A) 
and 5'-CTC AGC TTC CTT TCG GGC TT-3' (designated primer D).  Primer A 
corresponds to a region 36 bases upstream of the NdeI restriction site in the pET-
24a(+) vector.  Primer D corresponds to the complementary sequence of a region 20 
bases downstream of the His-tag region in pET-24a(+).  The internal primers were 5'-
AGA GAT CAT CGC CAT ATG TAT ATC-3' (primer B) and 5'-GAT ATA CAT 
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ATG GCG ATG ATC TCT-3' (primer C).  In each internal primer, the codon for the 
desired mutation is underlined and the remaining bases correspond to the coding 
(primer C) or the complementary sequence (primer B).   
  For the construction of the AB and CD fragments, the PCR reaction mixture 
contained 10× Herculase reaction buffer (5 µL), 10 mM dNTPs (1 µL), pET-24a(+) 
containing the gene for the α-subunit of CaaD (5 µL of a 1:500 dilution), 20 µM stock 
solutions of primers A and B or C and D (2.5 µL each), Herculase (0.5 µL), and 
sufficient water to make the final volume 50 µL.  The PCR protocol consisted of an 
initial 2-min incubation period at 92 °C, followed by 30 cycles of the PCR where 
each cycle contained a denaturation step at 92 °C for 30 s, an annealing step at 60 °C 
for 30 s, and an elongation step at 72 °C for 60 s, and a final 10-min incubation 
period at 72 °C.  Purification of the AB and CD fragments was performed using gel 
electrophoresis and the Wizard PCR Preps DNA purification system.  Construction 
and purification of the AD fragment was carried out as described above except that 
the external primers were used, and the AB and CD products (1 µL each) were used 
as template.  Restriction digests of the pET-24a(+) vector and the AD fragment were 
performed at 37 °C for 6 hours followed by purification using gel electrophoresis and 
the Ultrafree-DA units.  The ligation reaction was performed using the Quick 
Ligation Kit (New England Biolabs, Inc., Beverly, MA).  The ligated plamids were 
purified by ethanol precipitation and re-suspended in sterile water (5 µL).  The 
purified DNA (2 µL) was used to transform E. coli DH5α by electroporation.  
Transformed cells were plated onto LB/Kn (50 µg/mL) plates for selection.  Two 
colonies were selected at random for insert sequencing.  One colony, designated pET-
24a(+)-CaaD-αP1A-1, had only the desired mutation.   
  Overexpression and Purification of the α-P1A-CaaD Mutant.  For expression, 
pET-24a(+)-CaaD-αP1A 1 was co-transformed into E. coli strain BL21-
Gold(DE3)pLysS by electroporation along with pET-21a(+)-CaaDβ4 (containing the 
gene for the β-subunit of CaaD).  Cells were selected in triple antibiotic media (13), 
and subsequent growth and purification were performed as described for wild-type 
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CaaD.  Typically a 3L culture of the αP1A-CaaD mutant yields 9-10 g of cells and 
25-50 mg of protein, which was >95% homogenous as assessed by SDS-PAGE.  The 
observed monomer masses for the α- and β-subunits of αP1A-CaaD were 8315.9 
(calc. 8318.0) and 7505.3 (calc. 7507.0), respectively. 
  Kinetic Characterization of α-P1A-CaaD.  The kinetic assays were performed 
as described elsewhere for the wild-type enzyme (13).  The kinetic assays were 
performed in 20 mM Na2HPO4 buffer, pH 9.0, observing the decrease in absorbance 
at 224 nm corresponding to the hydration of trans-3-bromoacrylate (1, ε = 9700 M-1 
cm-1) and trans-3-chloroacrylate (2, ε = 4900 M-1 cm-1).  An aliquot of α-P1A-CaaD 
(240 µL of a 5.6 mg/mL solution) was diluted into buffer (40 mL) and incubated for 1 
h.  Subsequently, a 1 mL-portion of the enzyme was transferred to a cuvette and 
assayed by the addition of a small quantity of substrate (1 or 2) from a 5 mM or 50 
mM stock solution (in 100 mM Na2HPO4 buffer, pH 9.2).  The addition of 1 or 2 (as 
their free acids) to the 100 mM phosphate buffer adjusted the pH of the stock solution 
to about 7.0.  The 5 mM stock solution was made by dilution of an aliquot of the 50 
mM stock solution into 100 mM NaH2PO4 buffer, pH 7.3.  The concentrations of 
substrate used in the assay ranged from 10-150 µM.   
  The hydration of 2-oxo-3-pentynoate (2-OP, 5, Scheme 21) by CaaD was 
monitored by following the formation of acetopyruvate (6) at 294 nm (ε = 7,000 M-1 
cm-1) in 20 mM sodium phosphate buffer (pH 9.0) (17).  An aliquot of α-P1A-CaaD 
(240 µL of a 2.9 mg/mL solution) was diluted into buffer (50 mL) and incubated for 1 
h.  The assay was initiated by the addition of a small quantity of 5 from either a 5.4 
mM or 53.6 mM stock solution.  The stock solution (53.6 mM) was made by 
dissolving the appropriate amount of 2-oxo-3-pentynoate (8.5 mg) in 100 mM 
Na2HPO4 buffer (1.42 mL, pH 9.2).  The addition of 5 (as the free acid) adjusted the 
pH of the buffer to ~7.  The 5.4 mM stock solution was made by dilution of an aliquot 
of the 53.6 mM into 20 mM NaH2PO4 buffer, pH 7.3.  The concentrations of 5 used 
in the assay ranged from 8-536 µM.   
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  15N-Labeling of Wild Type CaaD and the α-P1A Mutant.  For NMR studies, 
the wild type and mutant enzymes were 15N-labeled by the modification of literature 
protocols (9, 10).  The M9 minimal medium was enriched with supplements found in 
the MOPS minimal media (10) and 15NH4Cl (99% enriched).  All other nitrogen 
sources (e.g., nitrates) were removed.  Accordingly, a liter of culture medium 
contained 5 × M9 salts without NH4Cl (200 mL), 1M MgSO4 (2 mL), 20% glucose 
(20 mL), 1 M CaCl2 (100 µL), B1 solution (1.4 mL), vitamin supplement solution (1.4 
mL), thymine-uracil solution (1.4 µL), Mg micronutrient solution (1 mL), and 25% 
15NH4Cl (2 mL).   
  The following procedures were used for the growth and purification of the 
15N-labeled enzymes.  Cultures of LB media containing both ampicillin (100 µg/mL) 
and kanamycin (50 µg/mL) were inoculated from single colonies of the appropriate 
enzyme in its expression strain and grown overnight at 37 °C.  Subsequently, cultures 
(500 mL) of the M9 medium described above and Ap/Kn (100 µg/mL and 50 µg/mL, 
respectively) were inoculated with 3 mL of the overnight culture and incubated at 30 
°C with vigorous shaking.  When the OD600 reading reached ~0.8, the cultures were 
induced with IPTG (1 mM) and then allowed to continue to grow at 30 °C.  
Additional aliquots of ampicillin (50 µg/mL) and kanamycin (25 µg/mL) were added 
to each culture to maintain the plasmids in the growing cells.  After a 24 hr total 
growth period, cells were harvested by centrifugation and stored at -80 °C until use.  
Typically 5 L of culture yields 30 g of cells for CaaD, and 25 g for the α−P1A mutant.  
Due to low yields of enzyme, 10-20 L of culture were processed in each purification 
procedure, which was performed as described previously.  If the protein still 
contained significant contaminanting protein after the G-200 sizing column (as 
assessed by SDS-PAGE), the concentrated protein was made 1 M in ammonium 
sulfate and reloaded onto the phenyl-5PW column for final purification.  Typically, 
the yields per liter of culture are:  CaaD, 1-3 mg (> 90% homogenous) and α−P1A-
CaaD, 2 mg (>95% homogenous). 
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  pH Dependence of CaaD Using 1.  The dependence of the rate of hydration of 
1 was determined in 20 mM sodium phosphate buffer, pH range 6.5-10.26.  
Compound 1 was used as the substrate due to its higher extinction coefficient, which 
greatly facilitated measurements.  The buffers were made up by combining 
appropriate quantities of 20 mM NaH2PO4, 20 mM Na2HPO4, and 20 mM Na3PO4 
buffers to maintain constant ionic strength.  For each pH value, a sufficient quantity 
of enzyme (from a stock solution of 8.5 mg/mL in 20 mM NaH2PO4, pH 7.3) was 
equilibrated in buffer (40 mL) for ≥ 1 hr at room temperature (29 °C).  The addition 
of the large amount of enzyme changed the pH, so that the reported pH values (6.50-
10.26) are those determined after the addition of the enzyme.  Subsequently, aliquots 
(1 mL) were removed and assayed for activity using 12 substrate concentrations 
ranging from 10-150 µM.  Stock solutions of substrate were made up as described 
(13).  The volume of substrate added was 8 µL or less in all experiments.  The 
amounts of enzyme used were 8 µL/mL (pH 6.50), 5 µL/mL (pHs 7.03-7.43), 4 
µL/mL (pHs 7.99-8.89), 4.5 µL/mL (pH 8.97), 6 µL/mL (pH 9.44-9.77), 9 µL/mL (pH 
10.02), and 10 µL/mL buffer (pH 10.26).  In order to show that the activity at high pH 
was due to the enzymatic reaction (and not the result of denaturation), CaaD (20 µL) 
was equilibrated at room temperature in 20 mM phosphate buffer (2 mL, pH 10.51) 
for 2 hrs.  An aliquot (200 µL) was subsequently diluted into 20 mM phosphate buffer 
(pH 9.0) and immediately assayed at two concentrations of (1) (100 µM and 150 µM).  
The resulting activity was comparable to that expected for the wild type at pH 9.0, 
suggesting that CaaD was not denatured at the high pH values investigated.   
  pH Dependence of α-P1A-CaaD Using 1.  The pH rate profile for the α-P1A 
mutant of CaaD was determined using a procedure similar to that used for the wild-
type.  Substrate solutions and buffers were made as described for wild-type CaaD.  
For each pH, a sufficient quantity of enzyme was equilibrated in buffer (40 mL) for ≥ 
1 hr at 22 °C.  The addition of the enzyme changed the pH, so that the reported pH 
values are those determined after the addition of the enzyme.  The range of final pHs 
was 6.50-10.82.  The amounts of enzyme (18.0 mg/mL stock in 20 mM NaH2PO4, pH 
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7.3) used were 1.5 µL/mL (pHs 6.50 and 10.82), 1 µL/mL (pHs 7.06 and 9.50), 0.75 
µL/mL (pHs 7.48-9.32), and 2.5 µL/mL (pH 10.26). 
  Determination of the pKa of 1.  A 1 M solution of 1 was made by dissolving 
the free acid (78.0 mg) in deionized water (517 µL).  An equivalent volume of 1 M 





  Production, Expression, and Characterization of α-P1A-CaaD.  The α-P1A-
CaaD mutant was constructed by overlap extension PCR, expressed in E. coli, and 
purified to homogeneity (>95% as assessed by SDS-PAGE) using the procedure for 
wild-type CaaD described earlier.  The sequence of the mutant was confirmed by 
DNA sequencing to ensure that no other mutations were present.  The range of 
overproduction was 8-17 mg/L.  Mass spectrometric analysis confirmed the 
molecular mass of the mutant α-P1A subunit, and that the N-terminal residues were 
not blocked by the initiating methionine. 
  Kinetic Characterization of α-P1A-CaaD.  The steady-state parameters for the 
α-P1A-CaaD mutant were determined using 1, 2, and 5 as substrates.  The observed 
values for kcat, Km, and kcat/Km are given in Table 5 along with those of the wild-type 
enzyme (13).  These values are similar, confirming that α-P1A is not essential for 
catalysis.  The major difference observed is for the Km value for 5, which is 2-fold 
higher in the wild-type enzyme than the mutant.  This is also reflected in the values 
for kcat/Km, since the kcat values are identical.  This may be due to an increase in the 
opening of the active site or another structural perturbation that allows 5 to bind more 
readily to the α-P1A mutant. 
  Expression and Characterization of Uniformly 15N-Labeled Enzymes.  
Previous efforts for uniform labeling of proteins in the Whitman laboratory have 
relied on a MOPS-buffered medium (6, 10).  To simplify this procedure, a 
modification of M9 minimal medium was used for the overexpression of labeled 
CaaD and α-P1A-CaaD.  Similar procedures are described elsewhere (18).  Due to 
difficulties with expression, which are likely due to the presence of the 15N-label 
compounded by the co-expression of two plasmids, the M9 minimal medium was 
enriched with several supplements (10).  Without supplementation, only low 
expression of labeled recombinant CaaD was observed.   
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  pH Dependence of the Kinetic Parameters for CaaD.  The dependence of the 
rate of hydration of 1 was determined in 20 mM sodium phosphate buffer over the 
range 6.50 – 10.26.  The addition of the large quantity of enzyme significantly altered 
some pHs, so that the values reported are the final values obtained after mixing buffer 
with enzyme.  A plot of log (kcat/Km) shows a bell-shaped dependence on pH with 
slopes of 1 on the ascending and descending limbs (Figure 35, open circles).  The 
slopes of unity indicate that a single basic group (ascending limb) and a single acidic 
group (descending limb) are important for catalysis.  These groups are either on the 
free enzyme or correspond to the carboxylate group of the substrate.  A non-linear 
least-squares fit of the data gives pKa values of 8.0 ± 0.2 and 9.1 ± 0.2 for these 
groups.  These values can be assigned to the free enzyme since the pKa of the 
substrate (1) is 4.6 by direct titration. 
  A plot of log kcat (Figure 35, filled circles) also shows a bell-shaped 
dependence on pH with slopes of 1 on both the ascending and descending limbs.  
Similarly, a non-linear least-squares fit for log kcat gives pKa values of 6.8 ± 0.2 and 
9.6 ± 0.2.  These results indicate that one acidic and one basic group in the enzyme-
substrate complex are important. 
 pH Dependence of the Kinetic Parameters for α-P1A-CaaD.  The dependence 
of the rate of hydration of 1 by the mutant enzyme was determined in 20 mM sodium 
phosphate buffer over the range 6.50-10.82.  Final pH values were those obtained 
after equilibration of the enzyme in buffer.  A plot of log (kcat/Km) shows a bell-
shaped dependence on pH with slopes of 1 on the ascending and descending limbs 
(Figure 36, open circles).  The slopes of unity indicate that one basic group 
(ascending limb) and one acidic group (descending limb), from either the enzyme or 
the substrate, are important in catalysis.  A non-linear least-squares fit of these data 
gives pKa values of 7.9 ± 0.2 and 9.0 ± 0.2.  These values can be assigned to residues 
in the free enzyme and not to the substrate. 
  The plot of log kcat vs. pH (Figure 36, filled circles) shows a similar bell-
shaped dependence on pH with slopes of unity on both limbs, indicating that one 
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basic and one acidic group are involved in the enzyme-substrate complex.  The non-
linear least-squares fit gives pKa values of 6.4 ± 0.2 and 9.7 ± 0.2 for the mutant 
protein.  These results indicate that one acidic and one basic group on the mutant 
enzyme are important in catalysis.  Overall, the pKa values are equivalent for the 
wild-type and mutant enzymes.  This indicates that α-Pro-1 is not involved in 
catalysis, and that β-Pro-1 does not function as a general base. 
  Determination of the pKa of 1.  The pKa of 1 was determined by direct titration 






  The discovery and initial characterization of trans-3-chloroacrylic acid 
dehalogenase was exciting for a number of reasons.  From an evolutionary standpoint, 
CaaD was of interest because it introduced a new activity to the tautomerase family – 
that of dehalogenation by hydration.  Thus far, the characterized members of the 
tautomerase family including 5-carboxymethyl-2-hydroxymuconate isomerase 
(CHMI), macrophage migration inhibitory factor (MIF), 4-OT, and YdcE, a 4-OT 
homologue from Escherichia coli K-12, have only been known to catalyze 
tautomerization and/or isomerization reactions (5, 19, 20).  CaaD, which shows 
sequence identity with 4-OT and YwhB, a homologue of unknown function from 
Bacillus subtilis, was initially placed in the tautomerase superfamily by virtue of its 
sequence similarity.  Catalytic residues of interest include the β-Pro-1 and the α-Arg-
11, which have been shown in other work to be crucial for catalysis (1).  The N-
terminal proline is also apparently conserved in the α-subunit of CaaD, although 
initial mutagenesis studies described elsewhere suggested it was not essential for 
catalysis (1).  These observations raised questions about the role of the amino 
terminal prolines in the α- and β-subunits.  The first question is whether β-Pro-1 
functions as a general base catalyst, as it does in the characterized tautomerases, or as 
an acid catalyst?  A second question is whether the conserved α-Pro-1 plays any role 
in the reaction.  To answer these questions, we investigated the properties of α-P1A-
CaaD and determined the pH rate profiles of both the wild-type and the α-P1A mutant 
enzymes. 
  In previous work, the α-P1A CaaD mutant was constructed but not rigorously 
characterized (1).  A crude extract of mutant protein, generated by lysis and 
centrifugation, was used without further purification in a colorimetric assay that 
monitors halide production.  Two measurements at a single substrate concentration (5 
mM) of either 1 or 2 provided a specific activity, expressed in terms of units (the 
amount of enzyme that catalyzes the production of 1 µmol halide ion per minute).  
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The relative activities, compared to a similar procedure performed with wild-type 
enzyme, were 0.06-fold lower for 1 and 0.16-fold for 2.  On the basis of these 
observations, the authors suggested that α-Pro-1 was not necessary for catalysis.  In 
view of the facts that the α-P1A mutant was not purified and kinetic parameters were 
not obtained, this mutant was re-examined. 
  The α-P1A mutant was made using site-directed mutagenesis.  The α-P1A 
plasmid was co-expressed with the wild-type β-subunit plasmid, and the enzyme was 
purified to near homogeneity using the protocol developed for wild-type CaaD.  DNA 
sequencing of the construct demonstrated that no other mutations had been introduced 
into the α-subunit plasmid.  Mass spectrometry of the mutant protein indicated that 
the amino-terminal residues were not blocked by the initiating methionine.  The yield 
of the mutant protein was slightly lower than that of the wild-type enzyme, but the 
purity was comparable as evaluated by SDS-PAGE.   
  UV assays have been developed to assess the activity of wild-type CaaD (13).  
One assay monitors the decrease in absorbance at 224 nm of the haloacrylate 
compounds 1 and 2 in phosphate buffer.  Another substrate, 2-oxo-3-pentynoate (2-
OP, 5) was used to assess the ability of CaaD to catalyze a hydration reaction.  The 
resulting product, acetopyruvate, shows a characteristic increase in absorbance at 294 
nm.  Hence, the three substrates were used to characterize the activity and properties 
of α-P1A-CaaD. 
  Accordingly, the steady-state parameters for the α-P1A-CaaD mutant were 
determined using trans-3-bromoacrylate (1), trans-3-chloroacrylate (2), and 2-OP (5) 
as substrates.  The values for kcat, Km, and kcat/Km that result from the UV assays are 
given in Table 5 together with those of the wild-type enzyme.  The kcat and kcat/Km 
values for the haloacrylate substrates 1 and 2 are slightly lower than observed for the 
wild-type, representing approximately 0.4 to 0.2-fold lower than the wild-type 
activity.  The Km values for these substrates are approximately equal.  These values 
suggest that although it may play a structural or catalytic role, α-Pro-1 is not an 
essential residue.   
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  For the hydration of 2-OP (5), the values for kcat are identical.  This suggests 
that α-Pro-1 is not crucial for the hydration reaction.  The most striking difference 
observed is in the Km value for 5, which is half that observed for the wild-type 
enzyme.  The difference in Km values is also reflected in the values for kcat/Km.  
Replacement of proline with an alanine residue, which removes a larger ring system 
in favor of a smaller methyl group, may allow 5 to better fit into the active site as it is 
a larger molecule than either 1 or 2.  Thus, α-Pro-1 may play a role in maintaining the 
structural integrity of the entrance to the active site. In the absence of a structure for 
CaaD, a structural role for α-Pro-1 cannot be determined. 
  The kinetic pH rate profile for wild-type CaaD was determined in an attempt 
to elucidate the role of β-Pro-1.  Two potential roles for β-Pro-1 have been proposed 
(1).  In one mechanism, the proline could function as a general base in catalysis, 
deprotonating water for attack on the double bond.  This hypothesis is consistent with 
the role of Pro-1 in other tautomerase superfamily members.  In 4-OT, Pro-1 is able 
to act as a catalytic base because its pKa is lowered approximately 1000-fold to 6.4 (6, 
7).  Thus, at physiological pH (~7-7.3), 80-88% of the N-terminal prolines are 
deprotonated.  If β-Pro-1 was a general base in the CaaD-catalyzed reaction, a similar 
drop in one of the pKas would be expected.  For instance, an observed pKa of 7.5 
would yield 24-39% deprotonation at physiological pH.  In the second mechanism, β-
Pro-1 functions as a general acid from which the proton at C-2 is obtained.  In this 
event, a decrease in the  pKa of β-Pro-1 would not be anticipated.  However, the 
absence of a low pKa value would only be indirect evidence that β-Pro-1 is a general 
acid catalyst.  Definite proof requires the assignment of the observed pKa value(s) to 
specific residues. 
  The pH rate profile for the wild-type enzyme was determined in 20 mM 
sodium phosphate buffer over the range of 6.5-10.26 at 30 °C.  The initial pHs 
examined varied at 0.25 pH increments.  However, the large amounts of enzyme 
required to detect activity altered the pH, particularly under fairly acidic or fairly 
basic conditions.  Thus, the final pHs are not at regular intervals due to the changes 
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caused by the addition of enzyme.  The pH dependence of log kcat/Km (Figure 35) for 
the wild-type enzyme showed two limbs, each with a slope of unity.  The slopes of 
one indicate that a single group is involved in base catalysis, and a single group is 
involved in acid catalysis.  These groups may arise from either the free enzyme or the 
free substrate.  The basic group, which corresponds to the ascending limb, has a pKa 
of 8.0 ± 0.2.  To confirm that this value was not attributable to the carboxylate ion of 
(1), the pKa of the substrate was directly measured to be 4.6.  Compound 1 has no 
ionizable groups near pH ~8, so the observed pKa does not correspond to that of the 
substrate.  Similarly, the pKa of the descending limb indicates that an acidic group is 
necessary for activity.  The pKa for this group is 9.1 ± 0.2.   
  These results are not consistent with β-Pro-1 functioning as a catalytic base.  
The pKa at 9.1 is comparable to the pKa (~ 9.4) of the model compound, proline 
amide.  Proline amide is not a base at physiological pH since the prolyl nitrogen is 
nearly fully protonated.  If β-Pro-1 were responsible for the observed pKa value at 
9.1, it would be 98-99% protonated and could not act as a base under cellular 
conditions.  If β-Pro-1 were responsible for the pKa at 8.0, approximately 83-91% of 
the proline would be protonated at physiological pH.  While this represents a 
significant increase in the amount of available base, it is unlikely that β-Pro-1 would 
be an efficient general base catalyst.   
  In order to determine whether one of the pKa values was due to α-Pro-1, we 
examined the pH dependence of the α-P1A-CaaD reaction.  The final pH values vary, 
again due to the amount of enzyme added at each pH.  The results, however, are 
strikingly similar to those of the wild-type.  The observed pKa values for kcat/Km 
(Figure 36) are 7.9 ± 0.2 and 9.0 ± 0.2 on the ascending and descending limbs, which 
both show a slope of one.  Thus, a single basic group and a single acidic group from 
the free enzyme or the free substrate are involved in catalysis.  Again, the substrate 
can be ruled out because its pKa is 4.6 and is not within the range observed here.  
Proline-1 of the α-subunit is also not responsible for either value.  If α-Pro-1 were 
responsible for one of the values, a change would have been observed.  However, the 
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corresponding wild-type pKa values were 8.0 ± 0.2 and 9.1 ± 0.2, which are 
equivalent to those observed for the mutant.   
  Similarities are also evident in the pH dependences of log kcat for the wild-
type and mutant enzymes.  The pKa values for kcat are 6.8 ± 0.2 and 9.6 ± 0.2 (Figure 
35) for the wild-type and 6.4 ± 0.2 and 9.7 ± 0.2 for α-P1A-CaaD (Figure 36).  In 
each plot, the slope of the ascending and descending limbs is equal to one.  Thus, a 
single basic residue and a single acidic residue are important for catalysis in the 
enzyme-substrate complex.  The plot of log kcat is indicative of the behavior of the 
enzyme under saturating substrate conditions.  Thus, any contribution by the substrate 
to the reaction can be ruled out.  The equivalence of the pKa values obtained 
reinforces the earlier results that show that α-Pro-1 does not contribute to the reaction 
as either the acid or base catalyst. 
  From these analyses, it is likely that β-Pro-1 does not function as a base 
catalyst.  However, the pKa values observed in the wild-type or α-P1A-CaaD pH rate 
profiles cannot be assigned to specific residues.  A pH rate analysis of the β-P1A-
CaaD mutant would have provided further insight into the pKa value for that 
particular residue.  If the β-Pro-1 was responsible for either the pKa value at 8.0 or 
9.1, the corresponding value would change upon substitution by an alanine.  
However, kinetic analysis of the β-P1A CaaD mutant was not possible due to the 
inactivity of the enzyme.   
  Thus, assignment of kinetically determined pKa values is performed by direct 
pH titration using NMR spectroscopy.  Such an analysis requires uniformly 15N-
labeled protein.  Previous studies in the Whitman laboratory have used a complex 
procedure involving a MOPS-buffered medium for 15N-labeling using 15NH4Cl as a 
sole source of nitrogen that required several temperature and media changes over the 
course of two days (6).  Despite the optimization of this process, the yield of 
isotopically labeled protein is typically less than that of non-isotopically labeled 
protein.  One reason for this effect is the slower bacterial growth under minimal 
media conditions.  LB medium, used for non-isotopically labeled protein, is a rich 
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medium that provides numerous carbon, nitrogen and amino acid resources.  Minimal 
media provides carbon and nitrogen only in the forms of glucose and salts, 
eliminating amino acid, vitamin, and nucleotide sources.  These conditions force the 
bacteria to synthesize not only proteins, but all of the necessary cofactors and nucleic 
acids required for growth using the minimal carbon and nitrogen sources. 
  In an effort to simplify the procedure, growth was performed in M9 minimal 
media that was enhanced with several supplements as described in the methods 
section.  The new protocol requires only an initial overnight growth in LB at 37 °C, 
followed by direct inoculation into minimal media.  The minimal media phase 
requires only 24 hr of incubation and induction at 30 °C.  Comparable procedures in 
the literature (18) indicated that high yields of ~98% labeled protein could be 
obtained in this fashion.  Initally, the growth of 4-OT in M9 minimal medium was 
performed as a control.  The yield and purity of the resulting protein were excellent 
(~40 mg/L).  Unfortunately, the same procedure used for CaaD resulted in low yields 
of 15N-isotopically labeled protein.  This may be due to the additional burden of dual 
plasmid retention and expression, since cells limit the number of different plasmids 
they will maintain.  Addition of nucleotides, vitamins, and trace mineral supplements 
allowed the bacteria to express labeled CaaD.  Still, the overall yields diminished 
greatly, dropping to ~10% of typical non-isotopically labeled yields.   
  Despite these difficulties, sufficient quantities of the 15N-labeled wild-type 
and α-P1A enzymes were purified for initial NMR titration experiments.  Although 
other work has shown that the 15N-chemical shift of the prolyl nitrogen in 4-OT is 
well resolved (7), titration of wild-type CaaD is complicated by the fact that both the 
α- and β-subunits have an amino-terminal proline.  Hence, the 15N-labeled αP1A 
mutant was also examined.  For the wild-type enzyme, NMR titration yielded two pKa 
values at 9.2 ± 0.1 and 11.1 ± 0.1.  In the 15N NMR spectrum of the mutant enzyme, 
the α-Pro-1 is absent.  NMR titration yielded a single pKa at 9.9 ± 0.2.  The similarity 
of the pKa to that observed for the acidic group (9.1 ± 0.2 in wild-type CaaD and 9.0 ± 
0.2 in α-P1A-CaaD) implicates β−Pro-1 as a general acid catalyst in the mechanism, 
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responsible for protonation at C-2 of 1.  An unknown basic residue, possibly having a 
pKa of 8.0 ± 0.2, is likely involved in the activation of water.    
  Although the role of β-Pro-1 in CaaD is reversed from that of the N-terminal 
prolines in other tautomerase superfamily members, it is not surprising in view of the 
evolutionary context and the nature of the reaction catalyzed.  Most dehalogenases 
have likely evolved over the past few decades, which is quite recent on the 
evolutionary timescale.  Thus, it is reasonable to assume that CaaD evolved from a 
progenitor that is closely related to 4-OT.  Perhaps the active site of the progenitor 
was, like 4-OT, very hydrophobic.  Phe-50 in 4-OT is crucial for maintaining the pKa 
of Pro-1 through hydrophobic interactions (21).  The active site of CaaD, however, is 
likely to be hydrophilic because it catalyzes a hydration reaction.  Mutations in the 
active site, affording greater hydrophilicity, resulted in an upward shift of the pKa of 
the β-Pro-1, forcing the enzyme to utilize the residue as an acid.   CaaD represents a 
new activity as well as a new structure within the 4-OT family, and provides evidence 
for the catalytic and structural versatility of the β−α−β structural fold.  The results of 
this study show that there is also versatility in the reactivity of Pro-1 within the 4-OT 
family:  it can be utilized as either a general base or a general acid catalyst.  Further 
elucidation of the principles used by Nature to manipulate the reactivity of key 
elements in the simple β−α−β motif may assist in the creation of new biocatalysts 
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Figure 35.  pH dependence of the kinetic parameters for the CaaD-catalyzed 
dehalogenation of 1.  The pH dependence of log (kcat/Km) (open circles) and log kcat 
(filled circles) are shown.  The curves were computed from a non-linear least-squares 
fit as described elsewhere (6).  The pKa values are 8.0 ± 0.2 and 9.1 ± 0.2 for log 



















































Figure 36.  pH dependence of the kinetic parameters for the α-P1A-CaaD-catalyzed 
dehalogenation of 1.  The pH dependence of log (kcat/Km) (open circles) and log kcat 
(filled circles) are shown.  The curves were computed from a non-linear least-squares 
fit as described elsewhere (6).  The pKa values are 7.9 ± 0.2 and 9.0 ± 0.2 for log 







































































5.1 ± 0.1 
 
 
37 ± 2 
 
1.4 x 105 
 2 3.8 ± 0.1 
 
31 ± 2 1.2 x 105 
 5 0.7 ± 0.01 
 
110 ± 4 6.4 x 103 
α-P1A-CaaD 1 3.9 ± 0.1 43 ± 3 9.1 x 104 
 
 2 2.5 ± 0.1 
 
33 ± 2 7.4 x 104 
 5 0.7 ± 0.01 
 




aThe steady-state kinetic parameters were determined in 20 mM potassium phosphate 
buffer (pH 9.0) at 23 °C.  Errors are standard deviations.  The values for CaaD have 








  4-Oxalocrotonate tautomerase (4-OT) catalyzes the conversion of 2-oxo-4-
hexenedioate (1, Scheme 22) to 2-oxo-3-hexenedioate (3) via the intermediate, 2-
hydroxy-2,4-hexadienedioate, known commonly as 2-hydroxymuconate (2).  The 
enzyme is a hexamer, made up of monomers consisting of 62 amino acids, and is part 
of the catechol meta-fission pathway, which is a degradative pathway found on the 
TOL plasmid.  Bacteria such as Pseudomonas putida mt-2 that harbor the TOL 
plasmid can utilize various aromatic hydrocarbons as their sole sources of carbon and 
energy.   
  The mechanism and structure of 4-OT have been extensively studied over the 
past decade.  On the basis of affinity labeling, NMR, kinetic, mutagenesis, 
crystallographic, and chemical synthesis studies, the amino-terminal proline of 4-OT 
has been implicated as the catalytic base responsible for the observed 1,3-suprafacial 
allylic rearrangement (1-8).  In addition, Arg-11 and Arg-39 play critical roles (9).  
Arg-39 binds the C-1 carboxylate group of 1 and provides one of the two hydrogen 
bonds to the carbonyl oxygen thereby facilitating catalysis, while Arg-11 binds the C-
6 carboxylate group and functions as an electron sink.  An ordered water molecule, 
held in place by Ser-37, provides a second hydrogen bond to the carbonyl oxygen (5).  
Finally, Phe-50 is largely responsible for maintaining the hydrophobic nature of the 
active site, which lowers the pKa of Pro-1 to ~6.4, enabling it to function as a general 
base catalyst (10).   
  4-OT is also the best-characterized member of the 4-OT family, one of three 
major families comprising the tautomerase superfamily (11, 12).  The members of 
this superfamily are structurally homologous proteins sharing a characteristic β−α−β 
structural motif as well as a conserved amino-terminal proline (11).  We recently 
identified 38 4-OT homologues in bacteria ranging from common organisms such as 
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Escherichia coli and Bacillus subtilis to more unusual organisms such as the 
thermophiles Archaeoglobus fulgidus and Methanobacterium thermoautotrophicum 
(13).  In contrast to 4-OT, these homologues are chromosomally encoded and most 
are found in organisms not known to degrade aromatic hydrocarbons.   
 The 4-OT homologue in B. subtilis, designated YwhB, is a closely related 
homologue, sharing ~36% sequence similarity.  The 61-amino acid YwhB sequence 
is a hexamer due to the presence of an AVAG sequence (residues 51-54), which 
generates a β-hairpin that is critical for hexamer formation (13).  The YwhB sequence 
retains the catalytic amino-terminal proline as well as Arg-11, and replaces Phe-50 
with a tyrosine.  A lysine residue replaces Ser-37.  The only “missing” catalytic 
residue in YwhB is Arg-39, which is replaced with a valine.   
 YwhB also shares ~35% sequence similarity with the α-subunit of trans-3-
chloroacrylic acid dehalogenase (CaaD) from Pseudomonas pavonaceae strain 170 
(14).  CaaD, a heterohexamer consisting of three α-subunits and three β-subunits, 
catalyzes the addition of water to the trans isomers of 3-bromo- and 3-chloroacrylate 
to form malonate semialdehyde (14).  Pro-1 of the β-subunit and Arg-11 of the α-
subunit have been identified as critical residues in the mechanism of CaaD (14).   
  These sequence similarities suggested that YwhB might be the precursor to 
both 4-OT and the α-subunit of CaaD and prompted us to clone, express, and conduct 
a kinetic and stereochemical analysis of YwhB.  The enzyme functions as an effective 
tautomerase, converting 2 to 1 (Scheme 22), 2-hydroxy-2,4-pentadienoate (5) to its 
respective β,γ-unsaturated isomer, 2-oxo-4-pentenoate (4, Scheme 22), the enol 
isomers of phenylpyruvate (7) and (p-hydroxyphenyl)pyruvate (9), to their respective 
keto isomers (8 and 10, Scheme 23), and 2-hydroxy-2,4-heptadiene-1,7-dioate (11) to 
2-oxo-4-heptene-1,7-dioate (12).  Despite its close resemblance to 4-OT, YwhB 
processes 2 to 3 only very slowly.  While these results demonstrate that YwhB has a 
tautomerase activity, the role this activity plays in the organism is not clear.  A more 
interesting question may be how this activity was transformed into 4-OT or the α-




MATERIALS AND METHODS. 
 
  Materials.  All reagents, buffers, and solvents were obtained from Sigma 
Aldrich Chemical Co. (St. Louis, MO) or Fisher Scientific Inc. (Pittsburgh, PA).  
Tryptone, yeast extract, and agar were obtained from Becton, Dickerson, and 
Company (Franklin Lakes, NJ).  The Ultrafree DA centrifugal filter units, the YM-3 
ultrafiltration membranes, and the Amicon stirred concentrators were obtained from 
Millipore Corp. (Billerica, MA).  Thin-walled PCR tubes were obtained from 
Ambion, Inc. (Austin, TX).  The syntheses of 2-hydroxymuconate (2), 2-hydroxy-2,4-
pentadienaote (5), and 2-hydroxy-2,4-heptadiene-1,7-dioate (11) are described 
elsewhere (15, 16).  The expression vector pET-24a(+) was obtained from Novagen, 
Inc. (Madison, WI).  Restriction enzymes, T4 DNA ligase, PCR reagents, agarose, the 
Wizard PCR Preps DNA purification kit, and the Wizard Plus Minipreps DNA 
Purification System were obtained from Promega Corp. (Madison, WI).  
Oligonucleotides for DNA sequencing, amplification, or mutant construction were 
synthesized by Oligos Etc. Inc (Wilsonville, OR) or Genosys (The Woodlands, TX).   
  Strains.  Escherichia coli strains JM109 (Promega), DH5α (Invitrogen Corp. 
Carlsbad, CA), and BL21-Gold(DE3)pLysS (Stratagene, La Jolla, CA) were used for 
transformation of ligated plasmids.  E. coli strains BL21(DE3)pLysS (Novagen) and 
BL21-Gold(DE3)pLysS were used for expression of the recombinant proteins.  Cells 
for general cloning and expression were grown in LB media supplemented with 
kanamycin (50-100 µg/mL) or kanamycin and chloramphenicol (25 µg/mL).  The 
composition of LB medium is described elsewhere (17).   
  General Methods. Techniques for restriction enzyme digestions, ligation, 
transformation, and other standard molecular biology manipulations were based on 
methods described elsewhere (17).  DNA sequencing was done at the University of 
Texas (Austin) Sequencing Facility.  Kinetic data were obtained on a Hewlett 
Packard 8452A or an Agilent 8453 Diode Array spectrophotometer.  The cuvettes 
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were mixed by a stir/add cuvette mixer (Bel-Art Products, Pequannock, NJ).  The 
kinetic data were fitted by nonlinear regression data analysis using the Grafit program 
(Erithacus Software Ltd., Staines, U. K.) obtained from Sigma Chemical Co.  High 
performance liquid chromatography (HPLC) was performed on a Waters (Milford, 
MA) 501/510 system or a Beckman System Gold HPLC (Fullerton, CA) using a 
TSKgel Phenyl-5PW hydrophobic column (Tosoh Bioscience, Montgomeryville, 
PA).  Protein was analyzed by Tris glycine sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) under denaturing conditions on 17.5% gels on a 
vertical gel electrophoresis apparatus obtained from Bio-Rad (Hercules, CA) (18).  
Protein concentrations were determined using the method of Waddell (19).  NMR 
spectra were obtained on a Bruker AM-250 spectrometer or a Bruker AM-500 
spectrometer as indicated.  Chemical shifts were referenced as noted below.   
  Construction of the Expression Vector for YwhB from B. subtilis.  The 
expression vector for YwhB was designed in previous work by Dr. Robert M. 
Czerwinski (manuscript in preparation).  The plasmid was designated pET-24a-
ywhB.  Subsequently, the plasmid containing the YwhB gene was transformed as 
described elsewhere into E. coli strains BL21(DE3)pLysS or BL21-Gold(DE3)pLysS 
for protein expression according to the manufacturer’s directions.   
  Overexpression, Purification, and Characterization of the YwhB Product.  
The product of the YwhB gene was overexpressed using a previously described 
protocol (10).  Typically, 4.5 L of culture grown under these conditions yields ~14 g 
of cells.  The enzyme was purified to near homogeneity (>99% as assessed by the 
presence of a single band in SDS-PAGE) by a procedure described elsewhere using 
both the Tosoh Phenyl 5-PW hydrophobic column and the Sephadex G-75 gel 
filtration column (2.5 × 100 cm) using 20 mM NaH2PO4 buffer (pH 7.3).  Typically, 
the yield of purified protein per liter of culture was ~50 mg.  The native molecular 
mass of the protein was estimated by size exclusion chromatography on a Superose 
12 column.  The enzyme was chromatographed in 100 µL portions (~6.2 mg/mL) on 
the column equilibrated with 20 mM NaH2PO4 buffer, pH 7.3, at a flow rate of 0.2 
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mL/min.  The protein was monitored at 280 nm and typically elutes at ~74 min.  The 
molecular mass (MH+) for the YwhB product was 7015.0 Da (calc. 7014.0 Da) as 
determined by ESI-MS.   
  Construction of K37A and K37A V39R YwhB.  The expression vectors for two 
YwhB mutants, K37A and K37A V39R, were constructed using overlap extension 
PCR by Dr. Robert M. Czerwinski (unpublished data).  These plasmids were 
designated pET-24a ywhB K37A and pET-24a ywhB K37A V39R, respectively, and 
transformed into E. coli strain BL21(DE3)pLysS for protein expression according to 
the manufacturer’s instructions.   
  Construction of P1A, R11A, and V39R YwhB.  The P1A, R11A, and V39R 
mutants of YwhB were generated using the gene for YwhB in the plasmid pET-24a-
ywhB as the template.  The gene is flanked by an NdeI restriction site and a NotI 
restriction site (one of the multiple restriction sites).  The mutations were made using 
the overlap extension polymerase chain reaction as described (20).  The external PCR 
primers were oligonucleotides 5'-GCG GAT AAC AAT TCC CCT CT-3' (designated 
primer A) and 5'-CTC AGC TTC CTT TCG GGC TT-3' (designated primer D), 
which were described in Chapter 3.  For the P1A mutant, the internal PCR primers 
were 5'-GAC AGT TAC GTA TGC CAT ATG TATA- 3' (primer B) and 5'-TAT 
ACA TAT GGC ATA CGT AAC TGT C-3' (primer C).  For the R11A mutant, the 
internal PCR primers were 5'-TTG TTC GTC TGT AGC GCC TTC GAG CAT-3' 
(primer B) and 5'- ATG CTC GAA GGC GCT ACA GAC GAA CAA-3' (primer C).  
For the V39R mutant, the internal PCR primers were oligonucleotides 5'-TTC TAT 
AAA GAC ACG AAT TTT TTC TTC - 3' (primer B) and 5' – GAA GAA AAA ATT 
CGT GTC TTT ATA GAA - 3' (primer C).  In each set of primers, the mutation is 
underlined and the remaining bases correspond to the coding sequence (primer C) or 
the complementary sequence (primer B).   
  PCR reactions were carried out as described for amplification of the wild type 
gene with the following modifications.  In two separate PCRs, the AB and CD 
fragments were constructed in reaction mixtures containing 10× buffer (5 µL), the 
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dNTPs (1 µL of a 10 mM stock solution), primers (2.5 µL of 20 µM stock solutions), 
MgCl2 (3 µL of a 25 mM solution), pET-24a-ywhB (1 µL of a 1:500 dilution of the 
plasmid), Taq DNA polymerase (0.5 µL of a 5 units/µL solution) and a sufficient 
volume of water to make a final volume of 50 µL.  The reaction protocol consisted of 
25 cycles of PCR (denaturation at 94 °C for 1 min, annealing at 55 °C for 75 s, and 
elongation at 72 °C for 75 s), preceded by an initial denaturation step at 94 °C for 5 
min and followed by a final elongation step at 72 °C for 5 min.  The PCR products 
were analyzed by electrophoresis on a 1% agarose gel and purified using either the 
Wizard PCR Preps purification system.  The AD fragments were constructed 
similarly except that the AB and CD fragments (2.5 µL of each) were used as 
template.   
  The AD fragments were electrophoresed, excised, and purified using the 
Wizard PCR Preps or the Ultrafree-DA centrifugal filter units.  In separate reactions, 
the PCR products and the pET-24a(+) vector were treated with NdeI and NotI for 5-7 
hrs at 37 °C.  Ligation using T4 DNA ligase was performed at room temperature 
overnight.  Subsequently, the ligated DNA was purified by ethanol precipitation and 
used to transform DH5α cells or BL21-Gold(DE3) pLysS by electroporation.  
Colonies (grown on either LB/Kn or LB/Kn/Cm agar plates) were randomly selected 
for plasmid purification and DNA sequencing.  The plasmids designated pET-24a-
ywhB P1A-4, pET-24a-ywhB R11A-A, and pET-24a-ywhB V39R-4 had the correct 
sequence and were used in subsequent experiments.   
  Overexpression and Purification of the YwhB Mutants.  All of the mutants 
were overexpressed and purified in the same manner as the wild-type.  Elution times 
for all of the mutants from both columns were approximately the same as those 
observed for the wild type.  The typical yields of cells from 3 L of culture were 10-14 
g for each mutant.  The yields of each mutant were comparable to that of the wild 
type (20-40 mg/L culture).   
  Kinetic Characterization of YwhB and the Mutants.  Kinetic runs were 
performed in 20 mM NaH2PO4 buffer, pH 7.3.  Stock solutions (50 mM) of 2, 10, and 
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11 were initially made up in ethanol, and diluted (with ethanol) to generate 5 mM 
and/or 10 mM solutions.  Solutions of 5 were made by diluting a stock solution 
(152.6 mM) stored in ethanol at -20° C, to give 3.05 mM and 30.5 mM solutions.  
The tautomerization activity of YwhB was measured by monitoring the ketonization 
of the following substrates at the indicated λmax and ε values, as follows:  2 (294 nm, ε 
= 19,400 M-1 cm-1), 5 (266 nm, ε = 12,100 M-1 cm-1), 7 (288 nm, ε = 18,000 M-1 cm-1), 
9 (292 nm, ε = 20,800 M-1 cm-1), 14 (276 nm, ε = 12,300 M-1 cm-1), and described 
elsewhere (1, 15, 16).  The formation of 3 from 2 was monitored at 236 nm (ε = 6580 
M-1 cm-1) (1).  The ranges of substrates were as follows for ketonization:  2 (20-150 
µM), 5 (3-150 µM), 10, 11, and 14 (10-150 µM).  For isomerization, the range of 2 
was 30-600 µM.  For a typical run, a sufficient quantity of YwhB as required for each 
particular activity was equilibrated in buffer (typically 4 µL of a 25.6 mg/mL solution 
in 40 mL for 2, 40 µL of a 25.6 mg/mL solution in 40 mL for 14) for at least an hour 
prior to use.  Aliquots (1 mL) were withdrawn and assayed for activity.  Reactions 






  Production, Expression, and Characterization of YwhB and the Mutants. In 
work described elsewhere, YwhB was cloned using Bacillus subtilis strain 168 
genomic DNA as template (unpublished data).  The construction of the expression 
system and the purification protocol followed those used for 4-OT (10).  Accordingly, 
YwhB can be purified to homogeneity (~99%), and elutes under the same conditions 
as 4-OT.  The yield of protein is high (~50 mg/L) of culture.  Mass spectral analysis 
of the purified wild-type protein indicates that it has the expected mass, and that the 
N-terminal proline is not blocked by the initiating methionine.  The native molecular 
mass as estimated by gel filtration indicates that YwhB exists as a hexamer in 
solution.  This has been confirmed by crystallographic studies (12).  Expression and 
purification of all of the mutants was carried out similarly.  All of the mutant proteins 
remained soluble and were readily purified with yields ranging from 50-100% of 
wild-type. 
  Kinetic Properties of the YwhB Protein.  The kinetic properties of YwhB were 
investigated using as potential substrates a monocarboxylated dienol (5), two enols (7 
and 9), and two dicarboxylated dienols (2 and 11).  For the four dienol substrates, the 
rates of formation of the corresponding β,γ-unsaturated ketones were monitored.  For 
5 and 11, the rates of formation of the corresponding α,β-isomers were not 
measurable.  For 2, however, it was possible to determine a rate of formation for 3.  
The kinetic data are summarized in Table 6.   
  Several trends emerge from the data.  First, YwhB clearly catalyzes an 1,3-
keto-enol tautomerization reaction using all of the substrates although with different 
efficiencies.  Second, the highest catalytic efficiencies are observed with the 
monocarboxylated dienol 5, the enol 7 (a 2.4-fold decrease in kcat/Km), and the 
dicarboxylated 2 (a 7.7-fold decrease in kcat/Km).  Replacing the vinyl group of 5 with 
a phenyl group (i.e., 7) has little effect on kcat and Km.  The addition of a second 
carboxylate group to 5 (i.e., 2), results in a 17.8-fold decrease in kcat, as well as a 2.3-
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fold decrease in Km.  The decrease in catalytic efficiency observed for 2 is primarily a 
reflection of the decrease in kcat.  Third, the addition of the hydroxyl group to 7 results 
in a 30-fold decrease in kcat as well as a 2-fold decrease in Km.  The overall effect is a 
38-fold decrease in the value of kcat/Km (compared with 5).  Finally, the addition of a 
carboxymethyl group to 5 (i.e., 11) results in a 59-fold decrease in kcat , a 1.9-fold 
increase in Km, and an overall 111-fold decrease in kcat/Km. 
        The data in Table 6 also show that YwhB will catalyze a 1,5-keto enol 
tautomerization using 2, although not as efficiently as 4-OT.  4-OT catalyzes the 
conversion of 2 to 3 with a kcat = 3500 s-1 and a Km of 180 µM, resulting in an overall 
kcat/Km of 1.9 x 107 M-1 s-1.  YwhB shows a 135-fold decrease in kcat, a 5.2 increase in 
Km, and a 680-fold decrease in kcat/Km.  Interestingly, the kinetic parameters obtained 
for YwhB are on the order of those obtained for the R39A mutant of 4-OT (kcat = 28 
s-1, Km of 290 µM, and kcat/Km of 9.7 x 104 M-1 s-1) (8).  Moreover, replacement of 
R39 in 4-OT with a bulkier glutamine group results in a further increase in Km (to 470 
µM).  Thus, the presence of Val-39 is likely to increase the Km for 2. 
  Kinetic Properties of the P1A, R11A, and V39R Mutants of YwhB.  The 
purpose of the mutagenesis studies was two-fold.  First, mutants of YwhB were 
constructed to determine whether the conserved catalytic residues (e.g., Pro-1 and 
Arg-11) were critical to the 1,3- and 1,5-keto-enol tautomerization reaction catalyzed 
by YwhB. Second, it was of interest to determine how many mutations would be 
necessary to convert YwhB into 4-OT.  Accordingly, the P1A, R11A, and V39R 
mutants were analyzed using 2, 7, and 9 (Tables 7-10).   
  The data indicate that both the P1A and R11A mutants of YwhB are critical in 
catalysis.  Both mutants are completely unable to process 2.  Neither a 
tautomerization or a ketonization ability using 2 is observed.  The corresponding 
mutants of 4-OT show decreased activity towards 2 (32-fold and 760-fold decreases 
in kcat/Km, respectively), but the activity remains observable (8, 22).  In the case of 7, 
which is the best substrate of the three investigated with the mutants, the Km values 
improved with the mutation (1.5-fold and 3.7-fold for P1A and R11A, respectively).  
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The kcat values decreased significantly, by 100-fold for P1A and 2300-fold for R11A.  
Thus the differences in kcat values are largely reflected in the decreased values for 
kcat/Km observed (71-fold and 610-fold), which more closely approximate the 
differences in kcat/Km observed in the P1A and R11A 4-OT mutants.  Finally, for 9, 
neither mutant can catalyze the keto-enol tautomerization. 
  Replacement of Val-39 with an arginine residue results in a decrease in the 
ability of the mutant enzyme to process the phenyl compound 7.   
A 2.6-fold decrease is observed in kcat.  However, only a 1.6-fold decrease is observed 
in kcat/Km as a result of the improvement in Km (1.6-fold).  The kinetic parameters for 
9 as substrate largely remain similar.  The values for kcat are equal, while a decrease in 
kcat/Km (1.4-fold) can be attributed to a similar increase in Km.  An increase in the 
ability of the V39R mutant to process 2 to either 1 or 3 is also observed.  A 21-fold 
improvement is observed in kcat for the 1,3-keto-enol tautomerization of 2 to 1.  The 
Km also increases 2.1-fold, thus leading to an overall 10-fold rate enhancement.  The 
kcat and Km values are also enhanced in the 1,5-keto-enol tautomerization by 3-fold 
and 1.7-fold, respectively, thus leading to an overall 5-fold rate enhancement. 
  Kinetic Properties of the K37A and K37A V39R Mutants of YwhB.  The K37A 
mutant was constructed in order to determine the importance of the lysine residue to 
catalysis.  Since the V39R mutant showed an improved ability to function as a 4-OT, 
the K37A V39R double mutant was constructed in order to determine whether it 
would show an increased enhancement compared to the V39R mutation alone.  If this 
were the case, 4-OT may have evolved from YwhB as a result of two primary 
mutations.  Accordingly, the K37A and K37A V39R mutants were analyzed using 2, 
7, and 9 (Tables 2-5).   
  The results indicate that lysine-37 carries out an important catalytic function.  
The K37A mutation results in changes for all of the kinetic parameters.  Most 
notably, the ability of the mutant to carry out the 1,5-keto-enol tautomerization of 2 is 
abolished.  K37A retains a very limited ability to catalyze the 1,3-keto-enol 
tautomerization, resulting in an overall 109-fold decrease in rate enhancement.  This 
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change is less than that observed for the R39A and R39Q mutants of 4-OT (200-fold 
and 1000-fold, respectively).  However, it appears that Lys-37 may fill a role in 
YwhB that is similar to that of Arg-39.  Using 7 and 9 as substrates, changes remain 
apparent but are less striking.  A 10-fold decrease in the tautomerization of 7 is 
observed in both kcat and kcat/Km, although Km improves slightly (1.4-fold).  A similar 
7.7-fold decrease in the rate enhancement for the tautomerization of 9 is observed.  In 
the case of 11, both kcat and Km suffer (5.9-fold and 1.2-fold, respectively). 
  The K37A V39R mutant did not achieve an improvement of the 4-OT 
functionality of YwhB.  The results of the double mutation indicate drops in all of the 
activities investigated.  The only improvements observed were a 2-fold increase in kcat 
for the 1,3-keto-enol tautomerization of 2, and a 1.7-fold decrease of Km with 9 as 
substrate.  In all other cases, the kinetic parameters were degenerated to varying 
degrees (50- to 5-fold in kcat, 2.9- to 3.5-fold in Km, and 1.7- to 27-fold in kcat/Km).  






  When 4-OT was first cloned and overexpressed in 1992, it was thought to be 
unique because no homologues, other than isozymes, could be identified by sequence 
analysis (23).  It was initially thought that this distinctiveness might be related to the 
small monomer size of 4-OT (62 amino acids), which was the smallest reported size 
for an enzyme subunit at the time.  Since then, several homologues have been 
identified as a result of the numerous genome sequencing projects.  These proteins, 
most of which have unidentified physiological functions, are found throughout the 
bacterial and archaeal kingdoms.  Many of the organisms that harbor 4-OT 
homologues are not known to degrade aromatic hydrocarbons.  Furthermore, these 
homologues have not been found in operons.  Although enzymes in metabolic 
pathways are not required to be grouped in operons, the presence of one homologue 
in an operon might provide clues about its physiological purpose. 
  The ywhB gene, from Bacillus subtilis 168, showed the highest sequence 
identity to 4-OT (~36%) of any homologue in 1998, when it was first identified.  Its 
cellular purpose was (and remains) unknown.  Interest in this particular protein was 
heightened upon the discovery of trans-3-chloroacrylic acid dehalogenase.  YwhB 
shows a similar amount of sequence identity (~35%) to the α-subunit of CaaD (14), 
raising the question of whether the ywhB gene gave rise to the genes for 4-OT and/or 
CaaD.  To investigate the relationship between YwhB and 4-OT, the Bacillus enzyme 
was overexpressed, purified, and characterized with a number of potential substrates.  
Five mutants were constructed and also characterized.  These mutants were chosen on 
the basis of sequence alignment and the crystal structures of the two enzymes.  Both 
4-OT and YwhB share Pro-1 and Arg-11, which are necessary for binding and 
catalysis.  Arg-39, which is required for both binding and catalysis in 4-OT, is 
missing in YwhB, and is replaced with a valine.  Lys-37 of YwhB may provide an 
equivalent charge in the active site.  Thus, the P1A and R11A mutants were 
constructed to determine their relative importance in catalysis.  The K37A, V39R, 
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and K37A V39R mutants were constructed to mimic the potential evolution of YwhB 
into 4-OT. 
 Our intensive kinetic studies of YwhB indicate that it although it is an 
efficient tautomerase (kcat/Km values ranging from 105-106 M-1 s-1), it is only a modest 
isomerase (kcat/Km 104 M-1 s-1).  The compounds used to test YwhB for activity were 
primarily chosen on the basis of the substrates for other members of the tautomerase 
superfamily.  4-OT readily tautomerizes 2 to 1 and to 3, and it tautomerizes 5 with a 
lower efficiency.  Another member of the superfamily, macrophage migration 
inhibitory factor (MIF), preferentially ketonizes 7 and 9.  5-(Carboxymethyl)-2-oxo-
3-hexene-1,6-dioate decarboxylase (COHED), which is not a member of the 
tautomerase superfamily, tautomerizes 11 in the process of its decarboxylative 
reaction (16).  It can be reasonably inferred that the preferred substrate, among those 
investigated, is 5.  However, in the absence of a crystal structure or stereochemical 
analyses, the relative preference YwhB has for these substrates cannot be explained.  
The compounds examined carry a wide range of functional groups that may be bound 
in different orientations by the enzyme.  Both stereochemical and crystallographic 
investigations are underway. 
  The mutations of P1A and R11A in YwhB were performed to verify the 
importance of each residue in catalysis.  The corresponding mutations in 4-OT have 
been performed and the mutant enzymes characterized, providing a useful reference 
point.  As expected, both are required for catalysis.  Of the four reactions investigated 
(Tables 2-5) only the reaction of 7 was observable.  Both mutants showed large drops 
in kcat (100-fold and 2300-fold, respectively), although the Km values also dropped.  
The drop in Km for the R11A mutant was unexpected.  An increase in the Km, as 
observed for the corresponding 4-OT mutant, would have been consistent with its 
proposed role in binding.  Determination of activity for the other three reactions was 
precluded by the large amounts of enzyme required.  Further investigation of these 
mutants with HPD as the substrate may provide more information as to their precise 
roles, particularly in the case of R11A YwhB.   
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 The K37A mutation of YwhB was performed to see if the lysine residue 
performed a role similar to that of arginine-39 in 4-OT.  Both residues are positively 
charged under physiological conditions.  As mentioned previously, lysine is likely not 
able to adequately replace arginine because it cannot form two hydrogen bonds in the 
same fashion.  The same reactions were investigated as for the other mutants.  The 
decreases in tautomerization ability for 7 and 9 were 10-20-fold for kcat and Km.  The 
largest decreases in activities were observed with 2 as substrate.  The isomerization 
ability was eliminated.  The 1,3-keto-enol tautomerization ability dropped 50-fold in 
kcat and ~100-fold in kcat/Km, while the value for Km increased two-fold.  This suggests 
that the lysine may play more of a role in catalysis than in binding.  Lys-37 may 
supply a hydrogen bond to C-2 of 2, facilitating deprotonation at C-3. 
  Both the V39R and the K37A V39R mutants were made with the intent of 
evolving YwhB into a better 4-OT.  Initially the V39R mutant was made to position 
the positively charged arginine residue for optimal catalysis of the 1,3- and 1,5-keto-
enol tautomerizations.  The V39R mutant showed the best ability to catalyze each of 
the reactions investigated. Most notably, the tautomerization and isomerization 
abilities improved by 10-fold and 5-fold in terms of kcat/Km, respectively.  Thus, the 
mutation of valine-39 to an arginine may have been one step involved in the evolution 
of 4-OT from YwhB.   
  The parameters observed for V39R YwhB led to the design of the K37A 
V39R double mutant.  In V39R YwhB, the presence of Lys-37 results in two positive 
charges in close proximity, which may be detrimental to catalysis.  Thus elimination 
of K37A would eliminate one of the neighboring positive charges in the V39R 
mutant.  It was presumed that the V39R mutation would continue to fill the role 
apparently observed in the single mutant.  Unfortunately, the K37A V39R double 
mutant failed to yield a better isomerase.  In fact, the double mutations diminished all 
of the observed activities in terms of kcat/KM.  Thus, it is impossible that these two 
mutations alone gave rise to 4-OT from YwhB as a progenitor. 
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    The results of this study indicate the importance of active-site residues 
identified by sequence alignment and crystallographic studies of YwhB.   
Common methods for determining the evolution of proteins include random 
mutagenesis and directed evolution.   However, in the absence of a simple screening 
technique for mutants, these methods lose their usefulness.  In the case of YwhB and 
4-OT, the crystal structures have been solved, allowing specific residues to be chosen 
for mutagenesis experiments.  Pro-1 and Arg-11 are critical for the activity of YwhB, 
as expected from the mechanism of 4-OT.  The differences in activity observed for 
the P1A and R11A YwhB mutants with 7 as substrate are similar to those observed 
for the P1A and R11A 4-OT mutants with 2 as substrate (9, 22).  Lys-37 appears to 
function in catalysis, perhaps fulfilling the role vacated by the “missing” arginine at 
position 39.  Mutation of Val-39 to an arginine increases the catalytic efficiency of 
YwhB while maintaining its broad substrate specificity.  Interestingly, removing Lys-
37 in the presence of Arg-39 is detrimental to its activity.  The presence of multiple 
charged groups in the active site pocket thus seems to be important.  Perhaps with the 
addition of arginine-39, lysine-37 is able to bind an ordered water molecule as is 
observed in 4-OT.  Crystallographic and stereochemical studies, along with the 
investigation of a K37S V39R mutant, may further elucidate the roles of these 
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Table 6.  Kinetic Parameters for YwhBa 
 
 
 reaction kcat Km kcat/Km  
 
  (s-1) (µM) (M-1s-1)  
 
 2 → 1 10.1 ± 1.1 75.9 ± 17.0 1.3 x 105  
 
 5 → 4 177.4 ± 10.3 176.2 ± 19.0 1.0 x 106  
 
 7 → 8 124.8 ± 18.2 303.3 ± 58.9 4.1 x 105 
 
 9 → 10 4.1 ± 0.4 157.1 ± 21.8 2.6 x 104 
 
 11 → 12 3.0 ± 0.4 334.8 ± 55.0 9.0 x 103  
  
 2 → 3 26.0 ± 1.4 938.9 ± 69.6 2.8 x 104 
 
 
aThe steady-state kinetic parameters were determined in 20 mM sodium phosphate 
buffer (pH 7.3) at 23 °C.  Errors are standard deviations. 
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10 ± 1 
 
76 ± 17 
 








n/ab n/a n/a n/a n/a 
R11A 
 
n/ab n/a n/a n/a n/a 
K37A 
 
0.2 ± 0.02 133 ± 33 1.2 x 103 0.02 0.0092 
V39R 
 
211 ± 30 161 ± 35 1.3 x 106 20.9 10 
K37A V39R 
 
21 ± 4 268 ± 60 7.8 x 104 2.1 0.6 
 
 
aThe steady-state kinetic parameters were determined in 20 mM sodium phosphate 
buffer (pH 7.3) at 23 °C.  Errors are standard deviations. 
 






























26 ± 1 
 
939 ± 70 
 








n/ab n/a n/a n/a n/a 
R11A 
 
n/ab n/a n/a n/a n/a 
K37A 
 
n/ab n/a n/a n/a n/a 
V39R 
 
78.3 ± 3.9 545 ± 46 1.4 x 105 3.01 5 
K37A V39R 
 
5.6 ± 1.7 2748 ± 
930 
 
2.0 x 103 0.21 0.071 
 
aThe steady-state kinetic parameters were determined in 20 mM sodium phosphate 
buffer (pH 7.3) at 23 °C.  Errors are standard deviations. 
 














































1.2 ± 0.1 208 ± 24 5.8 x 103 0.0096 0.014 
R11A 0.055 ± 
0.003 
















48 ± 3 193 ± 21 2.5 x 105 0.38 0.61 
K37A V39R 
 
2.6 ± 0.1 178 ± 16 1.5 x 104 0.021 0.037 
 
aThe steady-state kinetic parameters were determined in 20 mM sodium phosphate 
buffer (pH 7.3) at 23 °C.  Errors are standard deviations. 
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n/ab n/a n/a n/a n/a 
R11A 
 
n/ab n/a n/a n/a n/a 
K37A 
 
0.7 ± 0.1 195 ± 40 3.4 x 103 0.17 0.13 
V39R 
 
4.8 ± 0.4 264 ± 31 1.8 x 104 1.17 0.69 
K37A V39R 
 
n/ab n/a n/a n/a n/a 
 
aThe steady-state kinetic parameters were determined in 20 mM sodium phosphate 
buffer (pH 7.3) at 23 °C.  Errors are standard deviations. 
 





1Abbreviations:  Cm, chloramphenicol;  CaaD, trans-3-chloroacrylic acid 
dehalogenase;  ESI-MS, electrospray ionization mass spectrometry;  HPLC, high 
performance liquid chromatography;  IPTG, isopropyl-β-D-thiogalactoside;  Kn, 
kanamycin;  LB, Luria-Bertani Medium;  NMR, nuclear magnetic resonance; 4-OT, 
4-oxalocrotonate tautomerase;  PCR, polymerase chain reaction;  SDS-PAGE, 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis.   
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REACTIONS OF 4-OXALOCROTONATE TAUTOMERASE AND YWHB 
WITH TRANS-3-HALOACRYLATES AND 3-HALOPROPIOLIC ACIDS:  




  4-Oxalocrotonate tautomerase (4-OT, EC 5.3.2), a bacterial isomerase found 
on the TOL plasmid in Pseudomonas putida mt-2 (1), catalyzes the conversion of 2-
oxo-4-hexenedioate (1, Scheme 24) to 2-oxo-3-hexenedioate (3) through a dienol 
intermediate, known commonly as 2-hydroxymuconate (2).  The presence of the TOL 
plasmid enables this soil bacterium to use aromatic hydrocarbons like toluene as its 
sole sources of carbon and energy.  One of the more salient features of 4-OT is the 
small monomers (62 amino acids) that comprise its hexamer.  The enzyme has been 
intensively studied over the past 15 years by a battery of techniques, primarily due to 
the simplicity of the reaction coupled with the small monomer size (2-9).   
  As a result of these efforts, the basic elements of the mechanism have been 
established.  The amino-terminal proline functions as a general base catalyst.  Arg-39 
and an ordered water molecule provide hydrogen bonds to the carbonyl oxygen of 1, 
thereby facilitating deprotonation at C-3 (10).  Arg-11 has a binding and a catalytic 
role:  it interacts with the C-6 carboxylate group and functions as an electron sink to 
draw electron density to the C-5 position for protonation.  Phe-50 plays a structural 
role in maintaining the hydrophobic active site environment, which assists in catalysis 
and contributes to the lowered pKa of Pro-1 (11).   
  Despite these extensive mechanistic studies, it was only with the recent 
discovery of trans-3-chloroacrylic acid dehalogenase (CaaD), that the structural and 
mechanistic versatility of the β−α−β structural motif encoded by the 4-OT monomer 
was realized.  CaaD transforms the trans-isomers of 3-bromo- and 3-chloroacrylates 
(4 and 5, respectively, Scheme 25) to malonate semialdehyde (7), presumably through 
an unstable halohydrin intermediate (6) (12).  CaaD is found in a degradative pathway 
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for 1,3-dichloropropene (13), which is used as a nematocide.  The enzyme is a 
heterohexamer comprised of three α -subunits and three β-subunits.   
  Sequence analysis and mutagenesis identified CaaD as a member of the 4-OT 
subfamily of the tautomerase superfamily (12).  The α-subunit of CaaD shares 35% 
sequence identity with YwhB, a 4-OT homologue found in Bacillus subtilis, while the 
β-subunit has 25% sequence identity with 4-OT.  Both subunits have an amino-
terminal proline, one of which, the β-Pro-1, is a critical mechanistic residue that 
functions as a general acid catalyst to protonate C-2. Arginine-11 in the α-subunit is 
also important in the mechanism (11). 
  In view of these sequence and mechanistic similarities, we examined 4-OT 
and YwhB for low-level dehalogenase activity and found that both exhibited the 
activity, resulting in the dehalogenation of both 4 and 5.  The presence of this activity 
further substantiated a relationship between CaaD and the 4-OT family members, 4-
OT and YwhB.  It also prompted us to examine the behavior of 4-OT and YwhB with 
3-bromo- and 3-chloropropiolic acid (10 and 11, Scheme 26).  CaaD converts the 3-
halopropiolic acids into highly reactive acyl halides, which inactivate the enzyme by 
covalent modification at the β-Pro-1 (14).  A similar result with 4-OT and/or YwhB 
would provide further evidence for the hydratase activity.   
  Incubation of the enzymes with these two compounds results in their 
irreversible inactivation.  However, the rates of inactivation are much faster (i.e., 
minutes) than would be anticipated on the basis of the observed rates for the low level 
hydratase activity (i.e, several days), suggesting that another mechanism is operative.  
Herein, we report the characterization of the inactivation process for both enzymes, 
the identification of the covalently modified residue, Pro-1, and propose a mechanism 
leading to the modification.  The mechanism is different from that proposed for the 
inactivation of CaaD, highlighting differences between the active sites.  Although 
irreversible inhibitors of 4-OT have previously been reported (5, 6), 10 and 11 are the 
first reported irreversible inhibitors of YwhB.  Moreover, the inactivation of YwhB 
by the modification of its Pro-1 confirms the importance of this residue in the 
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reaction.  These compounds will also be useful as ligands for crystallographic studies 
to further delineate the roles of active site residues in the YwhB-catalyzed reaction.  
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MATERIALS AND METHODS 
 
  Materials.  All reagents, buffers, and solvents were obtained from Sigma 
Aldrich Chemical Co. (St. Louis, MO), Fisher Scientific Inc. (Pittsburgh, PA), 
Spectrum Laboratory Products, Inc. (New Brunswick, NJ), or EM Science 
(Cincinnati, OH), unless noted otherwise.  The Amicon stirred cells, ultrafiltration 
membranes, and Ultrafree-15 centrifugal concentrators were obtained from Millipore 
Corp. (Billerica, MA).  4-OT, YwhB, P1A- and R11A-4-OT, and P1A- and R11A-
YwhB were purified by previously described procedures (6).  Synthetic 4-OT was a 
gift from Dr. Michael C. Fitzgerald (Department of Chemistry, Duke University).  
Literature procedures were used for the syntheses of trans-3-bromoacrylate (4), and 
3-bromo- and 3-chloropropiolic acids (10 and 11) (15, 16).  The trans-3-
chloroacrylate (5) was obtained from Fluka Chemical Corp. (Milwaukee, WI).  
Sequencing-grade trypsin was from Promega Corp. (Madison, WI).   
  Methods.  Kinetic data were obtained on an Agilent 8453 Diode Array 
spectrophotometer.  The solutions in the cuvettes were mixed using a stir/add cuvette 
mixer (Bel-Art Products, Pequannock, NJ).  The kinetic data were fitted by nonlinear 
regression data analysis using the Grafit program (Erithacus Software Ltd., Horley, 
U. K.) obtained from Sigma Chemical Co.  HPLC was performed on a Beckman 
System Gold HPLC (Fullerton, CA) using a TSKgel Phenyl-5PW hydrophobic 
column (Tosoh Bioscience, Montgomeryville, PA).  Protein was analyzed by Tris 
glycine sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
under denaturing conditions on 17.5% gels using either the Mini-Protean II or III 
vertical gel electrophoresis apparatus obtained from Bio-Rad (Hercules, CA) (17).  
Protein concentrations were determined using the method of Waddell (18).  The 
NMR spectra were recorded in 100% H2O on a Varian Unity INOVA-500 
spectrometer using selective pre-saturation of the water signal with a 2-s pre-
saturation interval.  The lock signal is dimethyl-d6 sulfoxide.  Chemical shifts are 
standardized to the dimethyl-d6 sulfoxide signal at 2.49 ppm. 
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  Enzyme Assays.  The activity of 4-OT was determined by a previously 
described assay using 2 (19), following the increase in absorbance at 236 nm due to 
the formation of 3.  The activity of YwhB was determined by a previously described 
assay using phenylpyruvate (12).  Ketonization of 12 to generate 13 is followed by 
the decay at 288 nm (20).   
  The 4-OT-catalyzed Hydration of trans-5.  To an NMR tube containing 100 
mM Na2HPO4 buffer (0.6 mL, pH 9.2) was a added solution of trans-5 (4 mg, 0.04 
mmol) dissolved in DMSO-d6 (30 µL).  The addition of trans-5 adjusted the pH of the 
buffer to 6.8.  Subsequently, an aliquot of 4-OT (50 µL of a 12.7 mg/mL solution) 
was added to the NMR tube to initiate the reaction.  After incubating at room 
temperature for 136 h, a 1H NMR spectrum was obtained of the reaction mixture was 
recorded.  The 1H NMR analysis indicated the presence of 5 (~26%), 8 (~38%), and 9 
(~36%).  5:  1H NMR (H2O, 500 MHz) δ 6.09 (1H, d, J = 13 Hz, H2), 6.89 (1H, d, J = 
13.5 Hz, H3).  8:  1H NMR (H2O, 500 MHz) δ 2.04 (3H, d, J = 13 Hz, H2), 9.48 (1H, 
q, H1).  9:  1H NMR (H2O, 500 MHz) δ 1.13 (3H, d, H2), 5.5 (1H, q, H1).  The 
relative amounts of 5, 8, and 9 were determined by integration of the C-3 proton of 5, 
the C-1 proton of 8, and the C-2 proton of 9, respectively.   
  The experiment was repeated twice.  Incubation of 4-OT (50 µL of a 12.7 
mg/mL solution) with trans-5 for 96 hr resulted in 71% conversion of 5 to 8 and 9.  
Incubation of 4-OT (9 µL of a 21.5 mg/mL solution) with trans-5 for 139 hr resulted 
in 64 % conversion of 5 to 8 and 9.   
  Incubation of trans-5 under the same conditions (for 208 h) in the absence of 
enzyme resulted in no detectable amount of 8 or 9.   
  Incubation of P1A- and R11A-4-OT with trans-5.  The two reactions were 
made up in NMR tubes as described above for the wild type enzyme.  The P1A-4-
OT-catalyzed reaction was initiated by the addition of 60 µL of a 12.4 mg/mL 
solution of enzyme.  The final pH of the solution was 6.8.  The R11A-4-OT-catalyzed 
reaction was initiated by the addition of 25 µL of a 26.9 mg/mL solution of enzyme.  
The final pH of the solution was 6.8.  After 114 hr at room temperature, the P1A 
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reaction showed ~2% conversion to 8 and 9, while the R11A mutant converted ~74% 
of 5 to 8 and 9.  A second experiment involving the incubation of R11A (12 µL of a 
17.7 mg/mL solution) with trans-5 for 208 hr resulted in ~49 % conversion of 5 to 8 
and 9.   
  The 4-OT-catalyzed Hydration of trans-4.  Incubation of 4-OT (20 µL of a 
21.5 mg/mL solution) with trans-4 for 209 hr resulted in ~92% conversion of 5 to 8 
and 9. The incubation of trans-4 under the same conditions (for 552 h) in the absence 
of enzyme resulted in no detectable amount of 8 or 9.   
  Incubation of 4-OT with cis-5.  Incubation of 4-OT (50 µL of a 12.7 mg/mL 
solution) with cis-5 for 139 hr resulted in ~3% conversion of 5 to 8 and 9.  Incubation 
of 4-OT (20 µL of a 21.5 mg/mL solution) with cis-(5) for 209 hr resulted in ~4% 
conversion of 5 to 8 and 9. 
  The Synthetic 4-OT-catalyzed Hydration of trans-5.  Two experiments were 
carried out. Incubation of synthetic 4-OT (300 µL of a 1.2 mg/mL solution) with 
trans-5 for 208 hr resulted in ~67% conversion of 5 to 8 and 9.  Repeating the 
experiment with a different amount of synthetic 4-OT (100 µL of a 2 mg/mL solution) 
for 208 hr resulted in ~22% conversion of 5 to 8 and 9.   
  The YwhB-catalyzed Hydrations of trans-4 and 5.  The NMR experiments 
were set up as described above.  Incubation of YwhB (50 µL of a 12.7 mg/mL 
solution) with trans-4 for 616 hr resulted in ~93% conversion of 5 to 8 and 9.  
Incubation of the same amount of YwhB trans-(5) for 171 hr resulted in ~30% 
conversion of 5 to 8 and 9.   
  Incubation of P1A- and R11A-YwhB with trans-5.  The two reactions were 
made up in NMR tubes as described above for the wild type enzyme.  The P1A-
YwhB-catalyzed reaction was initiated by the addition of 100 µL of a 5.4 mg/mL 
solution of enzyme.  The R11A-YwhB-catalyzed reaction was initiated by the 
addition of 50 µL of an 11.9 mg/mL solution of enzyme.  After 108 h, there was no 
detectable product in the reaction mixture containing the P1A-YwhB mutant.  After 
137 h, the R11A-YwhB mutant had converted ~5% of trans-5 to 8 and 9.   
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  Incubation of YwhB with cis-5.  Incubation of YwhB (50 µL of a 6.6 mg/mL 
solution or 20 µL of a 25.6 mg/mL solution) with cis-5 for 137 hr and 209 h, 
respectively, resulted in no detectable conversion of cis-5 to 8 and 9.    
  Incubation of pET-24a(+) and Fumarase with trans-5.  An aliquot of pET-
24a(+) (0.5 µL) was transformed into E. coli strain BL21-Gold(DE3)pLysS by 
electroporation following the manufacturer’s directions.  Cells carrying the pET-
24a(+) plasmid were grown and induced for protein expression as described for the 
production of YwhB and 4-OT.  Cells were stored at -80° C until use.  Cultures (500 
mL) grown under these conditions yield 1.34 g of cells. 
  In a modified partial purification, the cells were re-suspended in 10 mL of 10 
mM ethylenediamine buffer (pH 7.4), placed on ice, and initially disrupted by 
sonication at 50% output for 15 s.  Phenylmethylsulfonyl fluoride (0.5 mM) and 6-
aminocaproic acid (1 mM) were added to inhibit cellular proteases.  Subsequently, the 
cell suspension was subjected to further sonication for two 5-min intervals using 5-s 
pulses with a cycle time of 50%.  Between intervals, the cells were allowed to sit for 
5 minutes.  The lysate was centrifuged at 19,000 rpm for 30 minutes at 4 °C.  The 
resulting supernatant was made 2M in (NH4)2SO4 and stirred at 4 °C for 2 hr.  
Subsequently, the solution was centrifuged for 30 minutes at 19,000 rpm.  The 
supernatant was transferred to an Ultrafree 15 (MWCO 5000 Da) centrifugal 
concentrator and exchanged into 20 mM sodium phosphate buffer (pH 7.3) to a final 
volume of 0.6 mL.  The concentration of the protein was estimated by the Waddell 
method to be 131.3 mg/mL.   
  Incubation of the partially purified protein solution generated from the empty 
pET vector (20 µL of a 1331.3 mg/mL solution) with either trans-4 or trans-5 for 252 
hr resulted in no detectable amount of 8 or 9.   
  Incubation of fumarase (100 µL of a 0.5 mg/mL solution) with trans-5 for 112 
hr resulted in no detectable amount of 8 or 9.   
  Irreversible Inhibition of 4-OT by 10 and 11.  The inactivation of 4-OT by 10 
or 11 was determined by incubating various concentrations of inhibitor (10:  50-600 
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µM and 11:  50-750 µM) with 4-OT in 20 mM sodium phosphate buffer (pH 6.0) at 
30°C.  At each inhibitor concentration, three runs were performed.  Stock solutions of 
10 and 11 (50 mM) were made in 100 mM Na2HPO4 buffer and had a final pH ~7.  
The 50 mM stock solutions were diluted with a sufficient volume of the 100 mM 
NaH2PO4 buffer (pH 7.3) to give 5 mM solutions of 10 or 11.  A quantity of 4-OT (4 
µL of a 21.5 mg/mL solution) was diluted 2000-fold into 20 mM sodium phosphate 
buffer (pH 6.0), resulting in a final concentration of 1.58 µM.  The diluted enzyme 
was stored at 4 °C.  Subsequently, the enzyme was divided into 105 µL aliquots and 
equilibrated at 30 °C for ~5 min prior to use.  The time zero point (i.e., 100% activity) 
was determined at each inhibitor concentration by removing and assaying an aliquot 
(5 µL) of enzyme just before the addition of inhibitor.  After the addition of inhibitor, 
aliquots (5 µL) were removed at 7-s intervals, (for a total 56 s), diluted into 1 mL of 
20 mM NaH2PO4 buffer (pH 7.3), and assayed for residual 4-OT activity.  The assay 
was initiated by the addition of 2 to give a final concentration of 500 µM.  The 
volume of inhibitor added did not exceed 7.5% of the total volume of the incubation 
mix.   
  Protection of 4-OT from Inactivation by 10 Using 1-3.  The protection studies 
of 4-OT from inactivation by 10 were carried out using the equilibrium mixture of 1-3 
as described elsewhere (6), with the following modifications.  A stock solution of 2 
(83.5 mM) was made in 100 mM Na2HPO4 buffer (pH 9.2), resulting in a final pH of 
~6.8.  The stock solution was diluted 10-fold into 100 mM NaH2PO4 buffer (pH 7.3).  
Quantities of 4-OT (105 µL) were prepared as described above.  Aliquots of 2 (0-5 µL 
from the 8.35 mM solution resulting in concentrations ranging from 0-1.04 mM) were 
added to the enzyme and incubated at 30 °C for ~5 min, thereby allowing the mixture 
of 1-3 to reach equilibrium.  Subsequently, an aliquot of 10 (2.5 µL from a 5 mM 
solution) was added, resulting in a final concentration of 125 µM.  Aliquots (5 µL) 
were removed at 7-s intervals (for a total of 56 s), diluted 200-fold into 20 mM 
sodium phosphate buffer (1 mL, pH 7.3) and assayed for residual activity as 
described above.   
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  Irreversibility of the Inactivation of 4-OT.  4-OT (1.58 µM based on the 
molecular weight of the monomer) was incubated with an excess of 10 or 11 (50 µM) 
in 4 mL of 20 mM NaH2PO4 buffer (pH 7.3) for 2 hr at 29 °C.  The final pH of the 
solution was ~7.  In a separate control reaction, an identical quantity of 4-OT was 
incubated without inhibitor under identical conditions.  The treated samples had no 
activity after 2 hr.  The three samples were dialyzed against 20 mM NaH2PO4 buffer, 
pH 7.3 at 4 °C.  After 2 weeks, the control sample lost none of its original activity, 
while the treated samples did not regain any activity.   
 Electrospray Ionization (ESI) Mass Spectrometric Analysis of 4-OT and 4-OT 
Modified by 10 or 11.  Each sample contained ~1 mg 4-OT (47 µL of a 21.5 mg/mL 
solution) in a final volume of 1 mL of 20 mM sodium phosphate buffer (pH 7.3).  The 
modified samples were generated by the incubation of 4-OT with either 10 or 11 (53 
µL of a 50 mM stock solution to give a final concentration of 2.65 mM).  The control 
samples were treated with an aliquot (53 µL) of a 100 mM sodium phosphate buffer 
(pH 7.3).  Samples were incubated for ~18 hr at 4 °C and assayed for activity.  The 
control retained activity while the treated samples had no activity.   Subsequently, the 
samples were passed through separate PD-10 Sephadex columns equilibrated in de-
ionized water.  Fractions (~0.5 mL) were collected, and protein was identified by the 
Waddell method (18).  Samples were loaded as 50% infusions with methanol (8-15 
µL) or through a peptide trap for ESI-MS analysis. 
  Proteolytic Digestion of 4-OT and 4-OT modified by 10.  Two samples were 
made up for mass spectral analysis.  Each sample contained ~1 mg of 4-OT (0.5 mL 
of a 21.5 mg/mL solution) in a sufficient quantity of 20 mM sodium phosphate buffer, 
pH 7.3, to give a final volume of 2.5 mL.  One sample was treated with 10 (50 µL 
from a 50 mM stock solution of 9 in 100 mM Na2HPO4 buffer).  After incubating the 
samples at 4 °C for ~12 hrs, the individual samples were exchanged (~99.8 %) into 
40 mM ammonium acetate buffer, pH 4.0, using an Amicon equipped with a YM-3 
membrane.  The treated 4-OT gave a yellow color, while the untreated sample 
remained colorless.  Subsequently, both samples were treated with sequencing grade 
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endoproteinase Glu-C from Staphylococcus aureus (protease V8) by a modification 
of a literature procedure (6).  Accordingly, two vials of endoproteinase Glu-C (25 µg) 
were each reconstituted in 40 mM ammonium acetate buffer (50 µL), pH 4.0.  A 
quantity (50 µL) of the reconstituted protease was added to each sample, and the two 
samples were incubated at 37 °C overnight.  The mixtures were subjected to matrix 
assisted laser desorption-ionization (MALDI) mass spectral analysis.   
  Irreversible Inhibition of YwhB by 10 and 11.  The inhibition studies of YwhB 
with 10 and 11 were carried out as described above for 4-OT with the following 
modifications.  A quantity of YwhB (100 µL of a 25.6 mg/mL solution) was diluted 
100-fold into 20 mM sodium phosphate buffer (pH 6.0), to give a final concentration 
of 36.5 µM.  The enzyme was stored at 4 °C.  The diluted enzyme was divided into 
220 µL portions and allowed to equilibrate to 30 °C for ~ 5 min just prior to use.  The 
inactivation of YwhB by 10 or 11 was determined by the incubation of inhibitor (10:  
50-1000 µM and 11: 50-750 µM) with enzyme (220 µL quantities) in 20 mM sodium 
phosphate buffer (pH 7.3) at 30 °C.  The volume of inhibitor added did not exceed 4 
% of the total volume of the inhibition mix.  Aliquots (20 µL) were removed at 
various time points (for 10: 10-s intervals for 50-150 µM, 7-s intervals for 200-1000 
µM and for 11: 10-s intervals for 50-100 µM, 7-s intervals for 125-750 µM), diluted 
into 1 mL of 20 mM sodium phosphate buffer (pH 7.3), and assayed for residual 
activity.  The assay was initiated by the addition of 12 to give a final concentration of 
150 µM.   
  pH Dependence of the Inactivation of YwhB Using 11.  Inactivation 
experiments were carried out as described above at five different pH values (pH 5.2, 
6, 7, 8, and 9) using a quantity of YwhB (10 µL of a 25.6 mg/mL solution) diluted 
100-fold into 20 mM sodium phosphate buffer at the indicated pH values.  The 
diluted enzyme solutions were incubated at 4 °C overnight.  The concentration of 11 
tested at each pH was 250 µM.  Time points were taken at 7-s intervals.   
  Protection of YwhB from Inactivation by 10 Using 1-3.  The protection of 
YwhB from inactivation by 10 was carried out using 1-3 as described above in the 4-
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OT protection studies with the following modifications.  Quantities of YwhB (220 µL 
portions made up as described above) were placed in 1.5 mL eppendorf tubes.  
Aliquots (0-6.6 µL) of 2 were added to the enzyme and the resulting solution was 
equilibrated for ~5 min.  The concentrations of 2 in the eppendorf tubes ranged from 
0-2.5 mM.  Subsequently, an aliquot of 10 (1.2 µL from a 50 mM solution) was added 
to the mixture, resulting in a final concentration of 300 µM.  Aliquots (20 µL) were 
removed from the mixtures at 7-s intervals, diluted 50-fold into 20 mM sodium 
phosphate buffer (1 mL, pH 7.3) and assayed for residual activity as described above.   
  Irreversibility of the Inactivation of YwhB.  The irreversibility of the reaction 
was established using both 10 and 11.  YwhB (142 µM based on the monomer 
molecular weight) was incubated with an excess of 10 or 11 (3 mM) in 1 mL of 20 
mM NaH2PO4 buffer (pH 7.3) for 2 hr at 29 °C.  The final pH of the solution was ~7.  
In a separate control reaction, the same quantity of enzyme was incubated without 
inhibitor under similar conditions.  The samples treated with inhibitors had no activity 
after 2 hr.  The three samples were dialyzed against 20 mM NaH2PO4 buffer, pH 7.3 
at 4 °C.  After 8 days, the control sample lost ~6% of its original activity, while the 
treated samples did not regain any activity.   
  ESI-MS Analysis of YwhB and YwhB Modified by 10 or 11.  Each sample 
contained ~1 mg YwhB (40 µL of a 25.6 mg/mL solution) in a final volume of 1 mL 
of 20 mM sodium phosphate buffer (pH 7.3).  The modified samples were generated 
by the incubation of YwhB with either 10 or 11 (60 µL from a 50 mM stock solution 
to give a final concentration of 3 mM).  The control samples contained an equivalent 
amount of 100 mM sodium phosphate (pH 7.3).  Samples were incubated for ~14 hr 
at 4 °C and assayed for activity.  The control samples retained activity while the 
treated samples had no activity.  Subsequently, the samples were passed through 
separate PD-10 Sephadex columns equilibrated in deionized water.  Fractions (~0.5 
mL) were collected, and protein was identified by the Waddell method (18).  Samples 
(5-10 µL) were loaded through a peptide trap for ESI-MS analysis.   
 219
 
 Proteolytic Digestion of YwhB and YwhB-modified by 10.  In order to 
determine the site of covalent modification, it was necessary to treat YwhB and 
YwhB modified by 10 with protease V8 and trypsin (in separate reactions).  For the 
proteolytic digestion using protease V8, each sample contained ~0.5 mg of YwhB (20 
µL of a 25.6 mg/mL solution) in a sufficient quantity of 20 mM sodium phosphate 
buffer (pH 7.3) to give a final volume of ~0.5 mL.  One sample was treated with 10 
(30 µL from a 50 mM stock solution in 100 mM Na2HPO4 buffer).  The samples were 
incubated at 4 °C for ~20 hrs.  Subsequently, each sample was exchanged into 
ammonium acetate buffer, treated with protease V8 using the protocol described 
above, and subjected to matrix assisted laser desorption-ionization (MALDI) mass 
spectral analysis.  For the proteolytic digestion using trypsin, the YwhB samples were 
prepared as described above and incubated at 4 °C for ~14 hrs.  Subsequently, they 
were passed through separate PD-10 Sephadex columns equilibrated in 100 mM 
(NH4)2CO3 buffer, pH 8.  Fractions (~0.5 mL) were collected, and protein was 
identified by the Waddell method.  Both samples were treated with sequencing grade 
trypsin according to the manufacturer’s instructions and subjected to (MALDI) mass 
spectral analysis.   
  Mass Spectrometry of the Intact and Digested Proteins.  The intact samples 
(4-OT, 4-OT-modified by 10 or 11, YwhB, and YwhB-modified by 10 or 11) were 
analyzed using an LCQ electrospray ion trap mass spectrometer (ThermoFinnigan, 
San Jose, CA), housed in the Analytical Instrumentation Facility Core in the College 
of Pharmacy at the University of Texas at Austin as described previously (14).  The 
protease-digested control and treated samples (using trypsin or protease V8) were 
analyzed on the delayed extraction Voyager-DE PRO MALDI-TOF instrument 
(PerSeptive Biosystems, Framingham, MA) using a previously described protocol 
(21).  The ions in the trypsin-digested treated YwhB modified by 10 were subjected 





  The 4-OT and YwhB-Catalyzed Hydrations of E-4 and E-5.  The dehalogenase 
activities of 4-OT and YwhB was examined with the E-isomer of 4 as well as the E- 
and Z-isomers of 5.  The results are summarized in Tables 11 and 12.  The wild type 
4-OT and YwhB have comparable dehalogenase activity using E-5 and may have 
comparable activities using E-4.  The prolonged incubation for YwhB with E-4 
precludes a direct comparison.  Interestingly, 4-OT will process the cis-isomer of 5, 
albeit very slowly, while YwhB will not.   
  Although the preparations of 4-OT and YwhB were highly purified (as 
assessed by SDS-PAGE), four control experiments were carried out in order to verify 
that the observed dehalogenase activity is due to 4-OT (or YwhB), and not a 
contaminating protein.  First, the non-enzymatic decay of both E-4 and E-5 were 
examined in buffer for several days.  There were absolutely no detectable amounts of 
acetaldehyde in either mixture.  Second, E-5 was incubated with fumarase, an 
abundant cellular protein, for several days.  Again, the compound was not hydrated 
by fumarase.  Third, E-4 and E-5 were incubated with a partially purified cell extract 
derived from the expression cells used to generate 4-OT and YwhB.  The “empty” 
pET-24a(+) vector was transformed into cells, which were subjected to lysis and 
ammonium sulfate precipitation as performed for of 4-OT and YwhB.  The resulting 
protein concentrate was exchanged into phosphate buffer for NMR analysis.  Again, 
there were absolutely no detectable amounts of acetaldehyde in either mixture despite 
the prolonged incubation (~10.5 days).  Finally, a 4-OT constructed by total chemical 
synthesis was incubated with E-5.  This enzyme was completely untouched by any 
biological system, such as culture flasks and columns used for protein purification.  
The synthetic 4-OT also displayed comparable dehalogenase activity, converting 
~67% of E-5 to acetaldehyde and the hydrate after 208 h.    
  Studies with two mutants of each protein (P1A and the R11A) further confirm 
that the activity is attributable to the proteins and identify the proline as a critical 
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residue in the mechanism.  Our results show that the N-terminal proline is critical for 
activity.  No detectable amounts of acetaldehyde and its hydrate were produced by the 
P1A mutant of either 4-OT or YwhB.  In contrast, Arg-11 is critical to the YwhB-
catalyzed dehalogenation of E-5, but not to the 4-OT-catalyzed dehalogenation of E-
5.   
  Time-Dependent Inactivation of 4-OT by 10 and 11.  The initial inactivation 
experiments of 4-OT by 10 and 11 were carried out at pH 7.3 (data not shown).  The 
data indicated that it was not possible to saturate the enzyme with inhibitor, which 
prompted us to examine the behavior of 4-OT with these inhibitors under different 
conditions.  In view of the observation that the inactivation of YwhB by 11 is pH-
dependent (vide infra) and the enzyme approached saturation kinetics at lower pH 
values, the 4-OT inhibition studies were carried out at pH 6.0.   
  Accordingly, incubation of 4-OT with either 10 or 11 results in a rapid time-
dependent, irreversible inactivation of the enzyme at pH 6.0 (Figures 37 and 38).  For 
10, the kobsd values measured in 27 experiments were plotted versus the inhibitor 
concentration and fit to a rectangular hyperbola (Figure 37B).  The values of kinact and 
KI values obtained from this plot are 0.08 ± 0.02 s-1 and 0.71 ± 0.23 mM, 
respectively.  Treating the kobsd values measured in 21 experiments for 11 (Figures 
2A, B) similarly yielded kinact and KI values of 0.47 ± 0.16 s-1 and 1.91 ± 0.85 mM, 
respectively.  The rapid loss of activity at higher concentrations of 10 (> 600 µM) or 
11 (> 750 µM) did not allow us to collect sufficiently precise data to obtain 
inactivation rates, thereby accounting for the large errors in the values of kinact and KI.  
Nonetheless, inactivation with both inhibitors nears saturation, indicative that a 
dissociable complex forms between enzyme and 10 (or 11) before inactivation.  This 
supposition is supported by the observation that the enzyme could be protected from 
inactivation (by 10) when incubated with the equilibrium mixture of 1-3 (Figure 
37C).  At ~1 mM, 4-OT is completely protected from inactivation by 10 (125 µM).  In 
the absence of 1-3, the enzyme loses ~80% of its activity within ~21 s.  Exhaustive 
dialysis of 4-OT (inactivated by 10 or 11) does not result in the reactivation of 4-OT, 
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which indicates that a covalent bond has formed between 4-OT and 10 (or 11) or a 
species derived from 10 (or 11).   
  ESI-MS Analysis of 4-OT and 4-OT Modified by 10 or 11.  In order to 
determine whether the enzyme had been covalently modified by 10 (or 11), 4-OT was 
incubated with each inhibitor in separate reactions, and the products were isolated and 
analyzed by ESI-MS.  The molecular mass of 4-OT increases from 6810.0 (± 3 Da) to 
6896.0 (± 3 Da) after incubation with 10, and it increases to 6895.0 (± 3 Da) after 
incubation with 11.  Hence, both treated proteins are covalently modified by a species 
having a mass of 85 (± 3 Da).  In addition, the spectra displayed another signal at 
6852 (± 3 Da), which is due to modification of 4-OT by species having a mass of 42 
(± 3 Da).   
  Identification of the Modified Amino Acid Residue in 4-OT by Mass 
Spectrometry.  In order to identify the covalently modified residue, 4-OT was 
inactivated by 10, (designated the treated sample), incubated overnight with protease 
V8, and was analyzed by MALDI-TOF mass spectrometry.  A control sample was 
made up similarly, but 10 was excluded from the mixture.  The site of covalent 
attachment was identified by a comparison of the two spectra (21).  In the MALDI-
MS spectrum of the control sample, there is a prominent peak at m/z 1033.59 ± 0.6 
Da, which corresponds to the calculated mass of the N-terminal sequence 
(PIAQIHILE) (Table 13).  Two smaller peaks at 1055.69 Da and 1071.64 Da are also 
present, and represent the sodium and potassium adducts of this fragment, 
respectively.  In the MALDI spectrum of the treated sample, these peaks are not 
present.  However, there are three new peaks at 1075.73 Da, 1097.71 Da, and 1113.68 
Da.  These new peaks are consistent with covalent modification of the N-terminal 
fragment by a species having a mass of 42 Da.  The two potential sites for covalent 
modification in this fragment are Pro-1 and His-6.  It can be reasonably concluded 
that Pro-1 is the site of attachment because the kinetic studies indicate that 10 binds in 
the active site and His-6 is not in the active site.  Finally, a comparison of the MALDI 
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MS spectra indicates no other fragments are modified, which is consistent with the 
results of the ESI-MS analysis (showing a single site of attachment).  
  Time-Dependent Inactivation of YwhB by 10 and 11.  When the inactivation 
experiments (using 10 and 11) were carried out at 7.3, YwhB was rapidly inactivated, 
which precluded the collection of accurate data for the determination of kobsd values.  
Hence, the pH dependence of the inactivation process was examined as a function of 
pH.  Because the process slowed at lower pH values, the inactivation studies of 
YwhB were carried out at pH 6.0.  Like 4-OT, the incubation of YwhB with either 10 
or 11 results in a rapid time-dependent, irreversible inactivation of the enzyme 
(Figures 39 and 40).  For 10, the kobsd values measured in nine experiments were 
plotted versus the inhibitor concentration and fit to a rectangular hyperbola (Figure 
39B).  The values of kinact and KI values obtained from this plot are 0.08 ± 0.02 s-1 and 
1.60 ± 0.47 mM, respectively.  Treating kobsd values measured in twelve experiments 
for 11 similarly yielded kinact and KI values of 0.11 ± 0.02 s-1 and 0.88 ± 0.18 mM, 
respectively (Figure 4B).  Inactivation with both inhibitors approaches saturation, 
indicative that a dissociable complex forms between enzyme and 10 (or 11) before 
inactivation.  The results of the protection studies (using a mixture of 1-3) further 
support binding at the active site (Figure 39C).  At ~2.5 mM, YwhB is partially 
protected from inactivation by 10 (300 µM).  In the absence of 1-3, the enzyme loses 
~ 80% of its activity within 1 min.  In the presence of 1-3 (2.5 mM), the enzyme only 
loses 60% of its activity within 1 min.  Exhaustive dialysis of YwhB (inactivated by 
10 or 11) does not result in the reactivation of YwhB, which indicates that a covalent 
bond has formed between YwhB and 10 (or 11) or a species derived from 10 (or 11). 
  ESI-MS Analysis of YwhB and YwhB Modified by 10 or 11.  ESI-MS analysis 
demonstrated that the incubation of YwhB with 10 or 11 resulted in an increase in its 
molecular mass from 7013.0 (± 3 Da) to 7099.0 (± 3 Da).  This observation is 
consistent with the covalent attachment of a species to YwhB with a mass of 86 (± 3 
Da).  ESI-MS analysis also showed another peak at 7055 (± 3 Da), which is 
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consistent with the covalent modification of YwhB by a species having a molecular 
mass of 42 (± 3 Da).   
  Identification of the Modified Amino Acid Residue in YwhB by Mass 
Spectrometry.  In order to determine the residue modified by 10, it was necessary to 
carry out two separate proteolytic digestions using protease V8 and trypsin.  The 
mixtures were analyzed by MALDI-TOF mass spectrometry.  The protease V8 
digestion of the YwhB and YwhB-modified by 10 generated nine fragments (Table 
14).  A molecular mass (1079.84 Da) corresponding to the N-terminal fragment 
(residues 1-9) was observed in the control sample, and was not present in the treated 
sample.  However, a signal appeared at 1121.58 Da, which corresponds to the N-
terminal fragment modified by a species with a molecular mass of 42 Da.  
Unfortunately, the intensity of this signal placed it just above the noise such that a 
definitive conclusion could not be made.  A second signal appeared in the control 
sample at 2962.49 Da, corresponding to residues 1-25.  This signal was not present in 
the YwhB sample treated with 10 (and digested by V8), but a new signal appeared at 
3004.58, which corresponds the N-terminal fragment modified by a species with a 
molecular mass of 42 Da.  A third signal appeared in the control sample at 1901.95 
Da, which corresponds to residues 10-25.  The same signal also appears in the sample 
treated with 10.  These observations localize the site of modification of YwhB by 10 
to the first nine amino acids of YwhB (PYVTVKMLE).   
  In order to identify the modified amino acid within this fragment, YwhB and 
YwhB modified by 10 were subjected to proteolysis by trypsin.  The digestion 
generated eight fragments with the most prominent signal being displayed at 1135.61 
Da, corresponding to residues 38-46.  The signal was also present in the sample 
treated with 10, indicating that these residues had not been modified, consistent with 
the results obtained for the V8 digestion.  A molecular mass (calc. 706.86 Da) 
corresponding to one expected product of the trypsin digest, the N-terminal fragment 
(residues 1-6), was not present in the control sample.  However, a signal appeared at 
748.38 Da, which corresponds to residues 1-6 modified by a species with a molecular 
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mass of 42 Da.  The MALDI-PSD spectrum of this peptide shows a series of b ions, 
which have a charge on the N-terminal side of the fragmented peptide (Figure 41).  
Each ion is modified by a mass of +42 Da (except the b5 ion, which is not detected) 





  Nature may exploit the catalytic promiscuity observed in some enzymes in 
order to create new enzymes.  A catalytically promiscuous enzyme is one that has 
multiple low level activities in addition to its primary, physiological activity (22).  
Duplication of the gene followed by a series of mutations to amplify the desired 
activity generates a new enzyme which has the progenitor’s low-level activity as its 
primary activity.  Our results clearly show that the bacterial isomerase, 4-
oxalocrotonate tautomerase (4-OT) and a homologue, YwhB, found in Bacillus 
subtilis, have a low-level dehalogenease activity, converting either trans-4 or trans-5 
to acetaldehyde and the hydrate.   
  The most reasonable scenario for the generation of acetaldehyde from trans-4 
or trans-5 is shown in Scheme 25.  Hydration of 4 or 5 by 4-OT (or YwhB) produces 
a chlorohydrin species (6), which decomposes to malonate semialdehyde (7).  The 
non-enzymatic decarboyxlation of 7 yields acetaldehyde (8), which is readily 
hydrated to form 9.  Intermediate 7 is not sufficiently stable to accumulate in the 
necessary quantities that can be detected by 1H NMR spectroscopy.  This is consistent 
with the observation that signals for the intermediates are not detected in the course of 
the experiment. 
  The demonstration of dehalogenase activity for 4-OT and YwhB is significant 
for three reasons.  First, it suggests that 4-OT and YwhB could be the progenitors for 
CaaD.  Second, the non-enzymatic reaction is a difficult reaction to carry out, but it is 
clearly accelerated by 4-OT and YwhB.  In 0.5 M aqueous NaOH at 60 °C, about 
10% of the chloride is removed from E-5 in 24 hr (23).  In contrast, 4-OT and YwhB 
convert ~75% of E-5 to acetaldehyde (and the hydrate) at room temperature and 
neutral pH after 5-6 days.  Third, the active site pocket of 4-OT is a hydrophobic one 
which is not set up to carry out a hydration reaction.  Despite this fact, the enzyme is 
able to perform a hydration reaction.   
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  Our results also indicate that Pro-1 plays a central role in the mechanism of 
the 4-OT-catalyzed dehalogenation reaction while Arg-11 does not.  In 4-OT, Pro-1 
has a pKa of ~6.4.  This indicates that at pH 7.3, about 88% of the proline is the 
conjugate base form while 12% is the conjugate acid form.  As a general base, Pro-1 
could activate a water molecule for nucleophilic attack at C-3.  While Arg-11 is not 
important to the 4-OT-catalyzed dehalogenation reaction, there is another arginine 
residue, Arg-39, which could be involved in binding the carboxylate group of the 
substrate and pulling electron density away from C-3 to create a partial positive 
charge at C-3. This charge would make C-3 susceptible to nucleophilic attack by 
water.  In another scenario, Pro-1 could protonate C-2, thereby creating a positive 
charge at C-3 that enables water to add at the activated carbon.   
  These results indicate that both Pro-1 and Arg-11 play a critical role in the 
mechanism of the YwhB-catalyzed dehalogenation reaction.  The pKa of the Pro-1 is 
not known in YwhB, but in view of the structural similarities between the two 
enzymes (10), it seems likely that they have comparable pKa values.  Accordingly, 
Arg-11 could function as an electron sink to pull electron density away from C-3, 
thereby creating a partial positive charge, which would make C-3 susceptible to 
nucleophilic attack by water.  Pro-1 must also participate in the process and may be 
involved in the activation of the water.  
  In order to obtain further evidence for this hydration reaction, the behavior of 
4-OT and YwhB with 3-bromo- and 3-chloropropiolic acid was examined (10 and 
11).  Inactivation of these two enzymes by 10 or 11 would provide further evidence 
for the hydration reaction if the inactivation proceeded through an acyl halide 
intermediate, as has been proposed for the inactivation of CaaD by these compounds 
(14).  Surprisingly, the inactivation of 4-OT and YwhB was much faster than would 
have been anticipated based on the rates for the hydration of E-5.  This observation 
suggested that an alternative mechanism might be involved.   
  A priori, the modification of Pro-1 can occur by a mechanism-based route to 
form an acyl halide (or a ketene) or by Michael addition of β-Pro-1 to C-3 (Scheme 
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27).  In the first mechanism (Scheme 27A), the enzyme hydrates 10 (or 11) to 
generate an unstable species 12, which will readily undergo a rearrangement to either 
the acyl halide (13) or the ketene (14).  Due to their reactivity, both species would be 
lethal to the enzyme.  As indicated above, the rapid rate of inactivation and the slow 
rate of hydrolysis of E-5 argue against this mechanism.   
  In the second mechanism (Scheme 27B), Pro-1 attacks the C-3 position of 10 
(or 11) in a Michael-type reaction.  While conjugate additions to α,β-unsaturated 
carboxylic acids are not normally known, the inhibitor would presumably be activated 
by an interaction between the carboxylate group of 10 and a residue on the enzyme 
(e.g., Arg-11).  Subsequent rearrangement would result in the covalent attachment of 
the propargyl moiety to the enzyme and the loss of the halide ion.   
  The covalent adduct on Pro-1 in both 4-OT and YwhB has a molecular mass 
of 85 Da, which is consistent with the attachment of a 3-oxoacetate moiety.  
Moreover, this adduct, a β-ketoacid, is quite susceptible to facile decarboxylation 
upon covalent attachment, resulting in an acetyl group (24).  This sequence of events 
could be consistent with either a mechanism-based route or by the rearrangement of 
the propargyl moiety as shown in Scheme 28.  A non-enzymatic rearrangement of the 
propargyl moiety would result in the formation of an electrophilic allene-type 
compound (15), which would be highly vulnerable to attack by a water molecule.  
Ketonization of the resulting enol could generate the observed 3-oxoacetate moiety.   
  We have previously found that the acetylene compound, 2E-fluoro-2,4-
hexenynoate (16) is a potent competitive inhibitor of both 4-OT and YwhB 
(unpublished data).  For 4-OT, the Ki is 0.19 nM while for YwhB, the Ki is 200 µM.  
These values parallel the lethality of 10 and 11 for 4-OT and YwhB and suggest that 
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Figure 37A.  The inactivation of 4-OT after incubation with varying amounts of 10 
(filled diamonds, 80 µM; filled squares, 175 µM; filled triangles, 225 µM; filled 
circles, 400 µM; empty diamonds, 500 µM).  
 
Figure 37B.  Determination of the kinact and KI values for 10. A plot of the kobsd values 
for inactivation measured in 27 experiments as a function of varying amounts of 10 
(50-600 µM). The values of kinact and KI obtained from this plot are 0.08 ± 0.02 s-1 and 
706 ± 227 µM, respectively. 
 
Figure 37C.  Protection of 4-OT from inactivation by 10 using 1-3 (filled diamonds, 


































































Figure 38A.  The inactivation of 4-OT after incubation with varying amounts of 11 
(filled diamonds, 50 µM; filled squares, 80 µM; filled triangles, 200 µM; empty 
triangles, 300 µM; empty squares, 500 µM).  
 
Figure 38B.  Determination of the kinact and KI values for 11. A plot of the kobsd values 
for inactivation measured in 21 experiments as a function of varying amounts of 11 
(50-750 µM). The values of kinact and KI obtained from this plot are 0.47 ± 0.16 s-1 and 
1.91 ± 0.85 mM, respectively. 
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Figure 39A.  The inactivation of YwhB after incubation with varying amounts of 10 
(filled diamonds, 50 µM; filled squares, 100 µM; filled triangles, 300 µM; empty 
diamonds, 550 µM; empty squares, 1000 µM).  
 
Figure 39B.  Determination of the kinact and KI values for 10. A plot of the kobsd values 
for inactivation measured in 27 experiments as a function of varying amounts of 11 
(50-1000 µM). The values of kinact and KI obtained from this plot are 0.08 ± 0.02 s-1 
and 1.6 ± 0.5 mM, respectively. 
 
Figure 39C.  Protection of YwhB from inactivation by 10 using 1-3 (filled diamonds, 
0 mM; filled squares, 0.835 mM; empty trianles, 1.67 mM, empty squares, 2.5 mM). 
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Figure 40A.  The inactivation of YwhB after incubation with varying amounts of 11 
(filled diamonds, 50 µM; filled squares, 75 µM; filled triangles, 125 µM; empty 
diamonds, 175 µM; empty squares, 300 µM).  
 
Figure 40B.  Determination of the kinact and KI values for 11. A plot of the kobsd values 
for inactivation measured in 36 experiments as a function of varying amounts of 11 
(50-750 µM). The values of kinact and KI obtained from this plot are 0.11 ± 0.02 s-1 and 










































Figure 41.  MALDI-PSD fragmentation spectra of the peak at 748.38 Da in the 
treated digest of YwhB, corresponding to the PYVTVK (1-6) fragment.  The b ions 
are labeled with open triangles.  The b1 ions are shifted by +42 Da.   
 























































0.64 (E)-5 96 71 
Wild type 
 
0.19 (E)-5 139 64 
Synthetic  
 
0.36 (E)-5 208 67 
Synthetic  
 
0.20 (E)-5 208 22 
Wild type 
 
0.43 (E)-4 209 92 
R11A  
 
0.67 (E)-5 114 74 
R11A 
 
0.21 (E)-5 208 49 
P1A 
 
0.74 (E)-5 114 2 
Wild type 
 
0.64 (Z)-5 139 3 
Wild type 
 































0.33 (E)-4 616 93 
R11A  
 
0.60 (E)-5 137 5 
P1A 
 
0.54 (E)-5 108 NDa 
Wild type 
 
0.33 (Z)-5 137 NDa 
Wild type 
 
0.51 (Z)-5 209 NDa 
 
aND: Not detectable 
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Table 13.  Mass Spectral Analysis of V8 Digest of 4-OT. 
 

















10-17 948.96 948.44 948.47 
    
18-22 
 
631.75 631.38 631.40 
23-44 
 
2357.70 2356.22 2356.33 
45-62 
 
1915.27 1913.98 1914.07 
 
aThese values were calculated using the average molecular mass (Da). 
 






Table 14.  Mass Spectral Analysis of the V8 Digest of YwhB. 
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